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Procollagen prolyl-4-hydroxylase (P4H) catalyzes the conversion of
peptidyl proline to trans-4-hydroxyproline (Hyp). P4H is a member of the !-
ketoglutarate-dependent mononuclear non-heme iron oxygenase (!KG/Fe(II)-
oxygenase) family of enzymes, which catalyze a wide variety of reactions.
The genome of Bacillus anthracis (B. anthracis), the causative agent of
anthrax, contains a gene that is annotated as a p4h based on the predicted
amino acid sequence. Recently the immunodominant protein of the B.
anthracis exosporium has been identified as BclA. BclA has collagen-like
repeat sequences and has a triple helical structure similar to that of animal
collagens. We have detected Hyp from the protein extracts of spores of B.
anthracis and this is the first report for Hyp detection in bacteria. These
results strongly support that B. anthracis contains a P4H-like protein, anthrax-
P4H.
We have expressed and purified a recombinant form of the putative
anthrax-P4H and found that it is a homodimer of 24.3 kDa subunit. The
anthrax-P4H exhibits activity and UV-vis spectroscopic properties
characteristic of an !KG/Fe(II)-oxygenase, and it can bind a collagen-like
substrate, (Gly-Pro-Pro)10, with an affinity comparable to that of human type
(I) collagen-P4H (human-P4H-1). This is the first report of any P4H-like
protein from a bacterial source. We propose that anthrax-P4H can serve as a
model for human-P4H-1 from its substrate specificity and kinetic parameters
comparable to human-P4H-1.
We also report the crystal structure of anthrax-P4H to 1.40 Å. The
structure reveals the double stranded "-helix core fold (jellyroll) motif,
characteristic of Fe(II)/!KG oxygenases. The oligomerization of the protein is
a homodimeric, !2, structure, which makes the anthrax-P4H a new member
to the P4H family of enzymes. A putative peptide-binding groove has been
proposed based on that identified in the structure of P4H from
Chlamydomonas reinhardtii (green alga) (Cr-P4H-1).  The anthrax-P4H
structure provides insight into the dimeric structure of the !-subunits of
human-P4H-1, as well as to help understand the mode of substrate
recognition that may aide in the development of selective inhibitors.
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Collagens are a family of extracellular matrix proteins that function to
provide mechanical strength and structural integrity in the body. Collagen
comes from the Greek words kolla (glue) and gennan (to produce).1
Collagens are the most abundant proteins in the human body making up ~ 30
% of total proteins.2 It is responsible for the formation of hair, fingernails,
teeth, eye lenses, bones, and joints in the body, as well as additional roles in
cell adhesion, chemotaxis, and migration.2
There are at least 27 types of collagen in vertebrates and they are
identified by roman numerals according to the order of their discovery.2 From
the 27 diverse types, the form of collagen present in a particular area is
determined depending on its role in the body. Collagens most often assemble
into supramolecular assemblies, such as fibrils and networks.  These can be
further divided into eight subfamilies depending on their structural assembly.2
They include: (1) fibril-forming collagens (types I, II, III, V, XI, XXIV, XXVII),
(2) fibril-associated collagens with interrupted triple helices and related
collagens (types IX, XII, XIV, XVI, XIX, XX, XXI, XXII, XXVI, XXVIII), (3)
collagens forming hexagonal networks (types VIII and X), (4) type IV
collagens forming chicken-wire structures that are the major components of
basement membranes, (5) type VI collagen, forming beaded filaments, (6)
2
type VII collagen, forming anchoring fibrils in basement membranes, (7)
collagens with transmembrane domains (types XIII, XVII, XXIII, XXV) and 8)
collagen types XV and XVIII.2
All collagens are made up of three polypeptide chains known as !
chains.2 Some collagens contain identical ! chains for all three of the chains
and some collagens, most commonly fibrils, contain different types of
collagens among the three ! chains.2 The ! chains contain a repeat Gly-Xaa-
Yaa sequence in which Xaa is often Proline (Pro) and Yaa is often 4-
hydroxyproline (Hyp). Gly occupies every third position and the Pro and Hyp
pyrrolidine rings have steric constraints all which favor the helical
conformation.3 Hyp is essential to the stability of the triple helix, which will be
discussed further in the chapter.  The ! chains each wind up into a left-
handed helix and then wrap up together to form a right handed coiled coil
triple helix. This forms an extremely stable rope-like structure, which gives
collagen its characteristic strength.
The biosynthesis of collagen is characterized by the post-translational
modification of the polypeptide ! chains.  Collagen processing can be divided
into two stages, intracellular, and extracellular.  The intracellular modifications
include removal of propeptide sequences, hydroxylation of Pro or lysine
residues and results in the formation of the triple helices (Figure 1.1).4 The
3
extracellular modifications convert the single triple helix into stable, cross-
linked fibril collagens (Figure 1.1).4
The intracellular events are catalyzed by five specific enzymes;
collagen prolyl 4-hydroxylase (P4H), prolyl 3-hydroxylase, lysyl hydroxylase,
collagen galactosyltranserase and collagen glucosyltransferase, which are all
Figure 1.1 The steps involving the biosynthesis of collagen.  The
intracellular process begins with the hydroxylation of proline or lysine
residues.  Glycosylation occurs at hydroxylysine and asparagine residues.
The three ! chains assemble and form intramolecular and intermolecular
disulfide bonds.  The triple helix assembles in a zipper-like fashion and the
procollagen is secreted from the ER to the extracellular matrix.  The N- and
C- propeptides are cleaved and the collagen self-assembles to form fibrils.
The formation of covalent cross-links completes the biosynthesis of
collagen.  This figure was reprinted from Trends in Genetics, 20, J.
Myllyharju, & K.I.Kivirikko, Collagens, modifying enzymes and their
mutations in humans, flies, and worms, 33-43, 2004, with permission from
Elsevier.
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located in the lumen of the Endoplasmic Reticulum (ER).5 The role of 3-
hydroxyproline that is formed from prolyl-3-hydroxyase is currently not well
defined, but minimal characterization from isolated chick embryo has been
reported.6,7 The product of lysyl hydroxylase, hydroxylysine has two functions
in collagen biosynthesis as it provides a site for glycosylation and is essential
to intermolecular crosslinking, catalyzed by lysyl oxidase.7
As stated previously, the formation of Hyp is essential to the stability of
the collagen triple helix.  Type I collagen contains 1000 amino acid residues
in which ~ 100 are Hyp.8 Elastin does not form a triple helix but does contain
Hyp at 10 - 25 for every 1000 residues.8 Hyp exists in vertebrates almost
exclusively in the Yaa position of the characteristic collagen sequence.
Nonhydroxylated collagens can form triple helices at low temperatures but
have a Tm of 24 °C.9,10 Full hydroxylation is therefore required for stable
collagen in vivo at 37 °C.
The crystal structure of (GlyProHyp)4-AlaProHyp-(GlyProHyp)5 was the
first collagen-like peptide structure to be determined.11 The structure
confirmed supercoiled ! chains and interchain hydrogen bonding.11 It also
identified that, either the pyrrolidine ring of Pro and Hyp or the C=O for Gly
were exposed to the solvent, creating an extensive hydration network.  The
H2O molecules establish bridges for hydrogen bonding and the Hyp residues
act as anchoring points for these bridges (Figure 1.2).11 Subsequent work
5
questioned this rationale with the synthesis of (GlyProFrp)10, where Frp is 4-
fluoroproline.  This peptide showed a characteristic triple helix in the Circular
Dichroism (CD) spectrum and a dramatic increase in Tm from 69 °C to 91
°C.12 The stability of this peptide was explained through inductive effects due
to the electronegativity of fluorine and its inability to form hydrogen bonds.
The stabilizing effect of Hyp is most likely a combination of both the
hydrogen-bonding network and inductive electron effects.
Figure 1.2 Representation of peptide-solvent hydrogen bonding (black lines)
network in collagen.  H2O molecules (cyan) stabilize collagen triple helix
with both interchain and intrachain hydrogen bonding through H2O bridges.
Figure reproduced from PDB:1CAG with Pymol.
6
1.2 Collagen Related Diseases
A thousand mutations have been identified in six out of the 42 collagen
genes currently known.2 These include COL1A1, COL1A2, COL2A1,
COL3A1, COL4A5, and COL7A1.  Most of the mutations are single nucleotide
polymorphisms, which convert Gly to an alternate amino acid.2 This
incorporates excess bulk in the triple helix and results in unstable collagen.
There are additional mutations such as those that cause the Xaa or Yaa
position to change or become a stop codon, but these mutations do not cause
as severe a phenotype as the Gly mutations.2 A vast majority of these
mutations have been identified from heritable diseases, as outlined in Table
1.1.13
Other diseases, such as fibrosis, occur not from mutations, but from
collagen overproduction.14 The up-regulation of collagen is a normal healing
response after injury, during wound healing, tissue remodeling, and repair.15
However, the overproduction and progressive accumulation of collagen after
repeated injury or long-term inflammation can lead to fibrosis.15 Fibrosis
results from chronic inflammation due to chemical, microbial or physical tissue
injury.  The fibrosis pathway is widespread in the body and exists in many
forms including pulmonary, renal, hepatic, myocardial, dermal, and ocular.16
Collagen's central involvement in fibrosis makes it a potential drug
target for inhibition.14,17 Specific attention has been paid to the proteins
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involved in the post-translational modifications of collagen.  Collagen-P4H is
of particular interest as it is the rate-limiting step in the biosynthesis of
collagen and the formation of Hyp is essential to its stability.14,17
1.3 !-Ketoglutarate Dependent Non-Heme Iron Oxygenases
P4H was identified in seminal work by Udenfriend18 and Prockop.19
Udenfriend showed that fetal rat skin exhibited P4H activity that was
dependent on Fe(II), !-ketoglutarate (!KG), and O2 (Scheme 1.1), hereby
Disease Gene or enzyme
Osteogenesis imperfecta COL1A1; COL1A2
Ehlers-Danlos syndrome type VIIA COL1A1








Ehlers-Danlos syndrome type IV COL3A1
Aortic aneurysms COL3A1
Alport syndrome COL4A5
Epidermolysis bullosa, dystrophic forms COL7A1
Spondylometaphyseal dysplasia COL10A1
Ehlers-Danlos syndrome type VI Lysyl hydroxylase
Ehlers-Danlos syndrome type VIIC ProcollagenN-proteinase
Ehlers-Danlos syndrome type IX Lysyl oxidase
Menkes syndrome Lysyl oxidase
Table 1.1 Mutations identified in collagen that results in heritable disease.
Table reproduced from Annals of Medicine, 25, K. I. Kivirikko, Collagens and
their abnormalities in a wide spectrum of diseases, 113-126, 1993, with
permission from Informa healthcare.
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identifying it as the first member of a family of enzymes known as the !KG-
dependent mononuclear non-heme oxygenases (!KG/Fe(II) oxygenases).18,20
P4H catalyzes the general reaction shown in Scheme 1.1A, where the active
site Fe(II) catalyzes the hydroxylation of peptidyl proline coupled to the
decarboxylation of !KG to yield succinate.18,19 In addition to O2 and !KG,
P4Hs require a pool of ascorbate to be fully active.21 In the absence of
substrate, P4H can still decarboxylate !KG at a slow rate, but the enzyme
becomes inactivated.22 Ascorbate can protect P4H against inactivation by
serving as a surrogate substrate to yield succinate and dehydroascorbate
Scheme 1.1 Procollagen-P4H catalyzes the hydroxylation of peptidyl proline
to 4-hydroxylproline (Hyp) coupled to decarboxylation of !KG to yield
succinate (A). In the absence of peptidyl proline, procollagen-P4H catalyzes
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(Scheme 1.1B), and this reaction is termed uncoupling.23 
Members of the !KG/Fe(II) oxygenases are diverse in function,
catalyzing a wide range of reactions from fatty acid metabolism to DNA repair
and antibiotic biosynthesis (Figure 1.3).24 Though their roles in nature are
extremely diverse, they have some common properties that classify them as a
superfamily.  All of the enzymes contain a H1-X-D/E-Xn-H2 facial triad binding
Figure 1.3 Diverse functions catalyzed by !KG/Fe(II) dependent
oxygenases.  Figure from J. Inorg. Biochem., 100, I.J. Clifton, M.A.
McDonough, D. Ehrismann, N. J. Kershaw, N. Granatino, & C. J. Schofield,
Structural studies on 2-oxoglutarate oxygenases and related double-
stranded "-helix fold proteins, 644-669, 2006, with permission from
Elsevier.
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site for Fe(II) in their active sites.20 Pioneering work by Hanauske-Able and
Günzler proposed a mechanism of O2 activation and substrate hydroxylation
by P4H, now termed the HAG mechanism (Scheme 1.2).25 Subsequent
characterization of other !KG/Fe(II) oxygenases determined that other
members of this family of enzymes undergo the same mechanism.
In the mechanism !KG first binds Fe(II) in a bidentate fashion and
displaces two H2O molecules coordinated to the Fe(II) (2).  The substrate
then binds and activates O2 to produce a proposed superoxo-Fe(III)-O2
intermediate (3). A peroxo-Fe(II)-O2 (4) is postulated to be formed by direct
nucleophilic attack on the uncoordinated O atom at the C2 position of !KG.
Decarboxylation of (4) and heterolytic cleavage of the O-O bond results in a
reactive Fe(IV)=O intermediate (5).  The highly reactive Fe(IV)=O undergoes
an H-atom abstraction to hydroxylate the substrate (6).  The loss of succinate
and binding of two H2O molecules reduces the Fe(II) back to its resting state.
Gaining a clearer understanding of the mechanistic intermediates can
aid in the design of specific inhibitors for fibrosis.  Many of the intermediates
have been identified experimentally through UV-vis spectroscopy, Resonance
raman or X-ray crystallography.20,26 The initial resting state (1) has been
established using X-ray absorption spectroscopy (XAS) for both 2,4-D/!KG
dioxygenase (TfdA)27 and deacetoxycephalosporin C synthase (DAOCS)28
and using CD for clavaminate synthase (CAS).29 Intermediate (2) exhibits a
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characteristic metal-to-ligand charge transfer (MLCT) absorption transition in
the UV-vis visible region at ~ 500 nm.30 This spectrum is seen in many
!KG/Fe(II) oxygenases including taurine dioxygenase (TauD), which shows a
lilac colored chromophore with a #max = 530 nm.31 The species has also been
identified in several crystal structures of the !KG/Fe(II) oxygenase family.24,30
Scheme 1.2 HAG mechanism for the hydroxylation of substrate by
members of the !KG/Fe(II) oxygenase superfamily of enzymes, including
P4H.
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The binding of substrates does cause a shift in the UV-vis spectra of
some enzymes.  In TauD, the binding of taurine causes a blue shift to #max =
520 nm.31 The species involved in the reaction of O2 with the substrate/Fe(II)
(intermediates 3 and 4) are very reactive and poorly characterized.  The
Fe(IV)=O species was first identified in TauD by Mössbauer,32 resonance
Raman33 and extended X-ray absorption fine structure (EXAFS).34 This
species was identified as an S = 2 ground state and undergoes H-atom
abstraction followed by a rebound step to hydroxylate the substrate.
The members of this family of enzymes are also characterized by a
double-stranded "-helix core (DSBH) or jellyroll core fold motif in their crystal
structures.24 The fold consists of eight "-sheets that form a "-sandwich
composed of two-four stranded anti-parallel "-strands.   The cupin and Jmjc
family of proteins also adopt this conformation leading to the nomenclature of
DSBH.24 The DSBH consists of a minor "-sheet (usually containing shorter
strands) and a major "-sheet (often has extended "-sheets other than in the
core fold).  Additional secondary structures further stabilize the DSBH
domain.  As of 2006, over 50 structures of the !KG/Fe(II) oxygenases have




 In humans, P4H exists as an !2"2 tetramer.  The hydroxylation activity
resides in the ! subunit and the " subunit is a protein disulfide isomerase
(PDI).35,36 The function of PDI as the " subunit is to keep the !  subunit
properly folded and solubilized in the ER.  There are three identified
isoenzymes of human-P4H, all of which associate with the same PDI "-
subunit (Figure 1.4).37,38 Evidence exists that the tetramers do not form mixed
!(1)!(2)"2 tetramers, but instead distinct ! (1)2"2, ! (2)2"2, and ! ( 3 )2"2
tetramers.36,37 The sequence identity among human-P4H-1 and -2 is 65 %
and the identity among -1 and -3 and -2 and -3 is 35 % and 37 %
respectively.14,36 The highest degree of similarity occurs at the C-terminal
Figure 1.4 A schematic representation of the three forms of human-P4H.
The variation in the forms is present in the ! subunit.  The " PDI subunit is
the same for all three forms.
PDI!1 PDI !2 !3 PDI
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end, which is involved in catalysis and includes the residues involved in the
facial triad Fe(II) binding.39 In this region, !(1) and !(2) have 80 % identity
while !(3) has ~ 56 % identity with the other two subunits over the last 120
residues.14 A peptide-binding domain (PBD) of ~ 100 residues is located at
the N-terminal region of each of the isoenzymes and is responsible for the
substrate recognition of human-P4H.14
The substrate specificity of the three forms differs slightly from each
other.  All three isoforms bind polypeptide (GlyProPro)10 with in one order of
magnitude (Table 1.2).37,38,40 Poly(L-proline) has long been an effective
competitive inhibitor with respect to (GlyProPro)10 in human-P4H-1.41
Therefore, it was surprising that human-P4H-2 had K i values for poly(L-
proline) which were 200 and 1000 fold greater for Mr 7,000 and Mr 44,000
poly(L-proline) respectively than for type-1 (Table 1.2).37 Human-P4H-3
shows intermediate IC50 values compared with human-P4H-1 and -2 when
tested with Mr 5,000 poly(L-proline).38 The difference in binding of both
(GlyProPro)10 and poly(L-proline) is most likely is due to differences in the
aRef 37 and 40, bRef 37, and cRef 38









(GPP)10 Km 15 95 27
Poly(L-Proline)
Mr 5,000 IC50 6 300 30
Mr 7,000 Ki 0.5 95 N/A
Mr 44,000 Ki 0.02 20 N/A
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PBD of the three forms. These differences in the substrate specificity present
the potential for the development of selective inhibitors to target fibrosis.
Human-P4H-1 is the most common type of C-P4H in cells and
tissues.37,42 It is found highly expressed in less differentiated cell lines
including malignant hepatocytes.42 Human-P4H-2 has been found mostly in
chondrocytes, osteoblasts, endothelial cells, and cells in epithelial
structures.42 It represents 70 % of P4H activity in cultured mouse
chondrocytes and 80 % activity in cultured mouse cartilage, providing
evidence that human-P4H-2 may have a role in the development of cartilage,
cartilagenous bone, and capillaries.37 Human-P4H-3 was found expressed in
various tissues, but at much lower levels.37 High expression levels were seen
in the fibrous cap of atherosclerotic human carotid arteries.43
The PDI/" subunit of P4H is a multidomain protein that catalyzes the
formation, reduction, and isomerization of disulfide bonds during protein
folding in the ER.44 In addition to P4H, PDI acts as the " subunit for the
microsomal triglyceride transferase dimer.45 PDI contains four domains, a, b,
b' and a', followed by a C-terminal extension in which the ER retention signal
KDEL is located (Figure 1.5).8,44 The a and a' domains are responsible for
catalytic activity, and the b and b' domains are not redox active. The first
crystal structure of full-length PDI from yeast has recently been solved to 2.4
Å resolutuion.46 The structure revealed the four domains adopt a thioredoxin
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fold and arrange in a twisted "U" conformation.46 The active sites of a and a'
face each other and are located at the ends of the U, with the b and b' making
up the base of the "U".  A continuous hydrophobic surface was seen for the
structure, which correlates the structure and function of the protein, as PDI's
substrates are misfolded proteins with exposed hydrophobic residues.46
The concentration of PDI in the ER in the mM range and is found at
greater levels than the !  subunit of P4H.44 The roles of PDI and its
relationship to the ! subunit of P4H have been explored through mutagenesis
experiments.  Domains a' and b' are significant for minimal tetramer
assembly, but assembly greatly increases when all four domains are
present.47 The primary substrate binding site for PDI has been identified as b',
but b' is not essential for P4H activity or assembly.48 The PDI active site
cysteine residues are also not necessary for P4H activity or tetramer
assembly.49
a b b! a! c KDEL
WCGHC WCGHC
Figure 1.5 Diagram of PDI domains.  PDI is the " subunit of human-P4H.
The catalytic activity resides in the a and a' domains.  Each active site
contains two cysteine residues in the sequence WCGHCK.  The b and b'
domain are not catalytically active.
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1.4.2 Inhibitors of Collagen Human-P4H
There are several approaches to the development of inhibitors to target
P4H.  The difficulty in designing inhibitors is specificity to human-P4H-1 as
well as delivery.  As stated previously, targeting inhibition via the PBD of
human-P4H is one strategy to address inhibitor selectivity, as the PBD
represents the major difference in the three isoenzymes of human-P4H.7
Poly(L-proline) is a good example of targeting the selective properties of the
PBD because it has a lower Ki value for human-P4H-1 versus the other two
forms. Peptide inhibitors substituting Pro with unnatural amino acids such as
5-oxaproline have also been shown to be effective suicide inhibitors of P4H.50
The most potent of these inhibitors, benzyloxycarbonyl-Phe-Oxaproline-Gly-
benzylester inactivated human-P4H-1 by 50 % in 1 hour at 0.8 µM.50 Divalent
cations are also competitive inhibitors of Fe(II), with Zn(II) being the most
effective with a Ki of 1 µM.7
Many of the current P4H inhibitors are designed to mimic the binding of
!KG (Figure 1.6 A) to Fe(II). N-oxalylglycine is structurally very similar to !KG
as it replaces the methylene at the C3 of !KG with an NH group (Figure 1.6
B). These inhibitors have functional groups that interact directly with the
binding coordination and active site of !KG. This is powerful inhibitor with a Ki
of 0.5-8 µM.51,52 Pyridine-2',4'-dicarboxyate and pyrindine-2',5'-dicarboxylate
(Figure 1.6 C and D) are the most potent competitive inhibitors with respect to
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!KG with Ki values of 2 µM and 0.8 µM respectively.53,54 3,4-
dihydroxybenzoate differs from the other inhibitors in that it is competitive
against both !KG and ascorbate and is effective with a Ki of 5 µM (Figure 1.6
E).55
 The difficulty in using these inhibitors clinically is bioavailability.  Many
of these inhibitors cannot permeate the cell membrane and therefore are not
effective as potential drug targets.  Further design is necessary to develop a
potent C-P4H inhibitor that is both selective and able to be delivered to the
cell for therapeutic approaches.  We hope to accomplish inhibitor selectivity
through the development of a chimeric inhibitor that incorporates an Fe(II)
Figure 1.6 Structures of !KG and several competitive inhibitors of P4H. A =
!KG, B = N-oxalylglycine, C = Pyridine-2',4'-dicarboxyate D = pyrindine-2',5'-

























Ki = 0.5 - 8 µM
Ki = 2 µM Ki =  0.8 µM Ki = 5 µM
A
19
chelator such as phenanthroline and a peptide tag which will be specific to the
human-P4H-1 PBD.  The inhibitor delivery issue will be addressed with the
addition of polar groups to both the Fe(II) chelator and peptide tag of the
chimeric inhibitor to increase biodelivery.
1.4.3 Hypoxia Inducible Factor-P4H
An alternate P4H was identified to regulate oxygen response called the
hypoxia-inducible transcription factor (HIF!).56,57 The lack of oxygen, or
hypoxia, causes stabilization of a DNA specific HIF transcription factor, which
in turn causes the transcription of hypoxia-responsive genes. HIF is
expressed as a !"  heterodimer in which the HIF! subunit stability is O2
dependent and HIF" subunit is not.
Under normal O2 conditions the HIF!  subunit is constitutively
expressed but is rapidly degraded by the hydroxylation of one or two
conserved proline residues in the Leu-X-X-Leu-Ala-Pro sequence of its
oxygen-dependent degradation domain (ODDD) as shown in Figure 1.7.14
The formation of the Hyp residue causes HIF! to bind to the von-Hippel
Lindau (VHL) E3 ubiquitin complex to undergo degradation. The enzyme
responsible for the hydroxylation of Pro was identified as a cytoplasmic P4H
(HIF-P4H).57,58
In hypoxic environments the above pathway is suppressed.  HIF-P4H
activity is inhibited and hydroxylation of the ODDD sequence is ceased.  The
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absence of prolyl hydroxylation causes the HIF! to dimerize with HIF". The
HIF!" complex is translocated into the nucleus where it binds to one of the
100 hypoxia-induced genes.14,36 These genes have involvement in
angiogenesis, oxidative stress resistance and tumor progression to name a
few.  HIF-P4H is a member of the !KG/Fe(II) oxygenases, but its function is
distinct from C-P4H.
Figure 1.7 Regulatory pathway of hypoxia inducible transcription factor HIF!
by !KG/Fe(II) oxygenase HIF-P4H.  Under normoxic conditions HIF! binds
to von-Hippel Lindau (VHL) complex and undergoes degradation.  Hypoxia
causes the prolyl hydroxylation to be ceased and the HIF! to bind to the
HIF".  The HIF!"  complex is then translocated to the nucleus and is
involved in gene expression.  Figure used from Matrix Biology, J. Myllyharju,
Prolyl 4-hydroxylases: the key enzymes of collagen biosynthesis, 15-24,
2003, with permission from Elsevier.
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1.5 Invertebrate P4H
1.5.1 Caenorhabditis elegans P4H
The nematode Caenorhabditis elegans (C. elegans) contains two
genes, phy-1 and phy-2, encoding for collagen-P4Hs that are involved in the
synthesis of cuticle collagen.59,60 The assembly of recombinant P4H from C.
elegans (PHY-1 and PHY-2) differs from previously described human
collagen-P4H.  The PHY-1 expressed in Sf9 insect cells was found to form !"
dimers with either human-PDI or C.elegans-PDI (Figure 1.8).59 The sequence
identity between human-P4H-1 and PHY-1 is 45 %, with the identity
increasing to 65 % at the C-terminus.59 PHY-1 mutants were found to play a
role in the post-embryonic body morphology.60
Coexpression of both PHY-1 and PHY-2 with PDI-2 from C. elegans
were found to form distinct PHY-1/PHY-2/(PDI-2)2 mixed tetramers most
prevalently, with less active PHY-1/PDI-2 and PHY/PDI-2 dimers also formed
Figure 1.8 Depiction of differing forms of P4H from C. elegans.  C. elegans
readily forms PHY-1/PHY-2/PDI2 tetramers, but also forms PHY-1/PDI and










(Figure 1.8).61 The discovery of these heterotetramers was significant, as
vertebrate P4Hs do not form mixed tetramers with their ! subunits.  The
assembly of the mixed tetramers was seen both in vivo and in vitro and was
found to be dependent on the phy-2 gene.61 Mutations of this gene did not
form the PHY-1/PHY-2/(PDI-2)2 mixed tetramer. The loss of this gene up-
regulates the otherwise low expression of the PHY-1/PDI-2 heterodimer.61
The PHY-1, PHY-2, and PDI-2 are coexpressed in cuticle collagen
synthesizing hydrodermal cells during the larval stages 1 - 4 and adult
nematodes when the collagen synthesis is at its highest.61,62
When expressed with human PDI, recombinant PHY-1 shows catalytic
activity almost equal to that of human-P4H-1.  However, PHY-1 in the
presence of human PDI is not inhibited by poly(L-proline) at concentrations up
to 30 µM .59 PHY-1/PHY-2/(PDI-2)2 mixed tetramer was shown to be the
dominant P4H in vivo, and showed similar activity to the human-P4H
tetramers when tested with using radiolabeled protocollagen substrate as
described previously (10280 ± 1540 dpm/10 µL vs. 17390 ± 4500 dpm/10µL
respectively),63 and had similar Ki values for the !KG analogs, pyridine-2'5'-
dicarboxylate (1 µM vs. 0.8 µM) and pyridine-2'4'-dicarboxylate (1 µM vs. 2
µM) for C. elegans and human respectivly.62 Poly(L-proline) was not tested for
inhibition with this form.
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A third phy-3 gene has been cloned and expressed as a 295 amino
acid residue protein.64 This differs from the more than 510 residues of the
PHY-1 and PHY-2 proteins.59,60 PHY-3 forms a distinct heterodimer with PDI-
1 of C.elegans and does not associate with PHY-1 or PHY-2.64 phy-3 deletion
nematodes had normal morphology at the adult and larval stages but showed
a decrease in Hyp levels of collagen in the early embryo stages most likely
associated with egg shell development.64
1.5.2 Drosophila melanogaster P4H
The genome of Drosophila melanogaster (D. melanogaster) encodes
19 !-subunit related p4h genes.65 Eight of these genes contained significant
homology to the C-terminal end of the ! subunit of human-P4H-1 and were
cloned, including a previously characterized form.65,66 The eight open reading
frames contained conserved residues involved in catalysis. The number of
genes in Drosophila was unexpected compared with human, as there are
usually three to four human homologues for each fly gene. It was speculated
that this may be due to the lower number of collagen types found in the D.
melanogaster genome. D. melanogaster has only two collagen genes, which
encode for proteins similar to collagen IV in humans. This is considerably
lower than the 38 known types of collagen found in humans.67 The higher
number of P4H proteins in Drosophila may have evolved to compensate for
the fly's low collagen content.65
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A recombinant P4H from D. melanogaster has been expressed in Sf9
insect cells and was found to assemble into a !2"2 tetramer similar to human-
P4H.66 The tetramer can assemble with either the Drosophila or human PDI
subunit. The ! subunit was found to be expressed in larvae, but not in
embryos or adults.66 The Km values for (GlyProPro)10 (260 ± 100 µM) were 12
times higher than for human-P4H-1 (21 ± 5 µM) and 3 times higher than
human-P4H-2 (88 ± 25 µM).66 The Ki values for poly(L-proline), Mr 7000, (18
± 8 µM) also resemble human-P4H-2 (95 ± 31 µM) more than human-P4H-1
(0.6 ± 0.1 µM), providing evidence that the P4H from Drosophila mimics the
less common human-P4H-2.66
1.6 Monomeric P4Hs
Though collagens are not present in plants they do contain Hyp. The
plant cell wall is a self-assembling, interactive network of structural
polysaccharides and Hyp rich glycoproteins (HRGP).68 HRGPs contain Hyp
that is O-glycosylated, which is seen only within the plant kingdom.  There are
no human homologs to these proteins.
The genome of Arabidopsis thaliana (A. thaliana) contains six open
reading frames coding for P4H-like polypeptides.69 Two forms of P4H from A.
thaliana, At-P4H-1 and At-P4H-2, have been cloned and characterized.69,70
Both proteins were found to form simpler monomeric structures, unlike the
forms discussed previously.  At-P4H-1 and At-P4H-2 both effectively
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hydroxylated poly(L-proline) with Km values of 2 and 30 µM respectively.69,70
At-P4H-1 binds (GlyProPro)10 with a Km of 60 µM, where as At-P4H-2 has a
Km of 2.8 mM.69,70 At-P4H-2 was found to act on substrates with three or more
Pro residues, like the sequences found in the extensin and arabinogalactan-
like peptides of plants.70
The cell wall in green algae Chlamydomonas reinhardtii (C. reinhardtii)
is also made up of 25 to 30 different HRGPs.  It is built of mostly extensin-like
HRGPs. Pro rich peptides have been identified in the HRGPs of the cells wall
and Hyp has been identified.71 The genome of C. reinhardtii has 10 p4h
genes similar to the ! subunit genes of other P4H systems. Since Cr-P4H-1
contained the highest identity to the ! subunit of human-P4H-1, it was
expressed in both Sf9 insect cells and E. coli where it purified as a soluble
monomer.72 The p4h gene was found to be essential for cell wall assembly,
as knockout forms of the gene lead to the inability of the algae to regenerate
their walls. Cr-P4H-1 was found to hydroxylate Pro-Pro-Ser-Pro-X and (Ser-
Pro)19 motifs found in HRGPs of the cell wall. It does not bind human
collagen-like peptides tightly and has a Km for (GlyProPro)10 of > 1.5 mM.72
Though virus and bacteria are believed not to contain Hyp, both virus
and bacteria genomes contain proline-rich, collagen-like sequences.73-75
Bacterial proline-4-hydroxylases have been identified from Streptomyces
griseoviridus76 and Dactylosporangium sp.77, but are distinct from
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procollagen-P4Hs as they cannot take peptidyl proline as substrates and do
not share significant sequence identity with procollagen-P4Hs.77 A viral P4H
from the eukaryotic algal virus Paramecium bursaria Chlorella virus-1 (PBCV-
P4H) has been cloned and characterized as a soluble monomer in E. coli.73
The function and native substrate of P4H in the virus is not known.  Activity
assays showed that PBCV-P4H binds (GlyProPro)10 substrate poorly with a
Km of 2.9 mM.  Poly(L-proline) also bound weakly to the PBCV-P4H.  Several
synthetic substrates representing proline-rich peptides from the viral genome
were screened and (Pro-Ala-Pro-Lys)10  had low Km values of 20 µM and
highest activity.73 This P4H is distinct from the other forms currently known.
1.7 Bacterial Collagens
Because bacteria are believed to not contain Hyp and their collagens
must be stabilized with other interactions.  Bacteria and phage contain
collagen-like sequences in their genomes and trimeric structures have been
identified that are similar to animal collagens.78 The bacterial enzyme
pullulanase from Klebsiella pneumoniae was the first bacterial protein shown
to assist in the generation of a triple helical structure through collagenase
digestion.79 Trimeric proteins have also been identified on proteins located in
the tail-fiber and head of bacteriophage.74
With recent bacterial genome projects, collagen-like proteins are
becoming readily identified and studies are looking into the stabilization of
27
their collagens. Collagen-related structural motifs (CSMs) have been
identified and are characterized by Gly at the primary position and a high Pro
content.80 Bacteria with these motifs most commonly contain Thr at the Yaa
position while the Xaa position can be Pro, Ser, or Ala.80 Collagen-like
proteins have been identified in group A Streptococcus and Bacillus anthracis
genomes, and are found to form stable triple helical structures similar to
animal collagens.75,81,82 Glycosylation and electrostatic interactions are
believed to stabilize bacterial triple helices, but are still being
investigated.81,83,84
Hydroxylation of Pro may occur in bacterial systems but has not been
identified to date.  Model peptides {Gly-Pro-Thr("Gal)}10 and {Gly-Hyp-
Thr("Gal)}10  showed that even when glycosylated, substituting Pro with Hyp
further stabilizes the triple helix.85 Animal collagens have been shown to
preferentially hydroxylate Pro at the Yaa position.  However, invertebrate
systems do show that hydroxylation can occur at the Xaa position as may be
occurring in bacteria.  Interstitial cuticle collagens from hydrothermal vent
worms glycosylate Thr at the Yaa position and amino acid analysis has
shown Hyp to be present at the Xaa position.86 Earthworm cuticle collagens
and collagens involved in cell wall assembly from C. reinhardtii also
preferentially hydroxylate collagen at the Xaa position.72,87
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1.8 Goals of Current Research
The current available systems for recombinant human-P4H-1
expression give low yield and low purity enzyme, which is not sufficient for
spectroscopic studies or structure determination.88,89 Both spectroscopic and
structural knowledge can aid in new strategies for the design of potential
therapeutic agents that target fibrosis.   
Table 1.3 is a compilation of the information discussed in this
introduction on the various forms of P4H. Current model systems for human-
P4H-1 include the monomeric PBCV-P4H and Cr-P4H-1. All P4Hs require
Fe(II), O2, and !KG for activity, and mechanistic intermediates have been
detected in the reaction of PBCV1-P4H, including the Fe(IV)=O
intermediate.73 A crystal structure of a Cr-P4H-1 has also been recently
determined to 1.85 Å.90 This is the first crystal structure of a collagen-P4H,
and identifies the mode of Fe(II) binding to the His-X-Asp/Glu-Xn-His facial
triad. However, neither of these forms of P4H bind collagen-like substrate
(GlyProPro)10 with the same affinity as human-P4H-1. Also both forms take
poly(L-proline) as a substrate, which is a known inhibitor for human-P4H-1.
Lastly their monomeric structures differ from the !2"2 tetramer of human-P4H.
The monomeric structure and differing substrate specificity of PBCV-P4H and
Cr-P4H-1 make these systems poor representative models for studying
human-P4H-1.
29
We propose to characterize a collagen-P4H from Bacillus anthracis
(anthrax-P4H) as a structural and spectroscopic model for human-P4H-1.  We
will show that anthrax-P4H exists in a homodimer, !2, form and binds
collagen-like substrate with the same affinity as human-P4H-1.  The specific
aims for this work were:
1. Determine if non-pathogenic Bacillus anthracis ($Sterne) produces Hyp.
2. Expression, purification, and biochemical characterization of recombinant
anthrax-P4H. Determine the suitability of anthrax-P4H as a model enzyme for
human-P4H-1 by defining its substrate specificity and kinetic parameters in
comparison to human-P4H-1.
3. Crystallization and structure determination of the recombinant anthrax-
P4H.
In addition:
4. Alternate P4H systems, including two viral forms and four chimeric P4Hs,




Chapter 2: Determination of Hyp in B. anthracis Cells
2.1 Introduction
Bacillus anthracis (B. anthracis) is an endospore forming, gram-
positive bacterium that is the etiological agent of anthrax.91 Although
uncommon in developed countries, anthrax still remains a threat in
underdeveloped areas of the world. It is in endemic levels in areas of Central
America, South America, Africa, and Asia.  Anthrax is primarily found in
herbivores, which ingest or inhale soil-containing spores while grazing (Figure
2.1).  Most human infections result from contact with contaminated animals or
animal products.92 Three types of human infection include cutaneous,
Figure 2.1.  Life cycle of Bacillus anthracis. Figure used from Annu. Rev.
Microbiol., M. Mock & A. Fouet, Anthrax, 2001, 55, 647-671, with
permission.
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gastrointestinal, and inhalation, which can all progress to fatal systemic
anthrax if left untreated.91  
The prominence of anthrax has gained much attention since the 2001
terrorist attacks.  Anthrax spores make an ideal bioterrorism weapon as they
can be generated in vitro in high quantities and can be aerosolized for
exposure to an expansive area.93 Making the potential to infect large
populations fairly easy to do.  The hardiness and dormancy of the spore coat
also allows for survival of the spore under even the most brutal of
environments, making it an ideal bioterrorism weapon.
The anthrax bacterium alternates between two morphologies: the
vegetative cell and the dormant endospore.  The vegetative rod-shaped cells
cannot survive outside of a host system, as they require an environment rich
in amino acids, nucleosides, and glucose from the blood and tissues of the
animal or human host.93 When the host's nutrients are exhausted and the
bacilli encounter oxygen, the cells begin to undergo sporulation.93 The spore
protects the bacterium from chemical and environmental stressors and allows
for survival until the environment is again suitable for stable growth.94 The
spore is protected by a multi-layered coat containing many proteins, and a
loose-fitting balloon like layer known as the exosporium (Figure 2.2).95,96 The
exosporium is made of a basal layer and a hair-like nap outer layer, and is
chemically complex as it is made up of proteins, polysaccharides, and lipids.97
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The exosporium is the first part of the bacteria that comes in to contact with
the host and so contains many of the antigens to which the antibodies in
vaccines react. 91
The immunodominant protein of the exosporium was identified to be a
glycoprotein, BclA (Bacillus collagen-like protein of anthracis), that exists in
the exosporium filaments.98 This protein was found to possess an internal
collagen-like region of Gly-Xaa-Yaa repeats of varying length, many which
contain Gly-Pro-Thr triplet repeat sequences. These repeats are similar to the
Gly-Pro-Hyp repeats found in human collagen.  The Thr residues are sites of
extensive glycosylation, which add stability to the "collagen-like" triple helix
Figure 2.2.  Structure of B. anthracis spore.  The outermost layer is called
the exosporium (EX), and is composed of the basal layer (BM) and hairlike
nap (N).  The inner spore is made up of the spore coat (SC), cortex (CX),
and core (CR). Figure used with permission from Levine, S., Tang, Y.W.,
Pei, Z., Recent advances in the rapid detection of Bacillus anthracis, Rev.
Med. Microbiol., 16, 4, page 127.
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structure in the absence of Hyp.83,84,96 The number of Gly-Pro-Thr repeats in
the collagen-like region (CLR) of BclA is highly strain specific. BclA from the
Sterne strain contains 76 Gly-Pro-Thr repeats, making the protein
hydrophobic and hard to solubilize in buffers.99 Similar Gly-Xaa-Thr repeats
have been seen in one of the cuticle collagens of deep-sea vent worms where
the Thr residues are glycosylated, and some of the residues in the Xaa
position have been identified as Hyp.86 Much like Bacillus anthracis, these
worms also survive in harsh conditions with dramatic fluctuation of
temperature, low pH, high sulfide levels, and low oxygen levels.100 Studies on
synthetic peptides by Bann and Bachinger showed {Gly-Pro-Thr(!Gal)}10
repeats obtained higher thermal stability with the substitution of Pro to Hyp.85
Earthworm epithelial collagens have also been shown to preferentially
hydroxylate Gly-Pro-Ala versus Gly-Ala-Pro.87 A second collagen-like
glycoprotein from B. anthracis (BclB) has been identified.101 Though it does
contain collagen-like repeats, these repeats do not contain Pro in the Xaa
position as BclA. The repeat in BclB is GITGVTGAT, with sites for
glycosylation likely present at the Thr residues as BclA.102
A crystal structure of the collagen-binding domain (151-318) of the
Staphylococcus aureus adhesin protein (Cna) has been determined to 2 Å
(PDB: 1AMX), where the binding interface of the domain is built along a
groove on a concave !-sheet and has significant structural and chemical
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complimentarily to the triple helix of collagen.103 The subsequent structural
study of Cna apo-protein (31-344, N1 and N2 subdomains) and Cna
complexed with a synthetic collagen-like peptide revealed that the peptide
penetrates through a spherical hole formed by the two subdomains and the
N1-N2 linker.104 Though there is no sequence or structural similarity between
Cna and procollagen-P4H, the structure and work on Cna establishes
prokaryotic binding of collagen.
Bacterial proline-4-hydroxylases have been identified from
Streptomyces griseoviridus 76 and Dactylosporangium sp.,77 but  are distinct
from procollagen-P4Hs as they cannot take peptidyl proline as substrates and
do not share significant sequence identity with procollagen-P4Hs.77 Peptidyl
proline has not yet been identified in prokaryotes.80,81 Therefore, we set out to
determine if B. anthracis "Sterne produces Hyp, and if its' production was
associated with sporulation.
2.2 Materials and Methods
2.2.1 Growth of B. anthracis "Sterne Cells and Spores and Fractionation
of Protein Extracts
B. anthracis strain "Sterne (spore concentrate in silica) was a kind gift
of Dr. George Stewart (University of Missouri, Columbia). "Sterne is a strain
derived from Sterne, but lacks the plasmids necessary for toxicity, pXO1 and
pXO2.  Initial growing conditions were followed based on the gram-positive
bacteria preparation from the Partial Bacterial Proteome Extraction Kit (P-
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PEK) (Calbiochem). Spores in silica were streaked on a LB agar plate, and
incubated at 37 °C overnight. A single colony was inoculated in 5 mL LB
media overnight with gentle agitation. One mL of the overnight culture was
diluted to 200 mL fresh LB and incubated at 37 °C, 225 rpm, until the OD600
reached 0.8 - 1.0.  Growth was stopped in mid-log phase after ~ 4 hrs by
placing culture on an ice bath for 15 minutes. Cultures were centrifuged at
20,000 g for 15 minutes at 4 °C.  The supernatant was decanted and the
pellet resuspended in a total of 2 mL cold Tris-buffered saline (TBS).
Centrifugation was repeated, the supernatant decanted, and pellets frozen at
- 80 °C.
Due to low detection of Pro and Hyp with the previous method
(Calbiochem), we used a protocol that monitors the cell growth and
sporulation with phase contrast microscopy. This method is modified from the
original spore growth method by Nicholson and Setlow.105 Twenty-five mL
Difco Sporulation Medium (DSM) was inoculated with the same "Sterne
spores absorbed on silica as previously described. The culture was incubated
at 37 °C with agitation at 150 rpm until an OD600 of 0.5 (mid-log phase) was
reached. The starter cultures were diluted 10-fold into 250 mL DSM, and the
degree of sporulation was monitored by phase contrast microscopy
(Microscopy and Analytical Imaging Laboratory at the University of Kansas)
every 24 hours. Vegetative cells were harvested at 24 hours, prior to
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sporulation (> 99% vegetative). Complete sporulation was observed after 36
hours. At both time points, cells were harvested by centrifugation at 8,000 g at
4 °C, and the pellets were washed with Milli Q water and centrifuged. Spores
were subjected to additional purification to remove residual vegetative debris
using Renografin (Bracco Diagnostics) purification according to published
methods.105 Renografin is used in a density gradient to separate the spores
from the cells.  B. anthracis cells and spores were stored at 4 °C until ready
for fractionation.
The P-PEK kit from Calbiochem was used to separate the complex
protein mixture from the cells and spores.  The kit uses reagent mixtures with
increasing solubility strength prior to separation by HPLC. Both B. anthracis
cells and spores were subjected to fractionation resulting in six samples each.
Samples were stored at - 20 °C until ready for hydrolysis.
2.2.2 Derivatization and Separation of Fractionated Protein Extracts
from B. anthracis Cells and Spores
Sample derivatization was based on published methods with minor
alterations.106 Hyp and Pro standards, o-phthaldialdehyde (OPA), and
reagents for the mobile phases and sample hydrolysis were purchased from
Sigma Aldrich, and were of HPLC-grade or equivalent.  A mixture of 17 amino
acid standards (H-type, 2.5 µmol/ml each in 0.1N HCl; except for L-cystine,
which is supplied at 1.25 µmoles/ml) and dabsyl-Cl were purchased from
Thermo Scientific-Pierce Protein Research Science.
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Fractionated cells and spore samples were subjected to acid
hydrolysis overnight.  500 µL of each sample was added to 500 µL 12 N HCl
in a hydrolysis tube (ChemGlass) and sealed under vacuum.  Samples were
heated at 110 °C for at least 12 hours to ensure complete hydrolysis.
Samples were removed from the hydrolysis tubes, neutralized with NaOH,
and freeze dried.
OPA (15 mg) was weighed and dissolved in 500 µL of acetone and 7.5
µL of !-mercaptoethanol. This OPA stock solution (100 µL) was diluted into
6.4 mL of 50 mM carbonate-bicarbonate buffer (pH 9.0). In addition dabsyl-Cl
(6.5 mg) was weighed and dissolved in 5.00 mL of acetonitrile (ACN).  The
mixture was heated to 70 °C in order to completely dissolve dabsyl-Cl in the
solution. The diluted OPA solution (500 µL) was added to each "Sterne B.
anthracis sample or standard and mixed well.  Samples were incubated for 5
minutes at room temperature. The dabsyl-Cl solution (500 µL) was added to
each of the samples, mixed well, and incubated at 70 °C for 20 minutes with
the lids closed.  After the incubation, 1 mL of ACN was added to each tube.
The samples were shaken gently and 1 mL of each sample was added to a 5
mL sample loop onto the HPLC.
The amino acid separation was performed with a HPLC system from
Shimatzu Scientific Instruments consisting of a SCL-10A system controller,
DGU-20A3 degasser, LC-20AT pump, CTO-20A column oven, and SPD-
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20AV UV-vis detector.  A Phenomenex Ultracarb 5µ ODS C18 column (250 x
4.60 mm) was used for separation with a Phenomenex guard column.  The
gradient program and mobile phases used for separation of Hyp and Pro
amino acids are outlined in Table 2.1 and in previously published methods.106
Fractions of the Hyp standards and samples were collected and subjected to
mass spectrometry for confirmation.
2.3 Results
2.3.1 Growth of B. anthracis "Sterne Cells and Fractionation of the
Protein Extracts
We received "Sterne B. anthracis from Dr. Stewart (U of Missouri-
Columbia), and grew vegetative cells in LB-agar.  Initial cell growth
progression was monitored only through OD600, not microscopy.  Vegetative
cells were grown for 4 hours, and hydrolysis was performed in sealed
Table 2.1.  HPLC gradient method for separation of Hyp and Pro from
complex protein samples.  Mobile phase A made up of 40 mM Na2H2PO4
pH 3.0 and mobile phase B made up of 4:1 ACN:H2O + 4 % DMF (v/v).







        A (%)            B(%) Curve
Initial 1.0 55 45 Isocratic
3.0 1.0 55 45 1
8.0 1.0 40 60 1
12.0 1.0 33 67 1
13.0 1.0 0 100 1
15.5 1.0 55 45 1
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ampules under vacuum.  These growth conditions were not optimized for
maximum growth of cells or to ensure growth of spores and cells separately.
We then subjected the B. anthracis cells to a double derivatization with
OPA and dabsyl-Cl to allow for detection with UV-vis.106 The OPA reacts only
with primary amines and therefore suppresses the signal from these in the
chromatograph. The dabsyl-Cl can then react with the secondary amines
present in Hyp and Pro, resulting in a less complex chromatograph.  Scheme
2.1 shows the reactions of OPA and Dabsyl-Cl with amino acids for pre-
column derivatization.
Initial experiments were performed to validate the method for
selectively determining Hyp and Pro from a complex amino acid mixture.106
Figure 2.3 shows that Hyp and Pro (2.5 µg/mol) are detected from of a
complex mixture of 18 amino acids.  Fractions containing the Hyp peak were
analyzed by mass spectrometry and confirmed as Hyp with an m/z of 419.1.
Scheme 2.1 Reaction schemes for the double derivatization of amino acids.
A) Fluorogenic amine-derivatization reaction of o-phthaldialdehyde (OPA).




Fractionation was performed per protocol from the P-PEK kit (Calbiochem)
using buffers of increasing solubility strength (Figure 2.4).
Figure 2.3. HPLC chromatogram of amino acid standards, detecting Hyp and
Pro.
Figure 2.4. Flow chart of partial proteome extraction, P-PEK.  Proteins are
sequentially extracted with four buffers with increasing solubilization
strength. Figure used from Calbiochem Cat. No. 539780 catalog.
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Figure 2.5 is an overlay of the HPLC chromatographs from each of the
fractions isolated. We were successfully able to detect small levels of Hyp in
fraction 2 containing Tris, Urea, Detergent, and DTT (Calbiochem), which
corresponds to the same retention time as the Hyp standard.  The retention
times of these runs differ slightly from more recent data because we were
using a different HPLC instrument in the KU-Analytical Lab at the beginning
stages of the project.
Figure 2.5. HPLC analysis of amino acid standards and fractionated
protein extracts from B. anthracis. A) Chromatogram of 18 amino acid
mixture detecting Hyp and Pro.  B) Chromatograms of four samples of





The initial method of cell growth resulted in low levels of Hyp that were
difficult to detect consistently from a sample consisting of a combination of
cells and spores.  We therefore set out to grow cells and spores separately
and determine if Hyp levels are associated with sporulation.  We modified a
sporulation protocol from Nicholas and Setlow in which we used a Renografin
(Bracco Diagnostics) density gradient to purify the spores from the cells.105
We monitored cell growth and sporulation with phase contrast microscopy
(KU-Microscopy and Analytical Imaging Laboratory), and were able to isolate
both cells and spores (Figure 2.6).
After the isolation and spore purification we repeated the P-PEK serial
extraction, acid hydrolysis, double derivatization, and HPLC separation of the
cells and spores separately.  We were consistently able to detect Hyp in the
Figure 2.6.  Phase contrast microscopy of B. anthracis !Sterne growth.  A) B.
anthracis vegetative cells after 24 hours.  B) B. anthracis spores after 36 hours.
A B
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Wash 2 fraction in both the cells and spores.  To confirm that the peak was
Hyp we spiked the sample with 20 µM Hyp standard and monitored the HPLC
chromatogram for co-elution.  Figure 2.7 shows the sample run with and
without the presence of the Hyp standard.  The two peaks co-elute at 11.2
minutes, providing evidence that Wash 2 contains Hyp.  Initial attempts to run
mass spectrometry on the Hyp fraction from the cells has been unsuccessful
due to low concentration.  We have combined the Hyp peaks from several
runs, but have still not detected anything above background.  High-resolution



























Figure 2.7. HPLC analysis of Hyp in the protein extracts from B. anthracis
(!Sterne).  HPLC traces of protein extracts of u nsporulated cells with (red
line) and without (blue line) standard addition of authentic dabsyl-Hyp (elutes
at 11.2 min).
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We next set out to determine if Hyp production levels were affected
from vegetative cells to sporulation.  Figure 2.8 shows a comparison of Hyp
present in cells (blue line) versus spores (red line).  The presence of Hyp in
the spore samples is greatly (> 10-fold) increased in the spore containing
samples, suggesting that Hyp formation is associated with sporulation.   High-
resolution mass spectrometry analysis is also being investigated for definite
confirmation that these peaks are Hyp.
2.4 Discussion
2.4.1 Absence of Hyp in Prokaryotic Systems
As discussed previously, Hyp is believed essential in providing thermal
stability and structural support to the collagen triple helix. In animal collagens
































Figure 2.8. HPLC analysis of Hyp comparison of the amount of Hyp in
protein extracts from sporulated (red line) and unsporulated cells (blue line).
46
sequences, with Xaa commonly Pro.  Collagenous domains vary in length
and can either contain uninterrupted Gly-Xaa-Yaa repeats or contain
imperfection in the sequence which cause flexibility in the otherwise rigid
triple helix structure.107
Though bacteria and viruses were generally believed not to synthesize
Hyp, collagen-related structural motifs (CSM) have been previously identified
in these organisms.80 Gly at the primary position and a high Pro content are
markers in identifying these proteins.81 In bacteria, the Yaa position is
occupied typically with a Thr residue, and in these Thr-rich CSMs the Xaa is
usually Pro, Ala or Ser.80 The Thr residue can form direct hydrogen bonding
with the backbone carbonyl as seen in animal collagens 80.  The closest
homologue to the Thr rich CSM is the cuticle collagen found in hypothermal
vent worms.80 Interestingly, these vent worms contain a P4H, which
hydroxylates Pro at the Xaa position rather than the conventional Yaa
position.86
Collagen-like sequences have been identified in several bacteria
genomes including group A Streptococcus proteins Scl1 and Scl2, which are
expressed as cell surface proteins on the gram positive bacteria.74,75,79 These
proteins were the first to be structurally characterized and showed direct
evidence that the collagen-like sequences formed triple-helical structures.75
Collagen-like proteins have also been identified and characterized in the
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genome of Bacillus anthracis.96,98,101 None of the proteins are thought to be
stabilized by Hyp as with animal collagens.  Recent research has been
performed to determine stabilization of collagen triple helix in the absence of
Hyp.81,83,84,99
2.4.2 Stabilization of Triple Helix in the Absence of Hyp
Though the identification of Hyp in prokaryotes has not been previously
shown, research on collagen stabilization has been performed to understand
how prokaryotes bind and stabilize collagen.  Work with the recombinant Scl2
protein from Streptococcus pyogenes shows that the collagens are stabilized
by electrostatic interactions caused by ion pairing, inter-chain hydrogen bonds
and hydration network associated with packing of polar groups.81 Though
Scl2 has only ~ 12 % Pro residues in the Xaa position, versus ~ 20 % found
in animal collagens, there are 30 % charged residues compared with ~ 15 %
seen in fibrillar collagens.81 These charged particles lend to the stability of the
triple helix due to the hydration network.
Structural studies have also been performed on Bacillus collagen-like
protein from anthracis (BclA).  This protein contains three domains: N-
terminal domain (NTD) made up of 38 amino acids, a variable amino acid
length collagen-like domain located in the center of the sequence (CLR), and
a 134 amino acid carboxy-terminal domain (CTD).96,98 The CLR varies from
17 - 91 amino acids and is responsible for the variation in length of the hair-
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like naps on the exosporium of 140 - 608 Å.108 rBclA in E. coli was found to
form trimers which are sensitive to collagenase and have characteristic CD
spectra similar to animal collagen.99 The Tm of the CLR was determined to be
37 °C and the entire rBclA trimer has a Tm of ~ 90 °C, which is greater than
seen in animal collagens.99 The high Tm for the triple helix structure is due to
the strong interactions of the CTD.  It is believed that these strong interactions
present in the CTD aid in the spontaneous refolding of the CLR after
denaturation.99
Within the CLR region of BclA, the majority of Gly-Xaa-Yaa repeats are
Gly-Pro-Thr repeats.  There is a high Pro content of ~ 25 % in BclA and the
Thr residues have been shown to be sites for O-glycosylation.83,98 Two O-
linked oligosaccharides were identified on BclA, a 715 Da tetrasaccharide and
a 324 Da disaccharide.  The 715 Da sugar is a novel sugar not seen in other
members of the Bacillus family and was given the name anthrose.83 This
sugar was found solely linked to the Thr residues present in the Gly-Pro-Thr
repeat sequences within the CLR.  The 324 Da sugar was found to attach
outside of the CLR.  The function of the glycosylation of BclA is still to be
determined, but may be involved in the stability of the triple helix.83
Glycosylation involvement in triple helix stability has been studied with
model peptides.84 Proteins with O-glycosylation have been shown to have
higher resistance to enzyme degradation.  Peptides Ac-(Gly-Pro-Thr)10-NH2
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and Ac-{Gly-Pro-Thr(Gal!)}10-NH2 were synthesized and characterized with
CD and NMR.  Only Ac-{Gly-Pro-Thr(Gal!)}10-NH2  was found to form a triple
helix similar to collagen in the absence of Hyp.84 One possible mechanism for
the triple helix formation in the glycosylated peptide is that the galactose
restricts the conformational space available in the polypeptide backbone
similar to what is seen with Pro and Hyp in the pyrrolidine ring.84 The increase
in stability seen in the glycosylated peptide may also be due to the increase in
hydrogen bonding of the sugar moiety to the polypeptide backbone creating a
more ordered structure.84
Animal collagens are known to require Hyp at the Yaa position for
stable, correctly folded collagen.  However, bacterial systems have shown
that in the absence of Hyp at the Yaa position they can still form stable
collagens with characteristics similar to animal collagens. Though rare,
evidence of Hyp at the Xaa position does occur in nature, most commonly in
invertebrates.87,109 We believe hydroxylation is occurring in bacterial systems
at the Xaa position to further stabilize the triple helix.
2.4.3 Hyp at the Xaa Position in Invertebrates
Vent worms exist in harsh environmental conditions with minimal
oxygen and fluctuating temperatures from 20 - 70 °C. The tube worm Riftia
pachyptila contains both a cuticle collagen localized on the worm surface and
an interstitial collagen located in the body wall underneath the epidermis.86
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The interstitial collagen has a Tm of 29 °C and hydroxylation exclusively at
the Yaa position.86 The cuticle collagen shows a higher Tm of 37 °C, lower
Hyp content and higher Thr content (200/1000) with 80 % being
glycosylated.86 Similar to BclA, Gly-Xaa-Thr repeats have been seen in the
cuticle collagens of deep-sea vent worms with some of the residues in the
Xaa position identified as Hyp.86,110 Earthworm P4H from Lumbricus terrestris
has also been shown to hydroxylate at the Xaa in its cuticle collagens.87
Tripeptides Gly-Hyp-Ala 111 and Gly-Hyp-Ser 112 were both isolated from
collagenase digests from earthworms in quantities of 10 % and 15 % Hyp.
Earthworm P4H has shown to hydroxylate at the Xaa position if the Yaa
position is a primary amino acid.  However, if the Yaa position is occupied
with a Pro residue it will preferentially hydroxylate the third position.87
Unhydroxylated natural collagen was used as an in vitro substrate as (Gly-
Pro-Pro)n repeats are rare or nonexistent in earthworm cuticle collagen.87,113
Further studies by Bann and Bachinger investigated the position of
Hyp at the Xaa position with and without glycosylation of Thr residue at the
Yaa position.85 The calculation study has shown that {Gly-Pro-Thr(!Gal)}10
has a Tm ~ 20 °C lower than {Gly-Hyp-Thr(!Gal)}10 and Hyp in the Xaa
position actually increases triple helix stability when Yaa is occupied by an
amino acid other than Pro.85 This is most likely due to the stereoelectronic
inductive effect in which the OH group draws the electrons from the imide
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bond and favors the trans isomer.114 All of the peptide bonds in the triple helix
are trans, and an increase in trans isomer increases the overall stability of the
triple helix.85
2.5 Conclusions and Future Directions
Our results show that there is a significant amount of Hyp associated
with sporulation in B. anthracis.  This strongly suggests that a P4H-like
protein able to catalyze the formation of Hyp exists in B. anthracis.  Studies
show that P4H can hydroxylate in the Xaa position in lower order organisms
and that Hyp in the Xaa position adds to the stability of these triple helices
when Yaa is a primary amino acid.
BclA does form strong triple helices on the hair-like naps of the
exosporium, which suggests that this is the natural substrate for anthrax-P4H.
The genome of B. anthracis does contain several predicted amino acid
sequences that contain proline-rich repeats that are annotated as collagen-
like proteins which may serve as substrates for anthrax-P4H
(http://www.tigr.org/CMR).115
We have not been able to identify the protein associated with Hyp to
date, but will undertake a proteomics approach to identify binding partners.  In
collaboration with Dr. George Stewart (University of Missouri), a p4h gene
knockout of B. anthracis has been developed.  We believe the levels of Hyp
will be negligible with the knockout as the gene responsible for Hyp is
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eliminated, providing conclusive evidence that P4H is responsible for the Hyp
formation.
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Chapter 3: Expression, Purification, and Biochemical Characterization
of a Collagen Prolyl-4-Hydroxylase Like Enzyme from Bacillus anthracis
3.1 Introduction
Collagens and collagen-like proteins are essential to provide structural
integrity and tensile strength for muscles and tissues in animals.2 The triple
helix structure of collagen is stabilized by Hyp at the Yaa position of (Gly-Xaa-
Yaa)n repeats, where Xaa is often Pro.2 Procollagen-P4H is the enzyme
responsible for the post-translational oxidation of Pro.  In humans, P4H is a
240 kDa #2!2 tetramer, where the !-subunit is a protein disulfide isomerase
(PDI) that serves to keep the #-subunit correctly folded and to retain the
tetramer in the endoplasmic reticulum.35,116 The #-subunit contains the active
site for Pro hydroxylation as well as a separate peptide-binding domain (PDB:
ITJC).117 Procollagen-P4Hs are also found in a variety of invertebrates that
contain collagen such as nematodes, sponges, mollusks, and worms, all that
contain collagen.36,107,118,119 Earthworm cuticle collagen has been found to
have hydroxylation predominantly occurring at the Xaa position rather than
the Yaa position.87,111 Deep sea vent worms have also been shown to contain
collagen that has Hyp at the Xaa position, when the Yaa position is Thr.86,110
Recombinant P4Hs from algae have also been shown to preferentially
hydroxylate Pro at the Xaa position.72
Several expression systems for a recombinant form of human-P4H-1
have been reported.  A baculovirus expression system using an Sf9 insect
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cell line and a yeast expression system are reported but the yields of the
isolated protein is low (~ 5 mg/L of culture) and no details for the purification
procedures are reported.120,121 In 2004, an E. coli expression of human-P4H-1
tetramer was reported.89 The expression vector contained mutations in the
thioredoxin reductase and glutathione reductase genes in order to increase
disulfide bond formation in E. coli.89 Site-directed mutagenesis studies have
shown that Cys276 and Cys293, and Cys486 and Cys511 (human-P4H
numbering) form disulfide bonds that are essential to the formation of an
active tetramer.122,123 The full-length form of human-P4H was expressed in
Origami BL(DE3) E. coli cells and the isolated proteins showed kinetic
properties similar to those obtained for human-P4H expressed in the
baculovirus expression system.89,121 The E. coli expression system yields only
1.5 mg/L of protein per liter of culture, which is not a high enough
concentration suitable for spectroscopic studies.  An alternate E. coli
expression for human-P4H was reported by Myllyharju and coworkers, in
which they obtained 25 mg/L of protein per liter of culture using a fermenter.88
This human-P4H was expressed in a double mutant of E.coli lacking both
thioredoxin reductase and glutathione reductase.  However, we have not
been able to reproduce the protein yield to date.
A recombinant expression system for human-P4H in E. coli has also
been developed by Dr. Hirakawa of the Limburg Lab (unpublished results).
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The vector contains promoters which express both the # and ! subunits
separately.  This expression system yields 5 mg of protein per liter of culture.
 A. thaliana,69,70 C. reinhardtii,72 and PBCV-173 all contain a monomeric
P4H which have about 30 % sequence identity to the C-terminal catalytic
domain of the #  subunit of human procollagen-P4H, but have distinct
substrate specificities from the human enzyme.  These P4Hs are currently
used as models to study human-P4H for spectroscopic and structural studies.
Plants and green algae contain HRGPs in the extracellular matrix.69,72 Two
forms of P4H from A. thaliana, At-P4H-1, and At-P4H-2, have been cloned
and characterized. Both of the proteins were expressed in Sf9 insect cells and
expressed as the soluble form only at low yields, as most of the protein was
expressed as inclusion bodies.69,70 Neither of the proteins were purified to
homogeneity. The crude mixture was used to examine the substrate
specificities of both proteins and found to differ significantly from that of
human-P4H.  Ten P4Hs have been identified in the C. reinhardtii genome, the
recombinant forms of one of the 10 P4Hs have been expressed both in Sf9
insect and E.coli cells, purified, and biochemically characterized.72 However,
the recombinant proteins hydroxylate HRGP motifs and collagen-like
peptides, which differ from (Gly-Pro-Pro)n peptide used in assays for human-
P4H.
56
A P4H from PBCV-1 produces soluble, monomeric protein that
hydroxylates collagen-like repeats located in the viral genome.73 The natural
substrate and current biological significance of P4H in PBCV-1 is not known.
Therefore, hypothetical proteins containing collagen-like sequences from the
genome were synthesized and used as potential substrates in the in vitro
activity assay.  The enzyme binds (Gly-Pro-Pro)10 with a Km of 2.9 mM, which
is 150-fold higher than human-P4H.40,73 Spectroscopic characterization of
PBCV-PH identified two chemically competent intermediates using stopped-
flow UV-vis, and Mössbauer spectroscopy.124 The first intermediate was
assigned as an Fe(IV)=O species.124 The high 2H-KIE also provided evidence
that the Fe(IV) activates the substrate through H-atom abstraction.124 The
second intermediate was identified as a high spin Fe(II) and assigned as a
Fe(II)·product complex with comparison of the data with TauD.32,124,125
In this chapter, we describe the characterization of a P4H-like protein
from B. anthracis (anthrax-P4H).  We have found that anthrax-P4H is an #2
homodimer #KG/Fe(II)-oxygenase that can catalyze the oxidation of
ascorbate and glutathione. Kinetic studies show that a (Gly-Pro-Pro)10
peptide, a common in vitro substrate for mammalian P4Hs, increases the rate
of O2 consumption in the presence of glutathione and exhibits Michaelis-
Menten kinetic behavior. This is the first report of a P4H-like protein from a
bacterial source.
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3.2 Materials and Methods:
3.2.1 Cloning, Expression, and Purification of N-terminally His-tagged
Anthrax-P4H.
The 651 bp ORF encoding the putative p4h gene (BA 4459) was
provided to us in Gateway (Invitrogen) entry vector pDONR21 by the TIGR-
PFGRC (Maryland).  We initially subcloned the gene into Gateway plasmid
pDEST-17 (Invitrogen), which contains an N-terminal His-tag for protein
expression in E. coli using the LRII clonase reaction.  A 150 ng aliquot of the
gene was mixed with 300 ng pDEST-17 vector and 2 µL LR clonase II
enzyme.  This mixture was incubated at 15 °C overnight to ensure completion
of the reaction.  The reaction was stopped with the addition of 1 µL proteinase
K, vortexed briefly and incubated at 37 ºC for 10 minutes according to
standard reaction protocols.
After the completion of the LR clonase II reaction, the recombination
reaction was transformed into competent DH5# E. coli cells (Invitrogen).
Transformed cells were analyzed by colony PCR, and the plasmids were
isolated from the overnight culture LB-ampicillin (LB-amp) of the positive
colonies. The pDEST-17 expression plasmid was transformed into BL21-AI
(Invitrogen) competent E. coli cells. Starter cultures (100 mL) were made in
LB-media containing 100 µg/mL ampicillin.  Ten mL of the starter cultures
were used to inoculate 1 L of LB-media containing 100 µg/mL ampicillin.
Cells were grown at 37 ºC until the OD600 reached 0.6 at which point they
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were induced with 20% L-arabinose to a final concentration of 0.2%.  After
induction, cells were incubated at 37 ºC for 3 hours and then harvested by
centrifugation at 8,000 rpm at 4 ºC for 20 minutes.  Cells were frozen at - 80
ºC until ready for use.
Cells were resuspended in 40 µM imidazole, 0.5 M NaCl and 20 µM
KPi (pH 7.4) containing protease inhibitors (1 mM PMSF, 1 mM leupeptin, 1
mM antipain, 1 mM pepstatin), lysozyme, and DNAse and RNAse.  Cells were
lysed by ultrasonic disruption and centrifuged at 20,000 rpm at 4 ˚C for 1 hour
in order to separate the soluble from insoluble portions of the cells.  Once
separated, both the soluble and insoluble fractions were analyzed by SDS-
PAGE to determine if anthrax-P4H was expressed as a soluble protein.  The
soluble portion was concentrated down to 10 mL using 10,000 MWCO
Amicon concentrators.
Recombinant His-anthrax-P4H was purified using a HisTrap HP (GE
Biosciences) Ni+2 Sepharose column. The protein was loaded onto the
HisTrap HP column equilibrated with binding buffer (20 mM sodium
phosphate, 0.5 M NaCl, 40 mM imidazole, pH 7.4).  Unbound proteins were
removed by washing with 5 column volumes of the binding buffer.  Increasing
the concentration of imidazole to 500 mM over 5 column volumes eluted His-
anthrax-P4H.  The fractions were analyzed with SDS-PAGE and those
containing pure protein were pooled, concentrated using 10,000 MWCO
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Amicon concentrators and desalted using a HiTrap Desalting (GE
Biosciences) column to remove the imidazole. The fractions containing
impurities were loaded on a Superdex 16/60 Size Exclusion column fitted to
an FPLC (Akta), and eluted with 50 mM KPi, 150 mM KCl, pH 7.0.  Additional
purifications were performed as above with the addition of 2 % Triton-X 100 in
an attempt to increase solubility. Fractions containing His-anthrax-P4H (>
99% purity) were combined, made 20% v/v with glycerol, concentrated to > 30
mg/mL and frozen at -80 ˚C.  Protein concentration was determined with the
BCA assay (Pierce) using BSA as the protein standard, and had an average
yield of 5 mg of protein per liter of culture.
3.2.2 Cloning, Expression, and Purification of Native Anthrax-P4H.
Precipitation was seen with the N-terminally His-tagged anthrax-P4H
protein. Therefore we decided to prepare an untagged version of the putative
anthrax-P4H.  The p4h gene was cloned using traditional methods.  PCR
primers (forward 5'-CATGCCATGGCAAACAACAATCAAATAGG-3' and
reverse 5'-GGAATTCCATATGGCCAACTTTGTACAAGAAAGC-3') were
designed to clone the gene between the NcoI and NdeI sites of pET15b
(Novagen) in order to express the recombinant protein without the N-terminal
His-tag. The NcoI and NdeI restriction recognition sites are underlined.  The
PCR product was initially ligated into pGEMT-Easy (Promega), and then
transformed into competent DH5# E. coli cells to select for expression clones.
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Transformation colonies were analyzed with colony PCR.  Purified plasmid
was sequenced in the forward and reverse direction (DNA sequencing facility
at University of California, Berkeley) and then subcloned into pET15b.
 The pET-15b expression vector encoding for the expression of the
putative anthrax-P4H was transformed into E. coli strain BL21(DE3)
(Novagen). A single colony from an LB-amp agar plate was used to inoculate
a 90 mL LB-amp starter culture, which was incubated at 37 ˚C overnight.
Aliquots of 15 mL of the overnight culture were used to inoculate 6 x 1.5 L of
LB-amp media. The cultures were incubated at 37 ˚C to an OD600 of 0.6, and
protein expression was induced by addition of 200 µM isopropyl-!-D-
thiogalactopyranoside (IPTG). The cultures were incubated at 37 ˚C for 3
hours after induction, at which point the cells were harvested by
centrifugation.
Cells were suspended in lysis buffer: 50 mM Tris (pH 7.4), 1 mM
EDTA, 5 mM !-mercaptoethanol, containing protease inhibitors (1 mM PMSF,
1 mM leupeptin, 1 mM antipain, 1 mM pepstatin), lysozyme, and DNase and
RNase. The cells were lysed using a sonifier (Branson) and then centrifuged
at 24,000 g for 1 hour at 4 °C.  The crude cell lysate was loaded onto a 100
mL DEAE-sepharose column (Tosoh Biosciences).  The column was washed
with three volumes of lysis buffer and then the protein was eluted with a four
column volume gradient rising from 0 - 250 mM KCl. Fractions containing
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anthrax-P4H were identified by SDS-PAGE, pooled, concentrated (Amicon)
and then loaded onto a HiLoad Superdex 200 column (Amersham) connected
to an Akta FPLC. Anthrax-P4H was eluted with 50 mM Tris buffer (pH 7.4)
containing 150 mM KCl and 5 mM !-mercaptoethanol, and the fractions
containing highly pure anthrax-P4H (> 99 % purity) were combined,
concentrated to > 20 mg/mL, and stored frozen at 4 ˚C.  Due to the presence
of ! -mercaptoethanol as a reducing agent in our buffers, protein
concentration was determined with Bradford assay (Pierce) using BSA as the
protein standard.  Standard yield for this protein prep is 10 mg protein per liter
of culture.
3.2.3 Quaternary Structure Determination of Native Anthrax-P4H
3.2.3.1 Gel Filtration
The molecular weight (Mr) of anthrax-P4H was estimated by gel-
filtration chromatography using a HiLoad Superdex 200 column (GE
Biosciences) connected to an Akta FPLC.  Low and High molecular weight
standards (GE Biosciences) were used to calibrate the column and the
approximate Mr of anthrax-P4H was determined from the retention time.
3.2.3.2 MALDI-TOF MS
The protein samples were submitted in the presence and absence of
!-mercaptoethanol for MALDI-TOF mass spectrometry (KU Proteomics
Facility). !-Mercaptoethanol was removed from the purified anthrax-P4H by
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dialysis overnight against 50 mM Tris buffer, pH 7.4 at 4 °C. The solution of
anthrax-P4H (100 µM) was diluted to 2 µM with Milli Q water. The protein
sample was mixed with the matrix (sinapinic acid, 20 mg/mL in 1 M
ammonium citrate, adjusted to pH 7 with ammonium hydroxide) at a 1:1 ratio,
and spotted on a stainless steel MALDI sample plate. Analysis was performed
using a MALDI TOF mass spectrometer (PerSeptive Biosystems, Voyager-
DE STR). The instrument was operated in positive linear mode with the
following parameters: accelerating voltage 25 kV, grid voltage 90%, guide
wire 0.1% and extraction delay time 500 nsec. Acquisition mass range was
5,000-80,000. External mass calibration was performed using m/z 12361.1
and 24722.2 ions of cytochrome c immediately prior to the analysis of
anthrax-P4H samples.
3.2.3.3 Monomer-Dimer Equilibrium Constant Determination
The purified anthrax-P4H in 150 mM KCl, 5 mM !-mercaptoethanol in
50 mM Tris buffer at pH 7.4 was placed in Ultracel YM30 membrane, MWCO
of 30,000 (Millipore) and centrifuged at 10,000 g for 15 min at room
temperature. The experiments were performed at three different
concentrations of anthrax-P4H with the corresponding buffer blank. The
sample remaining on the membrane and in the flow-through were diluted with
the corresponding buffer blank to 100 µL and the absorption at 280 nm was
measured. The concentration of each fraction was determined using the
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extinction coefficient for anthrax-P4H approximated, $ = 45,100 M-1cm-1
where we assume the $ value of the dimer is twice that of the monomeric form
of anthrax-P4H. The apparent dissociation constant (
! 
Kd
app) was determined by
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3.2.4 Preparation of C53S and C53A Mutants of Anthrax-P4H
Site-directed point mutations were incorporated into the expression
vector of the wild-type (WT) as a template using the QuikChange method
(Stratagene). For C53S, two complementary primers, forward primer: 5'-
GGAAATGTATTAAGTGATGAAGAGAGTGATGAATTAATTGAA-3' and
reverse primer 5'-TTCAATTAATTCATCACTCTCTTCATCACTTAATACATTT
CC-3' were used.  For C53A, forward primer: 5'-GTATTAAGTGATGAAGAG
GCTGATGAATTAATTGAATTG-3', and reverse primer 5'-CAATTCAATTAAT
TCATCAGCCTCTTCATCACTTAATAC-3'. The resulting plasmids were fully
sequenced and the point mutations were confirmed. The mutant proteins
were expressed and purified as described for the WT.
3.2.5 Anthrax-P4H Activity Assays
The activity of anthrax-P4H was assayed using a fluorometric detection
of # KG consumption,126 a coupled assay employing L-glutamic
dehydrogenase (Sigma Aldrich) to detect #KG or by an O2 sensitive Clark-
type electrode (Hansatech, UK).
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3.2.5.1 Fluorescence Assay
Schofield has reported an assay for monitoring #KG/Fe(II) oxygenase
activity based on the formation of a fluorescent product from the reaction of
#KG with o-phenylenediamine (OPD).126 This assay was used in the initial
screening of anthrax-P4H.  Limits of the assay were determined with an #KG
standard curve. Two-hundred µL of #KG standards (0-2 mM) were incubated
at 37 °C for 15 minutes after which time the reaction was quenched with the
addition of 400 µL 0.5 M HCl. Derivatization was initiated with the addition of
200 µL 10 mg/mL OPD in 0.5 M HCl and heated for 10 min at 95 °C. The
sample was centrifuged at 10, 000 g for 5 min, and the supernatant (600 µL)
was neutralized with 300 µL of 1 M NaOH and fluorescence was measured
on a Quantamaster-3 (QM-3) Scanning Luminescence Spectrofluorometer
with FeliX32 software (Photon Technology International, Birmingham, NJ)
with the excitation filter at 340 nm and the emission filter at 420 nm.  Samples
were run in triplicate.
Anthrax-P4H activity was measured within the detection limit of the
assay as determined above.  Ten µM anthrax-P4H was pre-incubated with 2
µM Fe2SO4 (prepared as 500 µM stock in 20 mM HCl and diluted with water)
at 37 °C for 5 min to ensure complete Fe(II) incorporation into the enzyme.
The reaction was initiated with the addition of 20 µl of enzyme/iron mixture to
180 µL of the substrate/#KG mixture pre-equilibrated at 37 °C for 5 min
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containing 750 µM DTT, 750 µM #KG, substrate, and 50 mM Tris buffer, pH
7.4. The absorbance change was monitored at various time points, the
reaction was quenched, and the product was derivatized and neutralized as
described above.  Data was also collected as described above.
3.2.5.2 UV-Vis Spectroscopy Coupled Assay
The fluorescence assay as described above did not yield reproducible,
consistent results in our hands therefore we developed a new, convenient
and highly reproducible assay for enzyme-based detection of #KG that
requires neither radioactivity nor derivatization. The coupled assay employs
L-glutamic dehydrogenase (Sigma Aldrich), which catalyzes the reductive
amination of #KG in the presence of 40 mM NH+4 and 80 µM NADH.  The
reaction can be monitored by the loss of absorbance at 340 nm
corresponding to the oxidation of NADH.  A standard curve was prepared to
correlate the consumption of #KG (5 - 50 µM) to the consumption of NADH.
Aliquots of #KG were added to a solution containing NH4Cl (100 mM), NADH
(80 µM), 0.3 mg L-glutamic dehydrogenase, Fe(NH4)2(SO4)2 (10 µM), sodium
ascorbate (500 µM), and EDTA (100 µM) in 50 mM KPi ( pH 7.0), with a total
volume of 800 µL. The Fe(II), ascorbate, and EDTA were added as they
would be carried over from the anthrax-P4H activity assays (see below).
Reactions were incubated at 30 ˚C in a cuvette while monitoring the
absorbance decrease at 340 nm. The reactions were typically complete within
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30 seconds.
To assay for the consumption of #KG by anthrax-P4H, anthrax-P4H
(20 µM) was added to 50 mM Tris buffer (pH 7.4) containing sodium
ascorbate (100 µM), and #KG (750 µM). The reaction was initiated by the
addition of 40 µM Fe(NH4)2(SO4)2 from a 20 mM stock solution in 0.2 N HCl.
The reaction mixture was incubated for 10 minutes at 37 ˚C and the reaction
was quenched by the addition of 1 mM EDTA. The amount of residual #KG
was monitored by adding the entire reaction mixture to 750 µL of 50 mM Tris
buffer (pH 7.4) containing NH4Cl (100 mM), NADH (80 µM), and 0.3 mg L-
glutamic dehydrogenase as described above.
3.2.5.3 O2 Electrode Assay
The O2 consumption by P4H was monitored by PC operated Oxygraph
oxygen electrode control unit where!the S1 Clark-type electrode disc was
mounted in DW1/AD liquid-phase oxygen electrode chambers (Hansatech
Instruments Ltd, UK). Temperature control of the sample and S1 Clark-type
polarographic oxygen electrode disc are achieved by connecting the water
jacket on the electrode chamber to a thermostated circulating water bath at
3 7  °C. A 500 µL of 50 mM Tris buffer (pH 7.4) containing variable
concentrations of #KG, sodium ascorbate, glutathione, and (Gly-Pro-Pro)10,
were equilibrated with air. Fe(NH4)4(SO4)2 was then added and the
background O2-consumption was measured for one minute. An aliquot of
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anthrax-P4H was added to a final concentration of 5 µM and the initial rate
was determined between 30 seconds to 1 minute of reaction time.
3.2.6 Anaerobic UV-vis Spectroscopy Monitoring Anthrax-P4H Cofactor
Binding
UV-vis spectra were recorded on an Agilent 8453 spectrophotometer
at 30 °C.  A 100 µL aliquot of 1 mM anthrax-P4H in 50 mM Tris buffer (pH
7.4) containing 2 mM sodium dithionite was placed in a septum-rubber sealed
50 mL cuvette and was degassed by gently purging with O2-free Ar for 30
min. The blank was taken with this anthrax-P4H solution. An equivalent molar
of Fe(II) was added by syringe from a degassed 100 mM stock solution in 20
mM HCl and the spectrum of the Fe(II)/anthrax-P4H binary complex was
recorded immediately. An equivalent molar of #KG was then added from a
degassed 50 mM stock solution in 50 mM Tris buffer (pH 7.4) and the
spectrum of the #KG/Fe(II)/anthrax-P4H ternary complex was recorded. After
10 minutes, the cuvette was open to air and additional spectra were taken
immediately and 10 minutes later.
The effect of binding of (Gly-Pro-Pro)10 peptide to the UV-vis
absorption spectrum of #KG/Fe(II)/anthrax-P4H ternary complex was also
studied under anaerobic conditions. A 25 mM imidazole buffer (pH 7.0)
containing 50 µL of 1 mM anthrax-P4H, 50 µL of 2 mM (Gly-Pro-Pro)10
peptide and 2 mM sodium dithionite was prepared anaerobically as described
above, yielding a 1:2 molar ratio of enzyme to substrate. Equal molar
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equivalents of Fe(II) and #KG to the enzyme were added under anaerobic
conditions as described previously to a final concentration of 0.5 mM. The
spectra were recorded repeatedly over a 15 min period. Binding studies were
also performed with the inhibitors N-oxaylglycine (Alexis Biochemicals),
DMHP (Calbiochem), and ciclopirox olamine (Sigma Aldrich).
3.2.7 UV-vis Spectroscopic Titration of Anthrax-P4H with #KG
An 1 µL of degassed stock solution of 200 mM sodium dithionite in 25
mM imidazole buffer (pH 7.0) and 100 mM Fe(NH4)4(SO4)2 in 2 N HCl was
added to the degassed anthrax-P4H solution prepared as above and the
spectrophotometer was blanked with this solution. 1 µL of degassed 20 mM
#KG stock solution was then added to the enzyme solution by syringe and the
spectrum was recorded immediately. Additional aliquots of the buffered #KG
stock were added to the sample and spectra were recorded until no further
spectral change was observed. The titration data were fitted to Equation 2
using KaleidaGraph, where "A510max is the maximum absorbance change at
510 nm, [ET] is the total enzyme concentration equal to 1.0 mM, [LT] is the
total ligand (#KG) concentration and Kd is the apparent ligand affinity. The
error bars represent the standard deviations from three independent
experiments.  Equation 2 is fit to a single line to determine the binding affinity
of #KG to anthrax-P4H.
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3.2.8 Determination of Fe(II) Binding Stoichiometry
The binding stoichiometry of Fe(II) to anthrax-P4H was assessed by
the Fe(II) concentration dependency of the initial rate of the uncoupling
reaction.  A solution of anthrax-P4H and molar equivalents of Fe(II) were pre-
incubated at 30 °C for 10 minutes. In order to minimize the oxidative
chemistry of Fe(II), apo-anthrax-P4H was reconstituted with Fe(II) in small
quantities, and used within 30 min. The mixture was transferred to the O2
electrode chamber containing #KG and sodium ascorbate, and initial rates
were recorded. The assay mixture contained 10 µM anthrax-P4H, 750 µM
#KG, 50 µM sodium ascorbate, and equivalents of Fe(NH4)4(SO4)2 ranging
from 0.2 - 3 mM. Initial rates were determined by subtracting background
rates due to oxygen consumption in the presence of Fe(II) in the absence of
the enzyme. The initial rates were plotted against the concentrations of Fe(II).
3.2.9 pH-Dependency of the Initial Rate of the Uncoupling Reaction
Catalyzed by Anthrax-P4H
The assay solution contained 5 µM anthrax-P4H, 750 µM #KG, 50 µM
sodium ascorbate, and 25 µM Fe(NH4)4(SO4)2 in 50 mM buffers at varying
pHs. NaOAc was used for pH 5.0, MES was used for pH 6.0, HEPES was
! 
"A510 = "A510
max{ ([ET ]+[LT ]+ Kd )
# [ET ]+[LT ]+ Kd( )
2
# 4[ET ][LT ] } /2[ET ]       (2)
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used for pH 7.0, Tris was used for pHs 8.0 and 9.0 and CAPS was used for
pH 10.0. The reactions were run in triplicate at each pH. Analysis of the pH
dependence of the initial rate was done by non-linear least squares fitting of
the data to Equation 3 using KaleidaGraph.
  
! 
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3.2.10 Initial Screening of Potential Substrates
Initial activity assays were run using poly(L-proline) (1 mg/mL) as the
substrate.  Poly(L-proline) acts as an inhibitor in human-P4H, however, plant
and viral P4Hs can use it as a substrate.  We obtained inconsistent results
using poly(L-proline) in our assays.  We therefore looked into the genome of
Bacillus anthracis for potential substrates.
3.2.10.1 Expression and Purification BclA
BclA gene BA1222 from Bacillus anthracis cloned into pQE-30
(Qiagen) expression vector containing a N-terminal His-tag was a kind gift
from Dr. George Stewart at the University of Missouri-Columbia.
Colonies were transformed into M15 (Qiagen) E. coli competent cells
and grown in LB-media containing 100 µg/mL ampicillin and 25 µg/mL
kanamycin.  Cells were grown at 37 °C to an OD600 of 0.6 and induced with
IPTG to a final concentration of 1 mM.  Cells were maintained at 37 °C for 1.5
hours, harvested, and frozen at -80 °C.   Though native BclA is known to be
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heavily glycosylated, no glycosylation occurred on the protein due to
synthesis in E. coli.  BclA was purified with His-Tag chromatography as
previously described. Additional impurities were removed by incubation at 70
°C for 8 min, followed by centrifugation at 10,000 g for 10 min at 4°C as
previously reported.99 Solubility of BclA was improved with the addition of 0.1
% Triton X-100 to all purification buffers.
3.2.10.2 Synthetic (GPT)5 and Collagen-Like Sequences from B.
anthracis Genome
The (Gly-Pro-Thr)5 pept ide was synthesized at the
Biopolymer/Genomics Core Facility at the University of Maryland. Other
peptides were synthesized at the Biochemical Research Service Laboratory




All were all tested as potential native substrates for recombinant anthrax-P4H
using both the UV-Vis coupled assay and O2 electrode assay.
3.2.10.3 (GPP)10 Peptide from E. coli Expression and Purification
Expression of polypeptide (GPP)10 as a recombinant Thioredoxin
fusion protein in E. coli was developed in by Dr. Hirakawa in the Limburg Lab
(unpublished results).  Briefly, the plasmid was transformed into TOP10
(Invitrogen) E. coli cells.  The fusion protein was grown in TB media
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containing 100 µg/mL ampicillin at 37 °C until OD600 reaches 0.4.  Protein
production was induced with L-arabinose to a final concentration of 0.1 %,
and incubated overnight at 30 °C.
The fusion protein was purified using a HisTrap HP (GE Biosciences)
Ni2+ Sepharose column, followed by a Superdex 16/60 sizing column.  The
thioredoxin fusion protein was cleaved off of the polypeptide with the enzyme
Enterokinase (Invitrogen) and incubated overnight at 37 °C.  The cleaved
thioredoxin and (GPP)10 were separated with a Superdex 16/60 sizing column
and fractions containing (GPP)10 were dialyzed into water.  The (GPP)10 mass




A BLAST search using the amino acid sequence of the # subunit of
type(I) human-P4H against bacterial genomes retrieved a similar sequence
from B. anthracis that was annotated as a p4h. The # subunit of human
type(I)-P4H (human-P4H-1) contains a separate collagen binding domain and
an active site domain at the C-terminus.127 Anthrax-P4H lacks the separate
collagen-binding domain similar to plant, algae, and viral P4Hs.
Figure 3.1 shows the amino acid sequence alignment for the putative
anthrax-P4H with the C-terminal end of the # subunit of human-P4H-1, A.
thaliana-P4Hs (At-P4H-1, At-P4H-2), PBCV1-P4H, and C. reinhardtii-P4H
(Cr-P4H-1). Anthrax-P4H shares 30 % sequence identity with PBCV1-P4H
and the C-terminal domain of the # subunit of human-P4H-1, and ~ 40 %
identity with the catalytic domains of At-P4H-1, At-P4H-2, and Cr-P4H-1.
The residues comprising the facial triad that bind iron are conserved in
all of the sequences (His127, Asp129, and His193 in anthrax-P4H). The
cationic residues that are essential for binding of #KG in human-P4H-1
(Lys493 and His501, human numbering)40 are also conserved in anthrax-P4H
(Lys203 and Arg211) as well as the other P4Hs. These residues are the
minimal set that can be used to annotate a protein sequence as an
#KG/Fe(II)-oxygenase. The superfamily generally shares little sequence
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homology beyond the Fe(II) and #KG-binding sites. A recent study of the
active site structure of Cr-P4H-1 (PDB: 2JIG) suggests that two Tyr residues
(Tyr134 and Tyr168, Cr-P4H-1 numbering) are also involved in #KG binding,
where the mutation of those residues to Phe increased the Km for #KG 6- and
Figure 3.1. Amino acid sequence alignment of P4Hs. Human-P4H-1: C-
terminal catalytic domain of the a subunit of type I human-P4H, residues
243 - 512; Cr-P4H-1: P4H from C. reinhardtii, At-P4H-1 and At-P4H-2:
P4Hs from A. thaliana; PBCV: P4H from Paramecium bursaria Chlorella
virus-1.     Iron binding,    #KG binding identified in human-P4H-1, ! #KG
binding identified in Cr-P4H-1,    collagen-like peptide binding identified in
Cr-P4H-1,    collagen-like peptide binding identified in Cr-P4H-1.  The
alignment was generated using the Mutlialin program
(http://bioinfo.genotoul.fr/multalin/multalin.html).
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3.5-fold respectively, but had no affect on the Km for poly(L-proline)
substrate.90 Those Tyr residues are conserved in anthrax-P4H (Tyr118 and
Tyr149) as well as the rest of the P4Hs shown in Figure 3.1.
The structure of Cr-P4H-1 revealed an extended shallow groove lined
by two flexible loops. Point mutation of residues in the groove (Arg93, Ser95,
Glu127, Tyr140, Arg161, and His245 in Cr-P4H-1 numbering) to Ala resulted
in complete loss of activity. Therefore it is proposed to serve in collagen-like
peptide recognition/binding.90 The corresponding residues are strictly
conserved in anthrax-P4H (Arg79, Ser81, Glu111, Tyr124, Arg142, and
Arg211, anthrax-P4H numbering), human-P4H-1, At-P4H-1, and At-P4H-2. In
the PBCV1-P4H, the first two residues are Lys and Arg but the rest are
conserved. In addition, mutation of Trp99, Gln130, and Trp243 in the groove
resulted in 1.8- to 2.5-fold increase in Km for poly(L-proline) and 2- to 12-fold
decreases in kcat for the algal-P4H, suggesting that those residues also
contribute to peptide substrate binding. The corresponding residues in
anthrax-P4H are Phe85, His114, and Trp209. Taken together, these results
support that the anthrax enzyme is a procollagen-P4H.
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3.3.2 Cloning, Expression, and Purification of Putative p4h Gene from B.
anthracis
The p4h gene (Ames) was provided to us in a pDONR221 Gateway
entry vector (Invitrogen) by The Institute for Genomic Research-Pathogen
Functional Genomics Resource Center (TIGR-PFGRC) (Maryland).  We
subcloned the gene into pDEST17 (Invitrogen) containing an N-terminal His-
tag by performing a LR recombination reaction with the enzyme LR Clonase II
(Invitrogen).  Unfortunately the purified N-terminally His-tagged protein was
found to be not stable.
We subcloned the gene into the pET15b expression vector in order to
prepare an untagged recombinant protein (Figure 3.2).  We detected the
recombinant protein in the cell extract of BL21(DE3) E. coli on a SDS-PAGE
gel with an apparent Mr of ~ 28 kDa compared to a predicted Mr of 24.5 kDa.
The protein was purified to > 99% purity based off SDS-PAGE gel by anion
exchange and gel filtration chromatography (Figure 3.3). The yield of purified











Figure 3.2. PCR amplification of p4h gene resulting in 651 bp gene.
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3.3.3 Quaternary Structure Determination of Native Anthrax-P4H
The Mr of recombinant anthrax-P4H was estimated from the retention
time on the gel filtration column to be ~ 57 kDa (Figure 3.4), suggesting the
protein is a homodimer of 28 kDa subunits.
MALDI-TOF mass spectrometry was run in the presence and absence
of ! -mercaptoethanol at room temperature to determine the quaternary
structure of the recombinant anthrax-P4H (Figure 3.5). The MALDI-TOF
analysis of the recombinant protein gave a dominant signal at m/z 24329.75
that is very close to the predicted mass of the monomer of 24605.53. A signal
corresponding to the dimer is present at 48693.92. These results clearly
Figure 3.3. A SDS-PAGE gel showing the purification profile of recombinant
anthrax-P4H. Lane 1) molecular weight marker; Lane 2) crude lysate; Lane
3) DEAE column fraction; Lane 4) size-exclusion column fraction. The
recombinant anthrax-P4H  was detected as a single band with an apparent
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indicate that the recombinant enzyme is in dimer-monomer equilibrium where
the monomer is predominant under the experimental conditions tested.  The
presence or absence of !-mercaptoethanol does not affect the MS results,
indicating that the dimer interactions are not covalent via a disulfide linkage.
We examined the solution properties of the recombinant anthrax-P4H
with dialysis run at room temperature and found that anthrax-P4H exists
predominantly as the dimer form in the monomer-dimer equilibrium in the
assay condition used in this study (Figure 3.6). The equilibrium constant was
Figure 3.4. Gel filtration analysis of the recombinant anthrax-P4H by
Superdex 16/60 S-200. A) Protein standards of known molecular weight and
retention volume. B) Gel filtration trace indicating anthrax-P4H retention
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Figure 3.6. SDS-PAGE of dialysis experiment to determine monomer-dimer
equilibrium constant.  Lane 1) 1 mg/ml anthrax-P4H dimer, Lane 2) 0.5
mg/ml anthrax-P4H dimer, Lane 3) Molecular weight marker, Lane 4) 1
mg/ml anthrax-P4H monomer, Lane 5) 0.5 mg/ml anthrax-P4H monomer.
Figure 3.5. MALDI-TOF mass spectrometry gives evidence that
recombinant anthrax-P4H exists in both a monomeric and dimeric form.
Dialysis of anthrax-P4H into 50 mM Tris, pH 7.4, was performed overnight
to eliminate recombinant anthrax-P4H of !-mercaptoethanol. MALDI-TOF
MS shows that recombinant anthrax-P4H exists in the equilibrium of
dimer/monomer in the presence and absence of 5 mM !-mercaptoethanol.




































3.3.4 Preparation of C53S and C53A Mutations of Anthrax-P4H
Since the predicted amino acid sequence of anthrax-P4H contains a
single cysteine residue, Cys53, we made the C53S and C53A mutants to
probe the role of Cys53 in dimer formation. The C53S mutant protein did not
fold correctly and was expressed as an insoluble inclusion body. The C53A
mutant protein was isolated as a soluble protein and exhibited activity
comparable with the wild-type, when tested with the uncoupling and (GPP)10
reactions. We also ran the protein on a gel filtration column to determine if the
size of anthrax-P4H reduced with the mutation.  Neither the gel filtration nor
activity changed for C53A compared with wild type.  These results suggest
that the subunit interaction in the wild-type dimer is not covalent, similar to the
results seen with the MALDI-TOF MS data.
3.3.5 Anthrax-P4H Activity Monitored by Fluorometric Detection
Assays for #KG/Fe(II)-oxygenase activities have been reported based
on the release of 14CO2 from radiolabeled-#KG18 and the dabsyl-labeled
substrate used in the HPLC assay for mammalian-P4Hs.128 The derivatization
of unreacted #KG with OPD is also used to monitor #KG consumption, where
the product can be quantitated by fluorescence spectroscopy.126 The reaction
scheme is shown in Scheme 3.1.
The greater the consumption of aKG in the P4H reaction, the lower the
amount of #KG available to react with OPD and the lower fluorescence
81
intensity (FI) will be.  Therefore, we expected to see low FI values if anthrax-
P4H was active in the presence potential substrates. A standard curve was
run to determine the sensitivity and linear response of the fluorescence
assay, which was determined to be 0.1 - 0.75 mM #KG (Figure 3.7).  Initial
activity assays showed increased #KG consumption in the presence of both
poly(L-proline) and anthrax-P4H (Figure 3.8).
Scheme 3.1. Reaction of OPD with the #-ketoacid motif of 2OG to form 3-(2-
carboxyethyl)-2(1H)-quinoxalinone.
Figure 3.7. #KG standard curve employing fluorescent assay. Samples
were run in the presence of 10 mM Fe(II), 1 mM DTT, 50 mM Tris, pH 7.4.

































The uncoupled reaction of anthrax-P4H with ascorbate could not be
used with this assay because the 1,2-dicarbonyl moiety of dehydroascorbate
interferes with 1,2-diamine of OPD and therefore alters the fluorescence
detection.  The uncoupling reaction is used to monitor anthrax-P4H activity
because the native substrate of anthrax-P4H is currently not known.
Therefore, further methods for assaying the anthrax-P4H activity were
Figure 3.8. Initial activity assay of 10 µM anthrax-P4H with 1 mg/mL poly-(L-
proline) in the presence of 750 µM #KG, 750 µM DTT, 10 µM Fe(II), 50 mM
Tris, pH 7.5.  The reaction mixture was incubated at 37 °C for 5 minutes,
and quenched with 0.25 M HCl, and reacted with 5 mg/mL OPD at 95 °C for
10 minutes.  The excitation wavelength was 340 nm and emission
wavelength 420 nm.  The red line corresponds to 1 mg/mL poly(L-proline),
blue line is 10 µM anthrax-P4H, and the green line is the total reaction with



































investigated and a coupled assay using UV-visible spectroscopy was
developed.
3.3.6 L-Glutamic Dehydrogenase for an Endpoint Assay for #KG/Fe(II)-
Oxygenases
We have developed a new endpoint assay using the NADH-dependent
reductive amination of #KG by L-glutamic dehydrogenase (Scheme 3.2),
where the reaction is driven to completion by the addition of a large excess of
NADH (80 µM) and NH4Cl (100 mM).
Figure 3.9 shows the standard curve where a linear response for
NADH consumption can be achieved even when the residual #KG in the
assay solution is down to 5 µM. This is a convenient, rapid, and specific
method to quantify the remaining #KG in solution at the end of the reaction.
Since procollagen-P4H and other #KG/Fe(II)-oxygenases are known to
catalyze the oxidation of ascorbic acid coupled to the oxidative
decarboxylation of #KG, i.e. uncoupling (Scheme 1.1 B), we used the
Scheme 3.2. Reductive amination of #KG by L-glutamic dehydrogenase






















uncoupling reaction as an alternative assay to confirm that recombinant
anthrax-P4H has activity consistent with an #KG/Fe(II)-oxygenase. This
reaction serves to protect human-P4H from inactivation.22 After 30 minutes
incubation of 20 µM recombinant anthrax-P4H in a buffer containing 40 µM
Fe(II), 100 µM ascorbate and 750 µM #KG, 150 µM #KG is consumed. The
amount of #KG consumed is dependent on available amounts of ascorbate
and anthrax-P4H in the assay mixture. In control experiments in the absence
of Fe(II), no consumption of #KG was observed. These results demonstrate
that anthrax-P4H has activity consistent with an #KG/Fe(II)-oxygenase.
Figure 3.9. A standard curve for the quantification of #KG by L-glutamic
dehydrogenase. Aliquots of #KG (2 - 50 µM) were added to 50 mM KPi
buffer (pH 7.0) containing NH4Cl (100 mM), NADH (80 µM), 0.3 mg L-
glutamic dehydrogenase, Fe(NH4)2(SO4)2 (10 µM), (+)-sodium L-ascorbate
























3.3.7 O2 Electrode Assay for Anthrax-P4H Activity
Initial O2 electrode experiments were performed to optimize the
uncoupled reaction.  Variation of anthrax-P4H concentration from 5 µM -
20 µM showed that high levels of enzyme (10 µM and higher) produce fast
rates, which are too high to see major differences in the presence of potential
substrates.  5 µM anthrax-P4H was found to produce a good background rate
for monitoring the uncoupled reaction.
 The dependence of anthrax-P4H on Fe(II) was determined for the
uncoupling reaction.  Fe(II)/#KG-oxygenases require one Fe(II) molecule per
monomer.31,129,130 The Fe(II)/anthrax-P4H binary complex was added to an
assay mixture containing 750 µM #KG and 50 µM ascorbate to a final
concentration of 10 µM anthrax-P4H. We observed a linear dependence of
the initial rate on the concentration of Fe(II) up to a stoichiometric amount
(Figure 3.10).   No inhibition occurred up to three molar equivalents of Fe(II).
The O2 concentration dependency of anthrax-P4H activity was
examined. Figure 3.11 shows a trace following the consumption of O2 in a
solution containing 750 µM of #KG and 50 µM of ascorbate at pH 7.4.  When
20 µM Fe(II) is added to the solution, there was small background of O2
consumption, but when 5 µM of anthrax-P4H was present, a clear inflection
point was detected and O2 was consumed at an initial rate of 5 mol of
#KG/mol P4H/min.  The total amount of O2 consumed is 46 µM, which
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corresponds to the total available ascorbate in the reaction mixture
(background control reaction in the absence of ascorbate consumed 8 µM).
The trace plateaued after the ascorbate in the reaction mixture was all
consumed.
Figure 3.10. Effect of Fe(II) concentration on initial rates of uncoupling
reaction catalyzed by anthrax-P4H. Initial rates were measured with an O2
sensitive Clarke-type electrode. The assay solution contained 10 µM

























We have measured Km values for Fe(II), ascorbate, and #KG. These
results are summarized in Table 3.1 along with those reported for other P4Hs
discussed in this chapter. The kcat for this reaction was determined to be 1.9 ±
0.3 min-1. When either #KG or Fe(II) is eliminated from the solution, only
background O2 consumption was observed.
Figure 3.11. An O2-sensitive Clarke-type electrode trace showing the
consumption of O2 by anthrax-P4H. The reaction was initiated by the
sequential addition of 20 µM Fe(NH4)2(SO4)2 and 5 µM anthrax-P4H into
the reaction chamber containing 50 µM (+)-sodium L-ascorbate and 750


















3.3.8 pH-Dependency of Uncoupled Reaction Catalyzed by Anthrax-P4H
The effect of pH on initial rates of the uncoupling reaction was
measured between pH 5.0 and 9.0. Anthrax-P4H exhibited a bell-shaped pH
dependence of the initial rate for the uncoupling reaction with the optimum
around 7.0 (Figure 3.12). Two pKa values of 6.92 ± 0.18 and 7.17 ± 0.18 were
determined by non-linear least square fit analysis using Equation 2
(Experimental Methods).
Fe(II) was also replaced with metals Mn(II) and Zn(II) and tested for
uncoupled activity.  In the presence of either Mn(II) or Zn(II) at the same
concentration as Fe(II), activity was abolished.
Table 3.1. Km values of anthrax-P4H, human-P4H-1, PBCV1-P4H, C.
reinhardtii P4H-1 (Cr-P4H-1), A. thaliana P4H-1 and -2 (At-P4H-1 and At-
P4H-2) for cosubstrates and (GlyProPro)10















!KG 27.4 ± 15.4 22 20 250 130 170
Fe(II) 8.8 ± 0.9 4 0.4 30 16 5
Ascorbate 15.6 ± 2.5 300 300 20 300 300
(GlyProPro)10 9.1 ± 1.3 18 2900 >1500 60 2800
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3.3.9 Anaerobic UV-Vis Spectroscopy Monitoring Anthrax-P4H Binding
The amino acid sequence and catalytic activity of anthrax-P4H
suggested that it is an #KG/Fe(II)-oxygenase.  Once the Fe(II) is bound to the
facial triad of these enzymes, the next step in the catalytic cycle is the binding
of #KG to Fe(II) where the formation of the ternary complex can be followed
by the appearance of a charge transfer band at ~ 500 nm in the visible region.
The extinction coefficient of this transition is generally weak (~ 200 M-1cm-1),
but since we were able to obtain multiple milligram quantities of recombinant
anthrax-P4H, we were able to use visible spectroscopy to probe this initial
step in the characterization of anthrax-P4H.
Figure 3.12. pH dependency of initial rates of uncoupling reaction catalyzed
by anthrax-P4H. The assay solution contained 5 µM anthrax-P4H, 750 µM



















Figure 3.13 shows the visible spectrum of Fe(II)-reconstituted anthrax
P4H before and after the addition of one equivalent of #KG under anaerobic
conditions. Upon addition of #KG, a band appeared in the visible region, as
shown by the red line in Figure 3.13, with a %max at ~ 480 nm and 510 nm.
This band is not seen in the absence of the protein.
The spectrum is similar to #KG to Fe(II) charge transfer bands seen for
TauD and alkylation repair homolog 1 (AlkB).32,131 The %max of anthrax-P4H is
somewhat blue-shifted compared to those enzymes. The extinction coefficient
at 510 nm is 250 M-1cm-1, which is consistent with that observed for TauD.32















Figure 3.13. A UV-vis spectrum of the Fe(II)/#KG/anthrax-P4H ternary
complex under anaerobic conditions (red line). The final concentrations are
1mM Fe(NH4)2(SO4)2, 1mM #KG and 1 mM anthrax-P4H in 50 mM Tris
buffer (pH 7.4).  Upon exposure to air, a species with the broad absorption
with %max at ~ 600 nm builds up within ten minutes (blue line).
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oxygenase.
When air was introduced into the solution of the #KG/Fe(II)/anthrax-
P4H ternary complex, the solution turned blue (the blue line in Figure 3.13).
The resulting spectrum has a broad peak centered at 615 nm with an
extinction coefficient of 500 M-1cm-1. This spectral change is analogous to that
seen in the #KG/Fe(II)-oxygenase TfdA.132 In TfdA, the blue color is caused
by hydroxylation of a Trp residue (W112)132 where the resulting hydroxyl
group coordinates to Fe(III).  The hydroxylation occurs concomitant with
decarboxylation of #KG and the resulting enzyme is inactivated.  It is possible
that similar chemistry is occurring with anthrax-P4H and there are several
strictly conserved Trp, Tyr, and Phe residues near to the putative iron-binding
residues determined by mutagenesis in human-P4H. It is possible that similar
chemistry is responsible for the inactivation of human-P4H.
Additional characterization of anthrax-P4H was achieved by titration of
O2 free #KG stock solution into an anaerobically prepared sample of the
protein:Fe(II) binary complex. The progress of the formation of the
#KG/Fe(II)/anthrax-P4H ternary complex was monitored by UV-vis
spectroscopy (Figure 3.14 A). One equivalent of #KG is required for full
activity as determined through non-linear least squares fitting using Equation
3 (Experimental Methods). The plot of the background-corrected change in
absorbance at 510 nm (%max of the ternary complex) as a function of #KG
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concentration (Figure 3.14 B) was used to determine a dissociation constant
(Kd) for the ternary complex to be 54 ± 25 µM. Elimination of absorbance at
510 nm was observed with the substitution of Zn(II) to #KG:anthrax-P4H
complex.
The binding of (Gly-Pro-Pro)10 peptide to the anthrax-P4H/Fe(II)/#KG
ternary complex showed no detectable change in the spectrum under the
conditions tested.  The binding of inhibitors N-oxaloglycine, ciclopirox, and
DMHP also showed no spectra shifts upon binding.
Figure 3.14. UV-vis spectroscopic titration of the Fe(II)/anthrax-P4H binary
complex with #KG under anaerobic conditions. The binary complex was
prepared by incubating 1 mM each of Fe(II) and anthrax-P4H in the
presence of 2 mM sodium dithionite. A) The spectra correspond to addition
of 0.2 mM, 0.4 mM, 0.6 mM, 0.8 mM and 1.0 mM #KG (bottom to top).  B) A
plot of the absorbance change at 510 nm versus concentration of #KG. The












































3.3.10 Recombinant Bacillus (Collagen-Like Protein) from anthracis
(BclA)
The bcla gene cloned in pQE-30 expression vector, which contains a
N-terminal His-tag, was obtained from Dr. George Stewart (University of
Missouri-Columbia), and transformed into the M15 (Qiagen) E.coli competent
cells.  Expression of the 35,000 Da BclA protein was induced with 1mM IPTG
when the OD600 reached 0.6, and grown at 37 °C for 1.5 hours. BclA
polypeptide runs higher on SDS-PAGE because its monomers form triple
helical structures. The soluble fractions were analyzed by SDS-PAGE. Initial
attempts to express and purify rBclA resulted in low yield.
rBclA is hydrophobic and forms stable triple helices, which make the
polypeptide difficult to solubilize. Triton X-100 was added at 0.1 % levels to
increase solubility of the protein and the amount of rBclA present after lysis
was greatly improved.  Soluble portions of the lysate showed greater
expression levels (Figure 3.15 lane 2).  Purification was performed with a Ni-
NTA column as previously discussed with the His-tagged anthrax-P4H
(Figure 3.15 lane 3) followed by size exclusion column (Figure 3.15 lane 4)
with the addition of 0.1% Triton X-100 to all of the buffers.
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3.3.11 Substrate Screening for Recombinant Anthrax-P4H
3.3.11.1 Screening Using the Fluorometric Assay
BclA and poly(L-proline) were assessed as potential substrates using
the fluorometric assay. Though the results were difficult to reproduce, initial
testing with both BclA and poly(L-proline) showed greater activity than the
uncoupled reaction.  Figure 3.16 shows a decrease in fluorescence with an
increase in BclA concentration in the presence of 375 µM #KG, 375 µM DTT,
20 µM Fe(II), 50 mM Tris, pH 7.4, and 20 µM anthrax-P4H.  The green line
Figure 3.15. Recombinant Bacillus anthracis collagen-like polypeptide in
the presence of Triton X-100 SDS-PAGE gel.  Lane 1) Molecular weight
marker.  Lane 2) The lysate of recombinant BclA with Triton X-100. Lane 3)
Recombinant BclA polypeptide after purification with Ni-NTA affinity
column. Lane 4) is purified recombinant BclA after gel filtration
chromatography.
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represents activity seen with 0.5 mg/mL BclA, and the red line represents 5
mg/mL BclA activity.  Poly(L-proline) (yellow line) was also tested and showed
greater activity compared with uncoupled reaction, but less than seen in the
presence of BclA. These results lead us to believe that BclA is potentially a
substrate for anthrax-P4H.  Additional activity assays were used to confirm
this hypothesis.
Figure 3.16. Substrate screening using fluorescence assay.  Assays were run
in the presence of 375 µM #KG, 375 µM DTT, 20 µM Fe(II), 50 mM Tris, pH
7.4 and 20 µM anthrax-P4H.  Blue line represents no substrate, orange line
represents 1 mg/mL poly(L-proline), green line represents 0.5 mg/mL BclA




































3.3.11.2 #KG Consumption Assay Utilizing L-Glutamic Dehydrogenase
Potential substrates were screened for enzyme activity using the L-
glutamic dehydrogenase assay, which measures #KG consumption. BclA and
(GPT)5 were screened for activity in the presence of 750 µM #KG, 1 µM DTT
40 µM Fe(II), 20 µM anthrax-P4H, and 50 mM Tris, pH 7.4. In addition,
(GPT)5 was run in the presence of 750 µM ascorbate.  BclA concentrations
varying from 7 µM - 56 µM and (GPT)5  concentrations from 5 µM - 31 µM
were run in triplicate (Table 3.2), and normalized against the uncoupled
reaction.  An increase of #KG consumption was seen with increasing
substrate concentrations. As shown by the error values in Table 3.2, it was
difficult to obtain consistent results from run to run as seen with the
fluorescence assay.
Table 3.2. #KG consumption by anthrax-P4H reaction.  BclA tests were run in
the presence of 750 µM #KG, 750 µM DTT, 40 µM Fe(II), 20 µM anthrax-P4H,
50 mM Tris, pH 7.4. (GPT)5 was run with the same conditions, with the
addition of 50 µM ascorbate.
!KG Consumed
7 µM BclA 6 µM ± 2
14 µM BclA 16 µM ± 12
29 µM BclA 32 µM ± 3
43 µM BclA 83 µM ± 29
56 µM BclA 58 µM ± 43
5 µM (GPT)5 71 µM ± 1.5
10 µM (GPT)5 85.5 µM ± 15
20 µM (GPT)5 139 µM ± 45
31 µM (GPT)5 157 µM ± 39
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We also screened (GPP)10 as a potential substrate of anthrax-P4H.
Though B. anthracis does not contain high numbers of (GPP)10 repeat
sequences, this is the common polypeptide used when studying the human
form of P4H. The Km of ascorbate was determined to be 15 µM, which is
considerably lower than the value for human, viral and plant forms of P4H of
300 µM (Table 3.1). The tight binding of ascorbate in anthrax-P4H leads us to
believe that ascorbate is out competing substrate binding, and we began
screening alternate reducing agents to use in activity assays.
Glutathione is a biological reductant that is ubiquitous in the body and
responsible for eliminating oxidative stress.  We determined that in the
presence of glutathione, anthrax-P4H can turnover (GPP)10.  We used this
system to study the time course of the anthrax-P4H reaction using the L-
glutamic dehydrogenase assay.  We incubated 20 µM of the enzyme at
various time points (0 - 60 min) in the presence of 2 mM glutathione, 100 µM
#KG, 100 µM (GPP)10, 200 µM Fe(II), and 50 mM Tris pH 7.8.  Figure 3.17
shows a plot of the consumption of #KG versus time.  This assay indicates
that the turnover of (GPP)10 is slow in the presence of anthrax-P4H with only
66 µM #KG out of 100 µM #KG being consumed after 1 hour.
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3.3.11.3 Substrate Screening of Anthrax-P4H with O2 Electrode
Substrate screening continued with the use of the O2 electrode, which
allows for the analysis on O2 consumption in a real time manner. Both BclA
and (GPT)5 were screened in order to reproduce the results seen with the L-
glutamic dehydrogenase coupled assay. The hydrophobicity of the substrates
resulted in a large background reaction. Triton X–100 was added to the
reaction mixture at a final concentration of 0.1% to improve solubility, but did
not show any effect in reducing the noise level.  Testing performed showed
Figure 3.17. The consumption of #KG over time by anthrax-P4H coupled
assay. Incubation of 20 µM anthrax-P4H at various time points (0 - 60 min) in
the presence of 2 mM glutathione, 100 µM #KG, 100 µM (GPP)10, 200 µM





























minimal activity of BclA compared with the uncoupled reaction and (GPT)5
was  seen to inhibit O2 consumption (Table 3.3).
Experiments were performed using the synthetic peptides of collagen-
like repeats from the B. anthracis genome: peptide 1, peptide 2, and peptide
3. Screening with the synthetic peptides showed promising results for peptide
1 and peptide 2, but peptide 3 did not produce activity over uncoupling (Table
3.3).  Interestingly, both peptides 1 and 2 contain GPP and GPT repeats in
their sequences, similar to collagens in humans and B. anthracis.  Peptide 3
contains a single GPQ and GPA sequence, which is found in bacterial
collagen structural motifs.80,81
We tested (GPP)10  for activity and were able to obtain a Km of 9 ± 1.3
µM (Figure 3.18). It is intriguing that the Km for (Gly-Pro-Pro)10 for anthrax-
P4H is almost identical to that reported for human-P4H (Table 3.1). These
Table 3.3. O2 consumption in the presence of substrate.  Samples were run




100 µM (GPP)10 9.2 ± 1.6
100 µM (GPT)5 -4.2 ± 0.6
10 µM BclA 2.5 ± 2.2
100 µM peptide 1 3.2 ± 1.1
100 µM peptide 2 3.4 ± 1.3
100 µM peptide 3 0.1 ± 2.0
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results suggest that anthrax-P4H can indeed bind (Gly-Pro-Pro)10 as tightly as
human-P4H-1. kcat was determined to be 2.7 ± 0.3 min-1 and the enzyme
inactivates within 3 turnovers. We only see the rate increase in the presence
of all the components in the reaction mixture, which shows that this activity
depends on anthrax-P4H, Fe(II), and #KG.
These experiments did produce some significant leads in identifying
the substrate for anthrax-P4H.  However, we have not been able to detect
hydroxyproline formation from any of these reactions using the double
derivatization method discussed in Chapter 2.  Further study is required to
maximize turnover as well as determine the native substrate for anthrax-P4H.





















Figure 3.18. Kinetics for the oxidation of (Gly-Pro-Pro)10 by anthrax-P4H
fits to the Michaelis-Menten equation. The assay solution contained 5 µM
anthrax-P4H, 750 µM #KG, 20 µM Fe(NH4)2(SO4)2 and 50 µM glutathione.
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approaches using antibodies specific for hydroxyproline (Gemacbio, France)
and BclA (Dr. Stewart).
3.4 Discussion:
3.4.1 Anthrax-P4H as an Improved System to Study Human-P4H
As discussed in Chapter 2, prokaryotes were not believed to produce
Hyp and therefore not thought to contain P4H proteins. However, the genome
of B. anthracis as well as B. cereus and B. thuringenesis all contain putative
P4Hs according to National Center for Biotechnology Information-BLAST
database. Therefore we sought to clone and express a recombinant collagen-
P4H from B. anthracis, anthrax-P4H, and biochemically characterize the
protein as a potential model system to study human-P4H. Improved
spectroscopic and structural knowledge can aide in new strategies for the
design of potential therapeutic agents that target fibrosis.  We have
successfully cloned, expressed, and purified the first recombinant P4H from a
prokaryote.   Initial characterization studies show anthrax-P4H exhibits both
spectroscopic and catalytic properties characteristic of an #KG/Fe(II)-
oxygenase.
Anthrax-P4H contains 30 % identity with the C-terminal end of the #
subunit of human-P4H.  This is approximately the same identity as the viral-
and plant-P4Hs demonstrate with human-P4H. Anthrax-P4H is a highly
soluble, monodispersed protein that can be purified to > 90 % with a two
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column purification.  Due to the complexity and restricted solubility of the #2!2
human-P4H, structural determination of the entire human form involved in
collagen synthesis has not been determined.  A crystal structure of the
catalytic domain of human HIF-P4H-2 (pdb 2G1M) has been determined as
well as a monomeric algal-P4H (pdb 2JIG) from C. reinhardtii.90,133 Human
HIF-P4H-2 has only 14 % identity to human collagen-P4H and was
determined to form a separate structural subgroup distinct from collagen-
P4Hs.90,133 Algal-P4H is the only crystal structure of a collagen-P4H currently
known.  However, it is monomeric and does not have substrate specificity
similar to human-P4H.72,90 We have determined the crystal structure of
anthrax-P4H, which will be discussed in detail in Chapter 4. Together both the
biochemical characterization and the crystal structure can serve to improve
the development and design of specific fibrosis inhibitors targeting human-
P4H.
3.4.2 Anthrax-P4H can Exist as an #2 Homodimer
Through gel filtration and MALDI-TOF analysis, recombinant anthrax-
P4H was found to be a homodimer. This is the first known P4H that can exist
as a homodimer. As stated previously, the human form exists as an #2!2
heterotetramer.  The major form of P4H in Caenorhabditis elgans (C. elgans)
is a # (I)#(II)B2 tetramer, but #(I)! and #(II)! heterodimers can also be
assembled at much lower efficiency.62 This is the only known P4H that
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contains two distinct catalytic subunits and is species-specific to the
nematode.62 Plant (At-P4H-1 and At-P4H-2) and viral (PBCV-1-P4H) forms
are monomeric, #.69,70,73
Gel filtration experiments did show anthrax-P4H primarily as a
homodimer, however, MALDI-TOF MS experiments showed anthrax-P4H
predominately in the monomeric state. This may be because the MS
experiments are run under harsh conditions that can denature and dissociate
the dimer form during analysis.134,135 The matrix used was a sinapinic acid
and ammonium citrate complex adjusted to a pH of 7.0.  This matrix has been
used previously to characterize protein quaternary structure as the pH of 7.0
stabilizes the protein during MS analysis.136 The dialysis experiments resulted
in almost exclusively dimer form of the enzyme.  We believe equilibrium is
occurring between the monomeric and dimeric forms of the enzyme.
Site-directed mutagenesis experiments were performed to determine if
the dimer is stabilized through a disulfide bond.  The # subunit of human-P4H
contains five cysteine residues (Cys150, Cys276, Cys293, Cys486, Cys511)
which have been shown through site directed mutagenesis studies to be
essential in complete tetramer assembly.122,123 Two intrachain disulfide bonds
are formed between Cys276 - Cys293 and Cys486 - Cys511 in the #-
subunit.122,123 To date there is no evidence for the role of Cys150, but
mutation to Ser did cause minor structural changes.123 Anthrax-P4H contains
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only one cysteine residue in its sequence, C53.  Mutagenesis studies on this
cysteine indicate it is not contributing to the dimerization.  This supports the
theory that the dimer is formed through other forces such as hydrogen
bonding or Van der Waals forces (non-covalent dimer).  X-Ray
crystallography experiments lead to a clearer understanding of the
interactions occurring at the dimer interface and will be addressed in Chapter
4.
3.4.3 Anthrax-P4H Undergoes Uncoupling Reaction with Ascorbate
While the rate of the uncoupling reaction (oxidation of ascorbate) by
anthrax-P4H is very similar to that reported for human-P4H-1 (1.9 min-1 for
anthrax-P4H versus 4 min-1 for human-P4H-1),23 the Km for ascorbate for
anthrax-P4H is an order of magnitude smaller compared to human-P4H-1 and
is similar to that for Cr-P4H-1 (see Table 3.1).
The Km for #KG for anthrax-P4H is very similar to that of human-P4H-1
and PBCV1-P4H, but 20 to 30-fold lower than At-P4H-1, At-P4H-2, and Cr-
P4H-1.37,69,72,73 Comparison of the structures of anthrax-P4H and Cr-P4H-1
shows that the flexible loop between !-strands II-III of the core fold in Cr-P4H-
1 is  ~ 4 Å longer than anthrax-P4H. The difference in length may cause the
loop in anthrax-P4H not to be as flexible towards conformational change and
leave the active site of anthrax-P4H more exposed compared than that of Cr-
P4H-1. The entrance to the active site cavity of the two structures also show a
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difference in size, where the Cr-P4H-1 cavity is 2.3 Å smaller in diameter than
anthrax-P4H (See Chapter 4). This may explain why #KG is more accessible
to the active site cavity of anthrax-P4H than that of Cr-P4H-1. The Km for
Fe(II) for anthrax-P4H is also comparable to that of human-P4H-1 and At-
P4H-2 (see Table 3.1).37,70
We determined the pH-dependency of the initial rate of the uncoupling
reaction and obtained a bell-shaped curve with a pH optimum at 7.0 (Figure
3.12). From the nonlinear least-square fit analysis, we have determined two
pKa values, 6.92 ± 0.18 and 7.17 ± 0.18, respectively. This suggests that
there are at least two ionizable groups involved in the catalytic reaction. In the
active site of the Cr-P4H-1, two His residues can be found and those residues
are conserved in anthrax-P4H, namely His127 and His193 as part of the
catalytic triad. Asp129 also as the part of the triad can be one of the ionizable
groups, when it is involved in a hydrogen-bonding network. These residues
correspond to His412, Asp414 and His483 in human-P4H-1 which have been
identified as the Fe(II) binding site residues by the site-directed mutagenesis
study,40 where H412E, D414N and H483E mutants resulted in complete loss
of activity.40
Anthrax-P4H takes ascorbate as a presumed surrogate substrate as
has been observed for human-P4H.23,137 Ascorbate can act as an alternate
oxygen acceptor in the catalytic cycle and is consumed stoichiometrically in
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the absence of substrate.23 P4Hs are known to require ascorbate as a co-
substrate that is essential for turnover and protects the enzyme from oxidative
damage leading to inactivation.22 The mechanism for the inactivation of
human-P4H is not well understood due to the limited amount of recombinant
protein that is not suitable for spectroscopic study. It has been shown in other
#KG/Fe(II)-oxygenases that the inactivation in the absence of substrate is
due to the self-hydroxylation of a Phe, Tyr or Trp residue in the active site,
where the blue chromophore is assigned as a charge transfer complex of
hydroxylated product to Fe(III).138-140 This self-hydroxylation occurs
concomitantly with decarboxylation of #KG and resulting enzyme is
inactivated. In the absence of ascorbate, the catalytic cycle of anthrax-P4H
lead to inactivation coupled to the formation of a blue chromophore with %max
at ~ 600 nm (Figure 3.13). The absorption maximum seen in anthrax-P4H is
very close to that seen when the hydroxyl group of Tyr (hydroxylated-Phe)
and hydroxyl-Trp coordinate to Fe(III).138-140 There are several strictly
conserved Phe, Trp, and Tyr residues near the iron-binding site of anthrax-
P4H as well as in human-P4H-1. It is possible that similar chemistry is
responsible for the inactivation of anthrax and human-P4H-1.
3.4.4 Anthrax-P4H Exhibits Spectroscopic Characteristics Similar to
other #KG-Fe Oxygenases
Anthrax-P4H exhibits both spectroscopic and catalytic properties
characteristics of an #KG/Fe(II)-oxygenase. The Fe(II)-#KG binary complex
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of #KG/Fe(II)-oxygenases have a distinct visible spectrum, which can be
monitored under anaerobic conditions.
DAOCS was the first #KG-Fe(II)-oxgenase to have both its Fe(II) and
Fe(II)/#KG-bound crystal structures published.141 These results confirmed the
octahedral coordination of Fe(II) surrounded by the His-Asp/Glu-His facial
triad and water molecules.  The binding of #KG to the ferrous ion showed the
displacement of two water molecules and bidentate binding of #KG.141
Reaction intermediates have been characterized spectroscopically through
UV-Vis, CD, and MCD spectroscopy studies.26,29-31
A characteristic spectra at 500 nm is correlated to the MLCT
absorption transitions under anaerobic conditions is widely believed to
represent the bidentate binding of #KG to Fe(II)-enzyme complex.  Krebs and
Bollinger obtained this characteristic spectra at 520 nm with viral-P4H, with a
$520 = 250 M-1 cm -1, which compares closely to that obtained with anthrax-
P4H.124 The shape of our peaks showed two maxima, %max ~ 480 nm and 508
nm, and we obtained the same extinction coefficient.  The titration of #KG into
the anthrax-P4H complex resulted in a KD = 54 ± 25 µM, which compares with
viral-P4H's KD = 27 ± 6 µM
Upon exposure to air, the solution turns blue, and the absorption
spectra shifts from %max ~ 508 nm to %max ~ 615 nm with an extinction
coefficient of 500 M-1 cm -1.  Similar spectra and blue chromophore formation
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have been seen in the #KG-Fe(II) oxygenase TfDa, which exhibits a shift from
a weak transition at %max ~ 530 nm to the strong, broad signal at %max ~ 580
nm.132 Through EPR data, the blue chomophore in TfDa was shown to arise
from a high-spin Fe(III) complex resulting from the hydroxylation of an active
site Trp residue as previously discussed.
Attempts were made to examine the effect of the binding of (Gly-Pro-
Pro)10 to the UV-vis spectrum of the #KG/anthrax-P4H/Fe(II) ternary complex.
However, no spectral changes were observed.  UV-Vis spectra of viral-P4H in
the presence of substrate (Pro-Ala-Pro-Lys)3 also resulted in no noticeable
spectral changes.124 A small spectral shift was seen upon the binding of
taurine to TauD from 530 nm ($530 = 140 M–1 cm–1) to 520 nm ($520 = 40 M–1
cm–1), with more distinctive features at 470 nm and 570 nm.31 Hausinger and
coworkers were able to use 5 mM taurine in their studies, and we were only
able to use 1 mM (Gly-Pro-Pro)10 in our experiments due to the solubility of
the peptide substrate.  This may be another factor in the absence of a shift
with the binding of (Gly-Pro-Pro)10 to anthrax-P4H.
3.4.5 Potential Substrates for Anthrax-P4H
As stated previously, prokaryotes including B. anthracis, do not contain
the (Gly-Pro-Pro)n repeats involved in collagen production in humans.
However, BclA protein has been found to contain Gly-Pro-Thr repeats.98
Turnbough and coworkers found the Thr residues to have extensive
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glycosylation,96 and recombinant BclA forms trimers which are sensitive to
collagenase and exhibit CD spectrum similar to that of the collagen triple-
helix.99 Because of its collagen-like properties, we believe BclA may act as a
substrate for anthrax-P4H.  Therefore, we obtained a recombinant form of
BclA from Dr. Stewart, University of Missouri, and were able to obtain soluble
protein in low levels.  The hydrophobic nature and tightly folded trimeric
structure of the recombinant BclA resulted in a inefficient reaction with
anthrax-P4H.
Establishing anthrax-P4H as an effective model system for human-
P4H requires that the enzyme hydroxylate collagen substrates. The Limburg
lab has developed an recombinant system for (Gly-Pro-Pro)10 expressed as a
fusion protein in E. coli.  This procedure allows for the purification of milligram
quantities of substrate for assays at a fraction of the cost and time as that with
peptide synthesis. (Gly-Pro-Pro)10 was tested for activity with anthrax-P4H in
the presence of ascorbate, Fe(II), #KG, and O2.  It is known that some
#KG/Fe(II) enzymes can use co-substrates other than ascorbate, such as
DTT, to support catalysis. Of these thiol-containing reagents, glutathione, a
reductant that is present in bacteria, supported limited turnover whose rate
increased in the presence of (Gly-Pro-Pro)10, an in vitro substrate for human-
P4H. On the other hand, other proline-substrates such as poly(L-proline), an
in vitro substrate for PBCV-P4H, At-P4H-1 and At-P4H-2, and Cr-P4H-1 and
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a synthetic (Gly-Pro-Thr)5 peptide mimicking the repeat in BclA showed no
effect. O-glycosylation of Thr in the (Gly-Pro-Thr)5 may be necessary for
substrate recognition by anthrax-P4H as seen in native BclA. It is intriguing
that the Km for (Gly-Pro-Pro)10 for anthrax-P4H is almost identical to that
reported for human-P4H (Table 3.1). These results suggest that anthrax-P4H
can indeed bind (Gly-Pro-Pro)10 as tightly as human-P4H-1.
It is not yet clear if the increase in turnover represents formation of Hyp
as we have not to date detected any using standard HPLC protocols. Further,
the rate of turnover is much slower than what has been reported for other
P4Hs (2 min-1 vs > 300 min-1). One possible explanation is that (Gly-Pro-
Pro)10 binds to the anthrax-P4H and promotes the uncoupled turnover of
glutathione.  A similar phenomenon has been reported for the interaction of
poly(L-proline) with human-P4H where the former acts as an inhibitor for (Gly-
Pro-Pro)10 but promotes the uncoupled oxidation of ascorbate two-fold.23,142
The similar Km between human and anthrax-P4H for (Gly-Pro-Pro)10 is
somewhat surprising as anthrax-P4H lacks the proposed PBD of human-P4H.
Removal or mutation of the human-PBD greatly raises the Km for substrate in
human-P4H-I.117 However, At-P4H-1 will react with (Gly-Pro-Pro)10 with a Km
of 60 µM, where the relative activity is ~ 1/30 of that of poly(L-proline), the
best substrate tested for that enzyme.69 It was not determined if (Gly-Pro-
Pro)10 was hydroxylated.69 It remains unknown whether (Gly-Pro-Pro)10 is
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hydroxylated by At-P4H-2.
The active site structure of Cr-P4H-1 revealed an extended shallow
groove near the active site that is proposed to serve as a collagen-like
peptide binding/recognition.90 The residues that are shown to be essential in
substrate binding in Cr-P4H-1 by site-directed mutagenesis studies are strictly
conserved in anthrax-P4H, human-P4H-1, At-P4H-1 and At-P4H-2 (Figure
3.1). It is possible that collagen-like substrates are primarily recognized by the
groove near the active site by P4Hs. In human-P4H-1, it is most likely that the
additional PBD is located spatially close to the groove and functions in
concert with the groove to bind procollagen.
3.5 Conclusions and Future Directions
 The attempt to establish an improved model system of human-P4H to
conduct structural and mechanistic study was initiated through the cloning
and expression of the first example of a bacterial P4H.  A putative P4H from
Bacillus anthracis was cloned, expressed, and purified in E. coli with yields of
~10 mg per liter of cell culture. Characterization studies showed enzyme
activity dependence on Fe(II), #KG, and O2, which fits its classification as an
#KG/Fe(II)-oxygenase.  Anthrax-P4H was found to adopt both monomeric
and dimeric forms dependent on conditions and types of analysis. MALDI-
TOF MS and site-directed mutagenesis studies showed that homodimer
formation is stabilized through forces other than a disulfide bond.  This is the
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first P4H found to form a homodimer.
Purified, highly soluble anthrax-P4H was obtained and tested for
activity. We developed an assay utilizing the enzyme L-glutamic
dehydrogenase's dependence on #KG, and monitored activity using an O2
electrode.  We were able to measure consumption of both #KG and O2 and
obtain leads for potential substrates.  BclA protein was expressed and purified
as a potential substrate and gave promising but irreproducible results. We are
currently screening additional synthetic peptides as possible substrates for
anthrax-P4H.   Once enzymatic turnover is optimized, further characterization
of the mechanistic intermediates will be determined.  This includes stopped-
flow UV-vis, Mössbauer, and rapid-freeze quenching EPR spectroscopic
analysis.
Anthrax-P4H shows apparent tight-binding of the collagen-like
substrate (Gly-Pro-Pro)10 with the same affinity as human-P4H-1 as well as
the surrogate substrate ascorbate. The structure of anthrax-P4H may be
structurally related to the #2 subunit of human-P4H-1, and may help
understand the assembly of the #2 subunit and interactions between the two
# domains.
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Chapter 4: X-Ray Crystal Structure Determination of a Proyl-4-
Hydroxylase-Like Protein from Bacillus anthracis
4.1 Introduction
C-P4Hs have long been targets for the development of selective
inhibitors against diseases such as fibrosis.17 Scar formation and fibrotic
tissue development are natural healing responses after injury.143 However, in
some situations the production of fibrotic tissue accumulation is excessive
and can lead to tumor formation. The organs most commonly affected are the
liver, lungs, kidneys, and skin.143 Human-P4H has gained much attention in
the development of a specific inhibitor as a potential therapeutic targeting
fibrosis, as it catalyzes the rate-limiting step in the biosynthesis of collagen. In
particular, Human-P4H-1 is the most abundant form of C-P4H in the body,
and therefore most involved in fibrosis formation after injury.14
There are three tissue specific isoenzymes of C-P4H in humans, with
amino acid differences among the three located in the # subunit.14 The
sequence identity among human-P4H-1 and -2 is 65 % and the identity
among -1 and -3 and -2 and -3 is 35 % and 37 % repectively.14 The
development of selective inhibitors for human-P4H-1 is difficult because the
isoenzymes are so closely related, with the C-terminus having the highest
percentage of identity.  #KG analogs have been shown to successfully inhibit
C-P4Hs in vitro.  2',4'- and 2',5'-Dicarboylate pyridines inhibit human-P4H-1
with Ki values of 2 µM and 0.8 µM respectively.7 However, these inhibitors
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have low permeability in vivo and the development of specific inhibitors is
needed to combat the delivery problem as well as specificity and selectivity.
The major difference in the isoenzymes of C-P4H is in the PBD.17,127
Studies have shown two regions in the PBD are responsible for poly(L-
proline) (inhibitor) binding corresponding to residues 162 - 192 and 231 - 240
in human-P4H-1.127 Site-directed mutagenesis studies strongly suggested
that Ile182 and Tyr223 (human-P4H-1 numbering) and Glu180 and Gln231
(human-P4H-2 numbering) are involved in peptide binding where mutations
E180I and Q231Y in human-P4H-2 lowered the Km of (GPP)10 to values
similar to human-P4H-1.127
The crystal structure of the full length #2!2 human-P4H-1 has not been
determined. The # subunit of human-P4H-1 is insoluble in the absence of PDI
and does not remain properly folded in the ER.  This has hindered attempts to
crystallize the #2 subunit of human-P4H-1.  An improved expression and
purification system for recombinant human-P4H-1 is required to obtain the
complete human-P4H-1 structure. We have successfully expressed a
recombinant form of human-P4H-1 in high purity and at yields of 5 mg/L. We
are currently screening crystallization conditions for structure determination.
The structural information can aid in developing selective inhibitors as
potential therapeutics for fibrosis.
The crystal structure of the isolated PBD from the #-subunit of human-
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P4H-1 has been determined to 2.3 Å resolution.117 The structure consists of
five #-helices and belongs to the family of tetratricopeptide-repeat (TPR)
domains that are involved in many protein-protein interactions.144,145 A groove
in the PBD containing eight tyrosine residues has been found to be essential
in substrate recognition through site-directed mutagenesis experiments.117
The crystal structure of a PDI from yeast has been determined to 2.4 Å.46
The crystal structures of a monomeric C-P4H from C. reinhardtii (Cr-
P4H-1) complexed with Zn(II) and the #KG analog 2,4-dicarboxylate pyridine
have been reported.90 The jellyroll motif characteristic of #KG/Fe(II)-
oxygenases was confirmed. Cr-P4H-1 lacks the separate PBD but instead, a
putative peptide-binding groove with high plasticity has been proposed.
Analyzing the structures of Cr-P4H-1 and anthrax-P4H can also provide
insights into the differing substrate specificity and affinity for #KG of the two
enzymes. The structure of HIF-P4H2 has also been determined, but was
found to belong to a structural subgroup distinct from C-P4Hs.90,133
We report here in the X-ray structure determination of the recombinant
anthrax-P4H.  We have shown that the anthrax-P4H binds (Gly-Pro-Pro)10
with a similar Km values as that of human-P4H-1 (Chapter 3), and its ability to
form homodimers may provide insight into the # domain interactions of
human-P4H-1 and its catalytic property, in particular the recognition mode of
the collagen-like peptide.
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4.2 Materials and Methods
4.2.1 Expression and Purification of Selenomethionine (SeMet)
Substituted Anthrax-P4H
To produce SeMet protein, the native anthrax-p4h plasmid was
transformed into methionine-requiring auxotrophic E. coli strain B384(DE3)
(Novagen). A 100 mL starter culture was grown overnight at 37 °C in
SelenoMet Medium (Molecular Dimensions Ltd.) containing 100 µg/L
ampicillin and 30 µg/L L-SeMet (Anatrace).  A 10 mL of starter culture was
used to inoculate 1 L of SelenoMet Medium containing 100 µg/L ampicillin
and 30 µg/L L-SeMet.  Cells were induced at an OD600 of 0.6 by addition of
200 µM IPTG as described for the native protein (Chapter 3). Cell growth was
maintained at 37 ˚C for 12 hours after induction.  After 12 hours the cells were
harvested by centrifugation similar to native anthrax-P4H as described in
Chapter 3.
The SeMet-anthrax-P4H was purified using the method described for
the native form of the enzyme (Chapter 3), and the overall protein yield of the
SeMet-anthrax-P4H was 12 mg/L, comparable to that of the native form
(Chapter 3). MALDI-TOF mass spectrometry analysis determined a mean
incorporation of 3 selenium atoms per anthrax-P4H monomer, where four




Initial crystallization screening was performed by the hanging-drop
vapor-diffusion method using commercially available sparse matrix screening
kits (Hampton Research and Emerald Biosystems). The purified SeMet-
anthrax-P4H was concentrated to 24 mg/mL in 50 mM Tris buffer (pH 7.4)
containing 150 mM KCl, and 5 mM !-mercaptoethanol. Equal volumes of
protein and reservoir solution (1 µL + 1 µL) were mixed and equilibrated
against the 750 µL reservoir solution at 293 K. Initial crystals were obtained
with 10% PEG-8000, 0.1 M MES pH 6.0, 0.2 M Zn(OAc)2 from the Emerald
Biosystems Wizard II kit. These crystals were not of diffraction quality and
further optimization was attempted. Because the initial mother liquor solution
contained Zn(OAc)2, co-crystallization of all the solutions in the presence of 1
mM Zn(II) was performed.  However, we have not been able to obtain
diffractable crystals with these screening kits.
Additional sparse-matrix screens were performed, and rhombic
crystals of varying sizes were obtained upon equilibration with 16% (w/v) PEG
8000, 40 mM potassium phosphate (monobasic) and 20% (v/v) glycerol from
the Emerald Biosystems Wizard III kit. The formation of crystals was found to
be pH dependent, and crystal growth was optimized at pH range 4.0 – 4.2.
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Co-crystallization experiments were performed in an anaerobic
glovebox  (COY Laboratories) in the presence of Fe(II), #KG, (GlyProPro)10 or
ascorbate under the same mother liquor conditions as apo-anthrax-P4H.
4.2.3 Data Collection
X-ray diffraction data from an apo-anthrax-P4H crystal was collected
in-house (KU-Protein Structure Lab) on an R-AXIS IV++ detector with Cu K#
X-rays generated by a Rigaku RU-H3RHB rotating-anode generator and
focused using an Osmic confocal optical system (Rigaku, Japan). The crystal
was flash-cooled by direct immersion into liquid nitrogen. No additional
cryoprotectant was necessary due to the high content of PEG-8000 and
glycerol in the well solution. A total of 113º of data were collected (0.5º
oscillation, 4.5 min exposure per oscillation) and the data was indexed,
scaled, and integrated using the CrystalClear software package.  The data
collection statistics are summarized in Table 4.1.
A three-wavelength anomalous dataset of the SeMet-anthrax-P4H was
collected at beamline BL9-2 at the Stanford Synchrotron Radiation Laboratory
(SSRL) to 1.4 Å resolution, and was solved using multi-wavelength
anomalous dispersion (MAD) phasing.146 The SeMet crystals were harvested
as described for the apo-anthrax-P4H, loaded into a sample cassette
designed for the Stanford Automated Mounting (SAM) system, and screened
for diffraction quality.147 The wavelengths were determined by the
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fluorescence absorption spectrum near the selenium LIII absorption edge. The
data set was collected at remote, peak, and inflection wavelengths (0.912 Å,
0.9793 Å, 0.912 Å).  Several MAD data sets were collected from separate
crystals and the data set producing the best overall figure of merit for the
experimental phases was used for structure determination.
A total of 180º of data were collected (1º oscillation, 2 sec exposure
per oscillation).  The data was processed with the program MOSFLM,148 and
scaled with SCALA of the CCP4 program suite.149 The space group was
determined as P21 with cell dimensions a = 41.38 Å, b = 63.80 Å, c = 98.50 Å,
! = 98.74°.  The data collection statistics are summarized in Table 4.2 (See
Results section).
Data collection of Fe(II)/#KG, Fe(II)/#K G / ( G P P )10,  and
Fe(II)/#KG/ascorbate crystals were collected to 1.39 Å, 1.65 Å, and 1.40 Å
respectively at the SSRL.  The data collection statistics are summarized in
Table 4.3 (See Results section).
4.2.4 Structure Determination and Validation
A data set from the SeMet-anthrax-P4H data collection was used to
solve the structure of apo anthrax-P4H.  Shelx150 was used to calculate the
heavy atom substructure.  Phases were calculated using SOLVE,151 which
was followed by electron-density modification using RESOLVE.152 The model
was further rebuilt manually using the graphical software COOT153, and
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crystallographic refinement was performed with the programs REFMAC5154
and Arp/wArp 6.1155,156 of the CCP4 suite.157 The structure refinement
statistics are summarized in Table 4.2.
The structure was validated using Procheck158, WHATIF,159 and
Molprobity.160 The geometry statistics are summarized in Table 4.2 (See
Results section).  All molecular figures were produced with PyMOL.161
4.2.5 Site-Directed Mutagenesis to Probe Self-Hydroxylation Reaction
As discussed briefly in Chapter 3, members of the Fe(II)/#KG-
oxygenases have been shown to undergo enzyme inactivation resulting in the
self-hydroxylation of a Phe, Tyr or Trp residue near the Fe(II) binding site in
the absence of substrate. Site-directed point mutations were performed using
the QuikChange method (Stratagene). Primers were designed using Primer-X
(http://www.bioinformatics.org/primerx/). For F178Y, forward primer: 5'-
GAAAGGGAATGGCAGTATACTATGAGTATTTCTATCAAGACC-3' and
reverse primer: 5'-GGTCTTGATAGAAATACTCATAGTATACTGCCATTCCC
TTTC-3' were used. For F178A, forward primer: 5'-GAAAGGGAATGGCAGT
ATACGCTGAGTATTTCTATCAAGACC-3' and reverse primer: 5'-GGT
CTTGATAGAAATACTCAGCGTATACTGCCATTCCCTTTC-3' were used.
The resulting plasmids were fully sequenced and the point mutations were
confirmed. The mutant proteins were expressed and purified as described for
the WT.
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4.2.6 Anaerobic Spectroscopy Monitoring Anthrax-P4H Self-Oxidation
Samples were prepared as discussed previously in Chapter 3.  Briefly,
100 µL of 1 mM enzyme (F178Y or F178A) in 50 mM Tris buffer (pH 7.4)
containing 2 mM sodium dithionite was placed in a septum-rubber sealed 50
µL cuvette and was degassed by gently purging O2-free Ar for 30 min.
Stoichiometric amounts of anaerobic solutions of Fe(II) and #KG were added
to the cuvette and the absorbance was measured.  After 30 minutes, the
cuvette was opened to air and the spectra were monitored over time up to 2
hours for spectral changes.
4.3 Results
4.3.1 SeMet Incorporation in Anthrax-P4H
Attempts to perform molecular replacement using the search model of
Cr-P4H-1 (2V4A, 2JIJ, or 2JIG), and the single wavelength anthrax-P4H data
were unsuccessful.  We therefore proceeded to use MAD methods to solve
the structure.  SeMet-anthrax-P4H could be easily prepared in large amounts
using auxotrophic E. coli strain 834(DE3). SeMet incorporation was confirmed
by MALDI-TOF MS (Figure 4.1 A).  Purified samples of native anthrax-P4H
and SeMet-anthrax-P4H resulted in the average m/z values of 24,432 and
24,585 respectively.  The additional mass of 153 corresponds to the
difference obtained when selenium replaces sulfur in three of the methionine
residues.  The fluorescence scan of the SeMet-anthraxP4H showed a strong
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signal at the selenium absorption edge (Figure 4.1 B) and was used to
determine the peak, edge, and remote wavelengths used in the MAD data
collection.
Figure 4.1. SeMet incorporation in recombinant anthrax-P4H.  A) MALDI-
TOF mass spectrometry of native (red) and SeMet-substituted (blue)
anthrax-P4H.  B) Fluorescence scan of SeMet anthrax-P4H crystal at SSRL






















4.3.2 Crystallization of Anthrax-P4H
Initial sparse matrix screening resulted in needle shaped urchin
crystals (Figure 4.2 A) and we were not able to optimize the conditions to
produce diffraction quality crystals.  We were able to obtain three-dimensional
crystals for both native and SeMet-anthrax-P4H with further screening (Figure
4.2 B).162 We have found that a subtle pH difference between stock solutions
was the controlling factor to obtain diffraction quality suitable crystals. The
optimum crystals were produced in the buffers between pH 4.0 - 4.2, and
crystals grew to a typical size of 0.8 x 0.5 x 0.1 mm over 1 to 2 weeks.162
A B
Figure 4.2. A) Initial crystals produced from Emerald Biosystems kit Wizard I,
solution # 7 made up of 10 % (w/v) PEG-8000, 0.1 M MES pH 6.0, and 0.2
M Zn(OAc)2. B) Crystals produced from Emerald Biosystems kit wizard III,
solution # 32 made up of 16 % (w/v) PEG-8000, 0.04 M potassium
phosphate (monobasic), and 20 % (v/v) glycerol. A pH of 4.0 - 4.2 is required
for crystallization seen in B.
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4.3.3. Data Collection and Structure Determination/Validation
Initial native anthrax-P4H crystals grew in the orthorhombic space
group P222 with unit cell parameters a = 63.76 Å, b= 80.12 Å, c = 98.63 Å,
and diffracted to 2.1 Å.  The presence of two protein molecules in the
asymmetric unit gave a calculated Matthews coefficient VM of 2.57 Å3/Da,
which corresponds to a solvent content of 52%.  The VM was within the range
commonly observed for protein crystals.163 Data collection is summarized in
Table 4.1
SeMet-anthrax-P4H crystals grew in the monoclinic space group P21
with unit cell parameters a = 41.38 Å, b = 63.80 Å, c = 98.50 Å, ! = 98.73 °,
and diffracted to 1.4 Å at three wavelengths around the selenium edge.162
The data set was collected at remote, peak, and inflection wavelengths (0.912
Table 4.1. Native anthrax-P4H data collection summary from Rigaku home
source (University of Kansas-Protein Structure Lab). Values in parentheses
indicate highest resolution shell.
! 
Rmerge = hkl i I i(hkl)"" # I(hkl) / hkl i I i(hkl)""
Space Group P222
Orthorhombic
Resolution (Å) 16.04 – 2.10   (2.17 – 2.10)
Unit-cell parameters (Å, °) 63.76 80.12 98.63
90.00 90.00 90.00
No. of measurements 96761
No. of unique reflections 28619
Redundancy 3.38   (3.39)
Completeness (%) 95.0   (93.2)
Rmerge (%) 14.6   (35.5)
Reduced ChiSquared 0.97   (1.01)
Average I/!(I) 6.0     (3.4)
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Å, 0.9793 Å, 0.9795 Å).  Figure 4.3 is a diffraction pattern representative of
the data collection at the SSRL. After repeated cycles of refinement and
model building the crystallographic R/Rfree factors are 17.9%/19.9% (Table
4.2).  Average B-factors of the structure are 12.5 for the main chain and 13.4
for the side chain.  Analysis of the structure with Procheck shows that 91 % of
the residues reside in the mostly favored region of the Ramachandran plot as
displayed in Table 4.2.  Because the SeMet dataset was collected to 1.4 Å,
we used it to solve the structure that will be the basis of the following
discussion.
Figure 4.3. Diffraction pattern of SeMet-anthrax-P4H obtained on beamline
BL9-2 at the SSRL. The resolution of this data set was 1.4 Å. The detector
edge was set at 1.36 Å.
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Crystals containing cofactors and substrates also grew in the P21
space group with unit cell parameters close in value to the SeMet-anthrax-
P4H crystals (Table 4.3).  Analysis of the data showed no electron density
consistent with the incorporation of Fe(II), #KG, (GPP)10 or ascorbate into the
crystals.
Table 4.2. Data collection, refinement and validation statistics for anthrax-
P4H structure determination. Values in parentheses indicate the highest
resolution shell.
Se peak Se inflection Se remote
Data Collection
Space Group P21 P21 P21
Wavelength (Å) 0.9793 0.9795 0.912
Resolution (Å)
53.38 – 1.40




 (1.44 – 1.40)
Unit-cell parameters (Å, °)
a = 41.38, b = 63.80,
c = 98.50, ! = 98.74
a = 41.38, b = 63.80,
c = 98.50, ! = 98.73
a = 41.38, b = 63.80,
c = 98.50, ! = 98.80
No. of measurements 374798 (27211) 374659 (27152) 376690 (27404)
No. of unique reflections 99723 (7385) 99692 (7369) 99677 (7368)
Redundancy 3.8 (3.7) 3.8 (3.7) 3.8 (3.7)
Completeness (%) 100 (100) 100 (100) 100 (100)
Rmerge (%) 4.4 (21.9) 5.0 (22.2) 4.1 (18.8)
Average I/"(I) 16.7 (4.8) 14.9 (4.3) 18.1 (5.9)
Refinement
Resolution 29.9 - 1.4
R (%) 17.9
Rfree (%) 19.9
Number of Reflections 94685
Number of atoms
     Protein 3233
     Waters 383
     Glycerol 16
Geometry Statistics
rmsd in bond length (Å) 0.018
rmsd in bond angle (º) 1.5
Average B-factor (Å2)
     Main/side chain 12.5/13.4
     Waters 25.1
     Ligands 21.4
Ramachandran plot (Procheck)
     Favored (%) 90.5
     Allowed (%) 9.5
! 
Rmerge = hkl i I i(hkl)"" # I(hkl) / hkl i I i(hkl)""
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4.3.4 Dimeric Structure of Anthrax-P4H
Anthrax-P4H crystallizes with two molecules in the asymmetric unit
(Figure 4.4 A).  Molecule A and B are similar with an RMSD value on C#
atoms of 0.334 Å.  Within the dimer, monomer A and monomer B are
arranged with intermolecular contacts between !2 and !9 (V) of the
neighboring molecule.  Residues Gln31-Glu38 from one molecule reacts with
Arg171 - Leu164 from the other and visa versa.  The symmetry of the
structure forms two groups of these interactions. The orientation of the dimer
arranges the active sites of each monomer directed toward the exterior of the
dimer.
The dimer interface is stabilized through both hydrogen bonding and
Van der Waals (VdW) interactions. Eight total hydrogen bonds (4 from each
interaction) from the peptide backbone (Figure 4.5 B, magenta lines) stabilize
Table 4.3. Data Collection of anthrax-P4H crystals co-crystallized with
cofactors and substrates (GPP)10 or ascorbate, SSRL.  Values in
parentheses indicate highest resolution shell.
! 
Rmerge = hkl i I i(hkl)"" # I(hkl) / hkl i I i(hkl)""
Fe(II)/!KG Fe(II)/!KG/(GPP)10 Fe(II)/!KG/ascorbate
41.34,63.37,98.12 41.21,63.06,98.60 41.38,64.07,98.63
Unit Cell 98.87° 99.03° 98.69°
Completeness 99.4% (99.9%) 95.8 % (92.5 %) 99.8 % (99.8 %)
Multiplicity 2.7 (2.6) 3.7 (3.6) 2.5 (2.5)
Rsym 0.050 (0.318) 0.062 (0.406) 0.069 (0.388)









the dimer over a distance of 2.86 - 2.96 Å. These stabilizing forces generate
an extensive network of !-sheets going from one monomer to the next. There
are a total of seventeen VdW interactions stabilizing molecule A and B over a
distance of 3.5 - 4.1 Å (Figure 4.5 B, orange lines). There are eight total
intermolecular VdW interactions stabilizing each interface, and one interaction
between the two Phe36 residues interacting with one another at 3.8 Å (Figure
4.5 B, interior view). There are three water molecules present in the dimer
interface.
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Figure 4.4. Oligomerization of anthrax-P4H.  A) Ribbon diagram of
asymmetric unit.  Each monomer A is displayed in green and monomer B is
displayed in blue.  Proposed active site residues are displayed in magenta.
B) Close up view of the hydrogen bonding (orange lines) and VdW forces
(magenta lines) occurring at the dimer: dimer interface.  Front view from the
face of one interaction and interior view between the two interactions. Three




4.3.5 Overall Structure of Anthrax-P4H
Anthrax-P4H is composed of 6 #-helices and 12 !-strands per
monomer, with eight (!6-!14) of the the !-sheets forming the DSBH motif
characteristic with #KG/Fe(II)-oxygenases (Figure 4.5).24 !-strands located in
the DSBH are labeled I-VIII for consistent nomenclature. There are three !-
strands (!1 - !3) at the N-terminus that extends the major sheet of the DSBH
conformation. The major sheet of the DSBH motif is comprised of !-strands I,
VIII, III, VI (Figure 4.5). A small !-strand of two residues (!4) extends the
opposite end of the major sheet.  The minor sheet of the DSBH motif is made
up of !-strands II, VII, IV, V (Figure 4.5).  There are three #-helices and three
310 helices located throughout the structure. The N-terminus of anthrax-P4H
consists of two #-helices and two 310 helices, that contribute to stabilizing the
backside of the major sheet of the DSBH motif (Figure 4.5), as commonly
seen among the #KG/Fe(II)-oxygenases.24 #5 (310 helix) is located on the
solvent exposed loop between II/III and most likely stabilizes Asp127 and
His129 of the iron binding site.  #6 is also in a loop created by VI/VII providing
stability for His193 in the iron binding site.  Both of these helices give
additional stability to the overall core fold of anthrax-P4H.
The N-terminal portions (residues Met1 - Lys11) of both molecule A
and B had poor electron density that could not be modeled. In addition, there
is one disordered loop region present in both monomers, which yielded low
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electron density.  This region corresponds to residues Ala65 - Ser71 in




















Figure 4.5. Overall view of the crystal structure of anthrax-P4H monomer B.
Ribbon representation of anthrax-P4H.  " helices are colored yellow, #-
strands in the DSBH core fold are colored orange, and additional #-strands
are colored blue. The s econdary structure is num bered sequentially and
Roman numerals indicate the eight #-strands of the DSBH core fold.
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4.3.6 Active Site of Anthrax-P4H
The putative Fe(II) binding site is located within the minor !-sheet in an
open end of the DSBH core (Figure 4.4) as seen in other #KG/Fe(II)-
oxygenases.24 Figure 4.6 depicts the three residues of the canonical H1-X-
D/E-Xn-H2 facial triad motif, His127, Asp129, and His193, that comprise the
putative Fe(II) binding site.  The H1-X-D of the motif is located at the end of
the second strand of the DSBH (II) motif, and the distal histidine (H2) is
located on the seventh strand of the DSBH (VII) motif.  Electron density
consistent with a glycerol molecule is detected at this site in both molecule A
and B (Figure 4.6). The Fe(II) binding site is conserved throughout the
members of #KG/Fe(II)-oxygenases.24 Asp129 forms further hydrogen bonds
with Thr145 (2.7 Å) of !III, Trp209 (3.1 Å) of !VIII, and glycerol (2.7 Å) for
greater stability (Figure 4.7).
In each monomer the proposed #KG binding site contains a water
molecule (A:Wat2, B:Wat592). Comparison with structures of other
#KG/Fe(II)-oxygenases indicates that in anthrax-P4H, binding of the 5-
carboxylate of #KG to the Fe (II) atom complex involves side-chains Tyr118
(3.0 Å), Tyr124 (3.1 Å), Thr159 (3.0 Å), and Lys203 (3.1 Å) (Figure 4.7).
Lys203 is a conserved basic residue corresponding to Lys493 in human type I
C-P4H, which through site-directed mutagenesis studies has been shown to
be essential in binding #KG.40 Residue Arg211, which is proposed to be
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involved in #KG binding stability, is not located in the active site (Figure 4.7).
This residue corresponds to His501 in human-P4H-1 and is proposed to
undergo hydrogen bonding to one of the oxygens in the oxygen-bridged
Fe(IV)-peroxo intermediate, assist in cleavage and the formation of the
Fe(IV)=oxo intermediate.25,40
Figure 4.6. The 2Fo-Fc electron density map, contoured to 1!, of canonical
H1-X-D/E-Xn-H
2 facial triad motif of anthrax-P4H.  Electron density consistent


















Figure 4.7. Proposed active site of anthrax-P4H.  Residues His127,
Asp129, and His193 involved in Fe(II) binding are displayed in cyan.
Residues Thr145, Trp209, and the glycerol molecule are involved in a
hydrogen-bonding network responsible for stabilizing Asp129 and are
shown in green.  Glycerol occupies the proposed Fe(II) binding site.  A
water molecule (Wat592) proposed in the putative #KG binding site is
labeled and colored magenta.  Residues Tyr118, Tyr124, Thr159, and
Lys203 proposed in the binding of the 5-carboxylate moiety of #KG are
shown in orange.
135
4.3.7 Self-Hydroxylation of Active Site Residues Leads to Inactivation of
the Enzyme
In the absence of ascorbate, the catalytic cycle of anthrax-P4H leads
to inactivation coupled to the formation of a blue chromophore with %max at ~
600 nm (Figure 3.13) as discussed in Chapter 3. In members of this
superfamily of enzymes including TauD and AlkB, it has been shown that the
inactivation is due to the self-hydroxylation of a Phe, Tyr, or Trp residue in the
active site, where the blue chromophore is assigned as a charge transfer
complex of hydroxylated residue to Fe(III).132,139,140 The self-hydroxylation
occurs concomitantly with decarboxylation of #KG and the resulting enzyme
is inactivated. Based on the active site structure of anthrax-P4H, we set out to
identify potential residues that may be hydroxylated through this mechanism.
In AlkB, Trp178 has been shown to undergo self-hydroxylation by UV-
vis spectroscopy and ESI-MS.164 By superimposing the active site structure of
anthrax-P4H with that of AlkB (PDB: 2FD8), Phe178 (anthrax-P4H) in the
active site is the most likely candidate to undergo self-hydroxylation (Figure
4.8 A).  We also performed structural overlays of anthrax-P4H with TauD
(PDB: 1OS7) as shown in Figure 4.8 B.  Tyr73 in TauD has been shown to
undergo hydroxylation by LC-MS/MS and Resonance raman spectroscopy.139
However, Tyr73 in TauD does not align well with Trp203 in the active site of
anthrax-P4H.  We therefore decided to prepare mutations of residue Phe178
to determine whether this residue undergoes self-hydroxylation.
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F178Y and F178A were expressed and purified in the same fashion as
WT. Both mutants showed lower O2 consumption when compared to WT.
F178Y had 54 % of the activity of WT and F178A had 10 % of the activity of
WT.  F178A was found to be not stable and precipitation was observed after
several days at 4 °C.  Thus this enzyme was characterized immediately after
protein purification.
The extent of self-hydroxylation was examined by UV-vis
spectroscopy. The #KG/Fe(II)/anthrax-P4H ternary complex  was prepared
under anaerobic conditions as described previously (Chapter 3).  The
Figure 4.8. Superimposition of anthrax-P4H (blue) active site structure with
#KG/Fe(II)-oxygenases, which undergo self-hydroxylation in response to
enzyme inactivation.  A) Trp178 in AlkB (PDB:2FD8) (magenta) is the
residue responsible for self-hydroxylation during inactivation.  The structures
overlay well and we have proposed F178 in anthrax-P4H undergoes self-
hydroxylation.  The bound iron present in overlay is from the AlkB structure
and is colored orange.  B) Tyr73 undergoes hydroxylation in TauD












absorbance of the #KG/Fe(II)/enzyme ternary complex was the same for both
mutants compared with WT %max = 510 nm.  However, when O2 was
introduced, the mutants behaved differently from WT (Figure 4.9). The %max of
F178Y is 530 nm, or 70 nm blue-shifted compared to WT. In contrast F178A


















Figure 4.9. A UV-vis spectrum of the Fe(II)/#KG/anthrax-P4H WT ternary
complex under anaerobic conditions (red line). The final concentrations are
1mM Fe(NH4)2(SO4)2, 1mM #KG and 1 mM enzyme (WT, F178Y or
F178A) in 50 mM Tris buffer (pH 7.4).  All samples showed the same
spectra, characteristic of the ternary complex.  Exposure to air results in a
difference between the WT and mutants.  WT (blue) displays %max = 615
nm, whereas F178Y (green) has %max = 530 nm.  F178A showed no
spectral change when exposed to air.
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4.3.8 Putative Peptide Binding Groove
The human-P4H isoenzymes are the only P4H proteins that contain
the PBD, which is the major domain distinguishing each of the forms.165 The
binding mode of a collagen-like peptide to C-P4H has not been defined.  This
may be due to the complexity of the polypeptide substrates that P4Hs use
compared with small molecule substrates of other members in #KG/Fe(II)-
oxygenases.
The structure of Cr-P4H-1 complexed with Zn(II) and the #KG analog
2',4'-dicarboxylate pyridine has been solved and revealed an extended
shallow groove lined by two flexible loops proposed in substrate binding.
Point mutation of residues in the groove (Arg93, Ser95, Glu127, Tyr140,
Arg161 and His245 in Cr-P4H-1 numbering) to Ala resulted in complete loss
of activity. Therefore these residues are proposed to serve in collagen-like
peptide recognition/binding.90 The corresponding residues are strictly
conserved in anthrax-P4H (Arg79, Ser81, Glu111, Tyr124, Arg142, anthrax-
P4H numbering).  In anthrax-P4H a shallow groove is formed from Phe85 of
!5 to Y124 of !II, which extends across the face of the molecule.  Figure 4.10
illustrates the shape of the groove and the residues in the groove.  The
groove is centered near the active site at residue Trp209.  Trp209 is stabilized
on the solvent side by a salt bridge made up of Glu111/Arg142.  Above
Trp209, residues shape the groove from I (Y118 for example) and II (Y124 for
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example).  Below Trp209, Arg211 (VIII) further stabilizes the salt bridge
formed by Glu111/Arg142.
The base of the groove is formed by Ser81 and Phe131 and extends to
large loops creating a distinct valley in which a large substrate such as
(GlyProPro)10 can bind.  The groove is shaped by two distinct "horns" that
form either side of the valley.  The top of one horn is made up of Asp74,
which is located close to the unmodeled portion of the structure after #1.
Arg136, which is located on #5, occupies the top of the other horn.  These
"horns" lend shape to a total valley that is 25.5 Å wide and 27.7 Å deep.
The assignment of the peptide binding groove is putative and based off
of the results of the Cr-P4H-1 structure.90 However, many of the residues are
located relatively close to the active site and may be necessary for catalysis
but not for substrate binding.  Further studies such as structure determination
of the collagen-like peptide bound form of anthrax-P4H are necessary to
evaluate the assignment of the peptide-binding groove.
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Figure 4.10. Stereoview diagram of putative collagen-like peptide binding
groove of anthrax-P4H.  Extends from !5 - II with Trp209 at the center of the
groove near the active site.  A) Surface representation of residues in the
groove colored yellow.  B) Representation of the residues in the groove


















4.4.1 SeMet Incorporation and Crystallization
A protein crystal structure is solved using both direct measurements
such as intensity and position (h,k,l) of the diffracted rays and by indirect
measurements such as the phase of the structure.  Both intensity and phase
give information about the atom arrangement in the crystal lattice. The phase
provides information on the electron density wave nature of the unit cell.  The
direct phase information is lost in the data collection process and must be
determined by indirect methods. If a structure of a homologous protein is
known then molecular replacement can be used.  This method translates and
rotates the unknown structure to obtain the phases from an already solved
crystal structure.166 However, this only works when the proteins are
structurally homologous.  Otherwise alternate methods are required.
The structure of anthrax-P4H was determined using MAD methods.
Molecular replacement could not be used at the time because no other
collagen-P4H crystal structures were solved.  Since then the structure of an
Cr-P4H-1 has been solved (PDB: 2JIG, 2JIJ, and 2V4A).  However, attempts
to solve anthrax-P4H using the data set of the Cr-P4H-1 have been
unsuccessful.
MAD uses the properties of anomalous scatters to indicate phases.
Anomalous scatterers are heavy atoms, which absorb X-rays at a wavelength
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near the element's absorption edge.166 These atoms absorb energy at
different wavelengths compared with the native protein and the difference can
be used to determine the phase.  MAD data collection must be performed at a
synchrotron radiation source as data must be collected at 3 different
wavelengths.166
SeMet was used as the anomalous scatterer for anthrax-P4H MAD
phasing experiment.  SeMet was easily incorporated into the protein with the
use of auxotrophic E. coli and substituting SeMet in the growing media for Se.
We were successfully able to incorporate 3 Se atoms out of the 4 present in
anthrax-P4H sequence as determined from MS analysis.  The native and
SeMet anthrax-P4H crystals were not isomorphous, meaning they did not
share the same unit cell parameters or space group.  Therefore, we used only
the MAD data set to solve the structure of anthrax-P4H.  The high-resolution
data set was collected at the SSRL and the structure was solved to 1.4 Å with
R/Rfree values of 17.9/19.9.
The crystallization of anthrax-P4H was performed with hanging-drop
diffusion method.  Three-dimensional crystals were obtained after a one time
screening with Wizard III kit from Emerald Biosystems.  The crystals were
birefringent, single, and large enough to collect data.  However, attempts to
remake the solution did not produce the same crystal morphology.  A
systematic screening of each of the solutions revealed that a change in the
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pH of the precipitant solution between the original batch of solution and
subsequent batches.  Lowering pH of the mother liquor solution to 4.0
resulted in diffraction quality, highly reproducible crystal formation.
4.4.2 Oligomerization
Members of collagen P4Hs exist in various oligomeric forms, which
have been determined experimentally.  Studies on human-P4H-1 have shown
the enzyme to form an #2!2 heterotetramer. Plant and viral forms of C-P4H
are monomeric. Nematode forms C-P4H from C. elegans have been seen as
heterodimers experimentally.36
Little is known about the #2 dimer interaction of human-P4H-1 as there
is no crystal structure for the catalytic subunit.  Through site-directed
mutagenesis studies, the #2 dimer has been shown to be stabilized by two
intrachain disulfide bonds (C486-C511 and C276-C293).122,123 Though these
disulfide bonds exist between the # subunits, they are also required for
tetramer assembly.123 There may be other interactions at work stabilizing the
#2 dimer in human-P4H-1. In addition to the two covalent bonds, human-P4H-
1 #2 subunit may contain a network of !-sheets stabilized with VdW forces
and backbone hydrogen bonding, similar to anthrax-P4H. Site-directed
mutagenesis experiments can aid in identifying the residues responsible for
the key stability of the dimer of human-P4H-1.
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Members of the #KG/Fe(II)-oxygenase family of enzymes exist in a
wide range of oligomeric forms. Human phytanoyl-CoA 2-hydroxylase167
(PAHX) crystallizes as a monomer whereas 1-aminocyclopropane-1-
carboxylic acid oxidase (ACCO) from P. hybrida crystallizes as a tetramer.168
Among some enzymes in the #KG/Fe(II) oxygenases, the orientation of the
C-terminus can play a role in the oligomerization and crystallization. In
DAOCS, the C-terminus peptide inhibited the co-crystallization with substrate
by forming a lid over the active site cavity.141 The mutation of the last four
residues was shown to abolish activity and is believed to be involved in
substrate recognition/binding.141 In ACCO168 and  factor Inhibiting HIF-1169
(FIH), the quaternary structure is formed by C-terminus peptide locking of the
monomers.  However, other enzymes such as alkylsulfatase (AtsK)170  and
proline 3-hydroxylase171 (P3H) have quaternary structures that are stabilized
by other forces such as hydrophobic or electrostatic interactions respectively.
The latter description applies to anthrax-P4H where the C-terminal peptide
has no role in the dimerization.
4.4.3 Overall Structure
The crystal structure of isopenicillin N synthase (IPNS) was the first
structure to be solved in the family of non heme Fe(II)-oxygenases, as IPNS
does not use #KG as a cofactor.172 Though Fe(II)/#KG-dependent
oxygenases catalyze wide range of reactions, a characteristic double
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stranded !-helix core fold was discovered and conserved in all the structures
determined so far.24,90,173 We have determined the crystal structure of
anthrax-P4H in its apo form to 1.4 Å. The closest structural homolog of
anthrax-P4H is the SeMet structure of a monomeric Cr-P4H-1 (PDB: 2V4A),
with a Z-score of 22.6 using the DALI server. These structures have a RMSD
of 1.68 Å for their C# chains. Comparison with HIF-P4H2 involved in hypoxic
response yielded a score of 13.6 and RMSD of 2.53 Å.
Anthrax-P4H forms a !-sandwich consisting of 4 anti-parallel !-sheets,
also known as the jellyroll core fold motif.  The sandwich is joined through a
"hairpin" loop which connects the fourth (IV) and fifth strands (V) of the DSBH
domain.24 In anthrax-P4H this hairpin loop is a tight turn/loop as seen with
some members of #KG/Fe(II)-oxygenases such as DAOCS (Figure 4.5).141
The Cr-P4H-1 adopts an extended conformation in its' IV-V loop similar to the
structure of TauD.174 The second !-strand in the DSBH (II) motif of anthrax-
P4H is short, but in an ordered conformation, unlike some oxygenases where
it is missing altogether (Figure 4.5).167 Therefore all eight !-strands of the
DSBH motif are seen in this structure, and stabilized through internal
hydrophobic interactions.24
Anthrax-P4H and Cr-P4H-1 share similar structural characteristics
(Figure 4.11).  These similarities include the DSBH motif, !3 at the N-
terminus, #1, #2, and 310 helix (2) also at the N-terminus, and #3 located in
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between !10 (V) and !11 (VI) in the DSBH. Both structures have no
secondary structure after !12(VIII) of DSBH, resulting in similar C-terminal
ends.
There are distinct structural differences between anthrax-P4H and Cr-
P4H-1 as well (Figure 4.11).  Anthrax-P4H has an additional !-strand (!1) at
its' N-terminus, and !2 is considerably longer than with the algal structure.
This may be due to insufficient electron density in the algal structure at the N-
terminus, as the first 28 residues in the sequence are not modeled in.  In
addition, there are 2 additional !-strands (!4-!5 algal numbering) in the algal
ternary structure that corresponds to an extended loop and missing electron
density in the anthrax-P4H structure (Ala65 - Ser71 in molecule B and Ser67-
Arg73 in molecule B). Instead anthrax-P4H forms a 310 helix not present in
the algal form. This short helix causes !4 to be shorter in the anthrax-P4H
structure compared to the algal structure.  Loop !8-!9 (IV-V) has a long loop
conformation with a 310 helix present in Cr-P4H-1 forming a large loop
insertion composed of 20 residues compared with the anthrax-P4H structure,
which contains a short, tight turn of 5 residues.  This is the loop that connects
the major and minor sheets of the DSBH.  In some #KG/Fe(II) oxygenases
this loop is long and flexible as seen with Cr-P4H-1 and in others in exhibits a
tight hairpin turn as seen in anthrax-P4H.24
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The ternary form of Cr-P4H-1 structure (2JIG) shows high plasticity at
loop II-III that undergoes a 19 Å conformational change with binding of Zn(II)
and an #KG analog, which causes the loop to reside in a "closed"
conformation.90 However comparison of the anthrax-P4H structure with the
SeMet Cr-P4H-1 structure (2V4A) revealed a similar conformation of this loop








Figure 4.11. Structural overlay of anthrax-P4H with Cr-P4H-1 SeMet(2V4A)
and ternary (2JIG) structures.  The portion of the st ructure with high
similarity is colored grey.  The flexible loops displaying key difference in the
structures are colored in blue for anthrax-P4H, orange for SeMet algal-P4H
(2V4A) and red for ternary Cr-P4H-1 (2JIG).  The cyan sphere represents a
Zn atom at th e active site of the ternary structure of Cr-P4H-1.  The
structural overlay was performed in COOT.
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not present in the ternary structure (2JIG) (Figure 4.11). Both Cr-P4H-1 and
anthrax-P4H structures are present in the "open" conformation, where the
central cavity is exposed to the solvent.  The loop in anthrax-P4H is 4
residues shorter, which may result in less flexibility and conformational
change upon binding of the cofactors.  Crystals of the Fe(II) and #KG bound
form are currently being screened. Except for the differences in these flexible
loop regions, the rest of the structures are conserved.
4.4.4 The Active Site Structure of Anthrax-P4H
The active site of #KG/Fe(II)-oxygenases is conserved among
members of the family of enzymes and is located on the minor !-sheet of the
DSBH motif.24 One of the roles of the DSBH motif is to provide a rigid scaffold
for the Fe(II) binding site.  Therefore, we can compare the active site of
anthrax-P4H with crystal structures containing a metal and an #KG analog to
examine putative interactions at the anthrax-P4H active site.
The spatial arrangement of the active site residues of #KG/Fe(II)-
oxygenases is not affected by binding of Fe(II) or 2',4'-dicarboxylate pyridine,
and therefore the amino acid residues align nicely with those of the Cr-P4H-1
ternary structure (Figure 4.12).  Both the H-X-D/E-Xn-H facial triad and the
Lys residue responsible for stabilizing the C5 position of the #KG are
conserved.  The Tyr124 in anthrax -P4H and corresponding Tyr140 in Cr-
P4H-1, do show different orientations.  In the algal structure this residue
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undergoes a conformational change upon binding of 2',4'-dicaroxylate
pyridine.90 In the ligand free and Zn(II) only binary (yellow residues) algal
structures Tyr140 is flipped toward the bulk solvent of the protein, away from
the active site, while the algal structure including both Zn(II) and 2',4'-
dicaroxylate pyridine (red residues) shows this residue stacking with His143
of the facial triad (Figure 4.12).90 In the anthrax-P4H structure (blue residues),
Tyr124 also points toward the active site and potentially stabilizes the bound
#KG by hydrogen bonding with its C1 carboxyl group.  This Tyr residue is
conserved throughout all P4Hs and may contribute to the differences









Figure 4.12. Structural overlay of the active sites of anth rax-P4H (blue),
binary complex of Cr-P4H-1 (yellow) (2JIJ molecule B), and ternary
complex of Cr-P4H-1 (red) (2JIG molecule A).  The active site coordination
does not change the facial triad or Lys residue identified as binding the C5
position of !KG.  Tyr124 (anthrax) and Tyr140 (algal) are spatially different
between all three structures and in anthrax-P4H may interact directly with
the C1 carboxy of !KG.  The numbering of the Cr-P4H-1 binary and ternary
structures are the same and displayed in red for simplicity, except for
Tyr140 where it is labeled in both red and yellow.  The Zn(II) atom (cyan
sphere) and 2',4'-dicarboxylate pyridine (green) are present from the ternary
Cr-P4H-1 structure.
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4.4.5 Self-Hydroxylation of Residues Leads to Enzyme Inactivation
We have shown through UV-vis spectroscopic study of F178Y and
F178A that Phe178 likely undergoes self-hydroxylation to inactivate anthrax-
P4H.  In the WT, Phe178 is most likely hydroxylated to form a tyrosinate-to-
Fe(III) MLCT band as seen in 4-hydroxyphenylpyruvate dioxygenase
(HPPD).140 The F178Y mutation blue-shifted the spectra compared with WT
(~ 600 nm) to a %max of ~ 530 nm (Figure 4.9). TauD has a similar spectra in
the presence of Fe(II) and #KG with a %max of 550 nm.175 Tyr73 has been
assigned as the residue that undergoes self-hydroxylation to form a catechol.
Similarly, we propose that a catechol is forming in F178Y.  The F178A mutant
showed no spectral change upon exposure of the Fe(II)/#KG/anthrax-P4H
ternary product to air.  The lack of any spectral feature supports the
suggestion that F178 undergoes the self-hydroxylation in the active site.
Contrary evidence to the results obtained in anthrax-P4H is seen in top
down mass spectrometry experiments performed on viral-P4H in which four
sites of oxidation were detected.176 This technique does not require
proteolytic digestion of the protein and uses intact protein for its analysis.
They were not able to identify exact residues, but only areas in the sequence
undergoing oxidation.  MS/MS data identified the four areas of oxidation as
R28 - V31 (22 %), E95 - F107 (28 %), K216 (34 %), and V125 - D150 (~4
%).176 These samples were examined in the presence of excess substrates
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and the residues identified do not correlate well with previous results obtained
from other members of the #KG/Fe(II)-oxygenases.177 Two of the four sites
contain aromatic residues (F107 and Y138), but four sites of oxidation have
not been observed in previous reports. Therefore, the mechanism of self-
hydroxylation in anthrax-P4H needs to be further investigated.
To determine if Phe178 is the residue undergoing self-hydroxylation,
the system can be examined with traditional proteolytic digest followed by
LC/MS.  Comparison of the samples with and without ascorbate will assist in
identifying the residue responsible for inactivation, as ascorbate protects the
enzyme from inactivation.  The crystal structure of the inactivated form of
anthrax-P4H could also be determined to identify the residue that undergoes
self-hydroxylation.
4.4.6 Peptide-Binding Domain of Anthrax-P4H
In addition to proline hydroxylation involved in hypoxia, HIF#
undergoes hydroxylation of an asparagine residue (Asn801) in the C-terminal
activation domain (CAD) of HIF#.178 This enzyme was identified as HIF
asparagine hydroxylase (FIH) and provides a secondary oxygen-dependent
mechanism whereby HIF# transcription is prevented.178 FIH is a member of
the #KG/Fe(II)-oxygenase family and binds to the polypeptide CAD domain of
HIF#.  The polypeptide nature of the CAD substrate for FIH is similar to the
collagen-P4H substrate of collagen. The crystal structure in the presence of
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Fe(II), #KG, and CAD polypeptide fragments has been determined to 2.25 Å
(Figure 4.13).179 Two binding sites were determined in the structure.  Site 1 is
a groove that adopts an extended conformation containing 10 hydrogen
bonds.179 Site 2 is on the surface of FIH and is stabilized by 2 hydrogen
bonds and appears to have weaker binding as determined from kinetic
analysis.179 The polypeptide had to be at least a 20-mer in order to obtain a
Site 1
Site 2
Figure 4.13.  Monomeric structure of FIH (PDB: 1H2L).  The ! helices are
colored yellow, "-strands in the  DSBH core fold are colored orange, and
additional "-strands are colored blue. The CAD peptide fragments are
shown in stick representation in cyan, the !KG is shown in s tick
representation in magenta, and the Fe(II) atom is represented as a grey
sphere.  The two sites of substrate binding are labeled.
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co-crystal structure.  Attempts to crystallize FIH with smaller substrates were
unsuccessful. The structure revealed an extended loop conformation of the
CAD fragments at site 1 as compared with the #-helical conformation these
same residues adopt when binding to the 1st transcriptional adaptor zinc-
binding domain (TAZ1).180,181 The conformational flexibility of the CAD
fragments in FIH reveal an induced fit binding process.179
Currently, there is no crystal structure of human-P4H-1 solved mainly
due to the poor solubility of the # subunit.  The available expression systems
for recombinant human-P4H-1 are also low yielding (~ 2 mg/L) and do not
produce pure protein.88,89 The crystal structure of the human-P4H-1 PBD
made up of residues Gly138 - Ser244 has been determined to 2.3 Å (PDB:
1TJC), and is composed of 5 antiparallel #-helices (Figure 4.14).117 The PBD
belongs to a tetratricopeptide repeat domains involved in protein-protein
interactions,144,145 and contains two TRP repeat domains and a solvating
helix. A groove containing eight tyrosine residues is the most unique feature
of the structure and site-directed mutagenesis studies have identified three
tyrosine residues as highly important for peptide binding.117 It is believed that
the peptide substrate binds in the deep groove in the concave surface of the
domain. The alanine scanning of all eight tyrosine residues suggested that
these residues have no role in the tetramer formation.117 However, no further
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analysis has been performed to determine if additional residues in the #
subunit are also involved in substrate binding.
A crystal structure of the collagen-binding domain (151-318) of the
Staphylococcus aureus adhesin protein (Cna) has been determined to 2 Å
(PDB: 1AMX), where the collagen binding interface of the domain is built
along a groove on a concave !-sheet and has significant structural and
chemical complimentarily to the triple helix of collagen.103 The Cna binding of
collagen can be used as a general model for collagen binding, and may
provide insight on the interactions of the PBD and active site of human-P4H-
Figure 4.14 Crystal structure of one TRP domain of human-P4H-1 peptide-
binding domain (PBD) (PDB: 1TJC). The 5 antiparallel !-helices are
colored red, and the t hree tyrosine residues proposed to be involved in







1. A subsequent structural study of Cna apo-protein (31-344, N1 and N2
subdomains) and Cna complexed with a synthetic collagen-like peptide
revealed that the peptide penetrates through a spherical hole formed by the
two subdomains and the N1-N2 linker.182 A "collagen hug" model has been
proposed for the binding of collagen to Cna in which a long linker is present to
wrap the collagen toward the binding site (Figure 4.15).182 It is possible that a
similar event may be occurring in human-P4H-1 where the PBD is acting as
the "linker" to draw the collagen substrate toward the binding site closer to the
Figure 4.15 Proposed "Collagen Hug" model shown in cartoon
representation.  A) The collagen triple helix associates with the groove in
the N2 domain (yellow).  B) The collagen is wrapped by the linker (blue)
between the N1 and N2 domains and the N1 domain (green). C) The N1
domain interacts with the N2 domain through hydrophobic interactions and
the C-terminal latch (red) interacts with the N1 domain to secure the
collagen triple helix in place.  Figure was reprinted with permission from
Macmillan Publishers Ltd: the Embo Journal, Zong et.al. 2005.180
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active site. This would locate the PBD spatially close to the groove and
function concertedly with the groove to bind procollagen.  It should be noted
that there is no sequence or structural similarity between Cna and
procollagen-P4H.
The structure of Cr-P4H-1 reveals a groove proposed to be essential in
substrate binding.90 Comparison of the algal and anthrax-P4H structures
show that the grooves are very similar as shown by Figure 4.16 A and B.
Both grooves extend from the !5 strand to the II strand close to the active
site.  Anthrax-P4H has a much more prominent groove that forms a deep
valley of ~ 28 Å flanked by residues Asp74 and Arg136 (Figure 4.16 C). The
algal structure forms a much more shallow valley from Lys102 to Glu156,
which is 11.40 Å wide and 6.9 Å at its deepest and 4.45 Å at its most shallow
(Figure 4.16 D).  The deep valley in anthrax-P4H may play a greater role in
recognizing collagen-like substrates and help to guide the substrate toward
the active site.  We have just begun to conduct docking studies and co-







Figure 4.16 Comparison of the putative peptide-substrate binding groove of
A) anthrax-P4H (blue) and B) Cr-P4H-1 (red). The putative peptide binding
groove is identified by yellow in both structures and extends from !5
(Phe85/Trp99) to !II (Tyr124/Tyr140) (anthrax/algal).  Comparison of valley
formed around the peptide binding groove for C) anthrax-P4H (blue) and D)
Cr-P4H-1 (red).
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4.5 Conclusions and Future Directions
 We have determined the crystal structure of apo anthrax-P4H, which is
the first identified bacterial P4H, to 1.4 Å. MAD phasing was used to
determine the crystal structure with SeMet substituted anthrax-P4H.  Anthrax-
P4H crystallized with 2 molecules per asymmetric unit. This is the first
putative homodimeric P4H that has been identified.  The dimer is stabilized
through hydrogen bonding of the peptide backbone and van der Waals
interactions in the dimer interface.
Anthrax-P4H contains the jellyroll core fold motif common among
#KG/Fe(II)-oxygenases.  It contains all 8 !-strands, which make up a major
and minor !-sheet.  The structure of anthrax-P4H contains fewer flexible
loops when compared with the structures of the other known C-P4H, Cr-P4H-
1.
The anthrax-P4H active site contains the characteristic H-X-D/E-Xn-H
facial triad and Lys residue responsible for binding the C5 position of the #KG
as defined from site-directed mutagenesis studies on human-P4H-1.  Tyr124
is also located in the active site and may play a role in #KG binding. Its
orientation in anthrax-P4H differs from that in all of the algal structures and
may form a direct interaction with #KG.
We have suggested that Phe178 may be responsible for enzyme
inactivation due to self-hydroxylation mechanism.  F178Y and F178A were
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purified and showed distinct UV-vis spectral changes upon exposure to O2
compared to the WT enzyme.   Crystallization and MS studies should be used
to confirm this theory.
Anthrax-P4H and Cr-P4H-1 both have putative peptide-binding
grooves.  This was surprising as the substrate specificity of the two differs
greatly with collagen substrate, (GlyProPro)10. We aim to determine the
difference in substrate specificity between anthrax-P4H and Cr-P4H-1.  The
proposed peptide-binding groove in anthrax-P4H consists of a deeper valley,
which may help with collagen-like substrate recognition.  The structure of
anthrax-P4H can provide insights in the catalytic properties as well as
dimerization of a subunits of human-P4H-1 and aide in the development of
more selective therapeutics to inhibit fibrosis.  The co-crystal structure of
anthrax-P4H and (GlyProPro)10 can provide essential information in this goal
and is under current examination.
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Chapter 5: Additional P4H Systems for Biochemical Characterization
5.1 Introduction
In order to gain further insight into the mechanism of P4H catalysis and
their substrate specificity, the recombinant forms of two viral P4Hs were
prepared in addition to anthrax-P4H. The genomes of both PBCV-1 and
MT325 contain putative p4h genes. PBCV-1 and MT325 are both large,
icosahedral, plaque-forming viruses that infect and replicate in differing
unicellular green algae, Chlorella.183 Members of the Chlorella viruses are
genetically diverse but similar in morphology and infect hosts in both marine
and fresh water.  PBCV-1 infects NC64A Chlorella, which resides in fresh
water isolated from the United States, Brazil, Argentina, Australia, Israel, and
Italy.184 Pbi Chlorella, which is infected by the MT325 virus, was initially
isolated in fresh water from Europe, but has been found in regions of higher
altitudes in Australia, Canada, and northern United States.184 The viruses
from these Chlorella do not affect one another.
PBCV-1 is the prototypic virus currently used in chlorovirus research to
study gene expression, proteomics, and virus-host relationship.183 The
genome of PBCV-1 contains a 621 bp putative p4h gene.  A recombinant
form of PBCV-P4H was expressed in E. coli and purified to homogeneity by
Eriksson and coworkers.73 The biological function and native substrate of
PBCV-P4H is currently unknown.  Proline-rich peptides deduced from the
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PBCV-1 genome were screened as potential substrates in the P4H activity
assay.  Among those tested, (Pro-Ala-Pro-Lys)10 had a Km of 20 µM and
showed the highest activity among the proline-rich peptides tested.73 This
substrate, and the others tested including (Ser-Pro-Lys-Pro-Pro)5 and (Pro-
Glu-Pro-Pro-Ala)5 are distinct from both animal ((Gly-Pro-Pro)n of collagen)
and plant ((Ala-Thr-Pro-Pro-Pro-Val)3) substrates.  The activity of PBCV-P4H
was assayed with both (Gly-Pro-Pro)10 and poly(L-proline) substrates and Km
values of 2900 µM and 500 µM were determined, respectively.73 A recent
spectroscopic study of PBCV-P4H identified one of the proposed mechanistic
intermediates, the high spin Fe(IV)=O complex, as discussed in Chapter 3.124
Another p4h gene was cloned from the genome of virus MT325.
MT325 has the smallest chlorella viral genome sequenced to date and has
not been extensively studied.185 Characterizing MT325-P4H has not been
previously performed and can add further insight into the role of the P4H
enzyme in lower order organisms.
To develop potential models for human-P4H-1, chimeric-P4Hs were
examined (Figure 5.1).  The chimeras were designed to contain both the
human-P4H-1 PBD and the catalytic domain of PBCV-P4H in attempt to
increase the solubility from that observed for the catalytic core of human-P4H-
1.
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5.2 Materials and Methods
5.2.1 Cloning of Truncated and Full-Length Forms of pbcv-p4h Gene
Initial cloning of a 621 bp pbcv-p4h gene was reproduced from
previously published methods by Erikkson et al.73 The genomic PBCV DNA
(GenBank accession number; U42580) was obtained from Dr. Van Etten at
the University of Nebraska. ! The gene of interest was amplified using the
PCR primers 5'-CGCGCATATGGAGGGGTTTGAAACCAGCGAT-3' and 5'-
CGCGCTCGAGTCATTTAACAGCACGGATCCATT-3', incorporating NdeI
and XhoI restriction sites, respectively (underlined). The resulting PCR
product was digested and ligated into NdeI/XhoI digested pET15b (Novagen)
expression vector, in frame with the 5" end His-tag coding sequence. This
PCR product codes for a 106 amino acid protein corresponding to residues
Figure 5.1 Schematic depiction of the four kinds of chimera proteins. Blue
blocks represent human-PBD domain and human-linker peptide. Red










Glu36-Lys242 without the putative signal peptide at the N-terminus.73 The
DNA of the purified plasmid was sequenced in the forward and reverse
direction at the DNA sequencing facility of University of California-Berkeley.
A full-length 684 bp pbcv-p4h gene was also amplified from genomic
DNA (GenBank™ accession number U42580) by PCR using primers 5'-CAT
GCCATGGAAACCCGAGAATACTTGTTG-3' and 5'-CCCTCGAGTTAGATC
CATTGGTTCGCGATG-3' containing NcoI and XhoI restriction enzyme sites,
respectively (underlined). The PCR product was first ligated into pGEMT-
Easy (Promega) cloning vector. The purified plasmid was sequenced in the
forward and reverse direction, and then subcloned into NcoI/XhoI digested
pET15b.
5.2.2 Cloning of Viral mt325-p4h Gene
A 672 bp open reading frame (ORF) encoding for the mt325-p4h gene
was amplified from genomic DNA (GenBank™ accession number DQ491001)
using the PCR primers 5'-CATGCCATGGATGGAAAATCCGAGTATATTC-3'
and 5'-CCCTCGAGTTAAATAGCTCGAATCCATTG-3' containing NcoI and
XhoI restriction enzyme sites, respectively (underlined). The mt325 genomic
DNA was obtained from Dr. Van Etten at the University of Nebraska. The
resulting purified PCR product was ligated into a pGEMT-Easy cloning vector
and sequenced in the forward and reverse direction. The sequence verified
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plasmid was digested with NcoI and XhoI and the purified insert was ligated
into the digested pET-15b.
5.2.3 Expression of Truncated PBCV-P4H and MT325-P4H
The truncated form of PBCV-P4H (Glu36-Lys242) without the N-
terminal putative signal peptide was expressed as previously reported by
Eriksson, et.al.73 Briefly, purified expression plasmid of the truncated gene
was transformed into BL21(DE)3 (Invitrogen) E. coli.  Fifteen mL of LB-amp
starter cultures were used to inoculate 2.8 L shaker flasks containing 1.5 L
LB-amp media.  Cells were grown at 37 ºC until the OD600 reached 0.6 at
which time the temperature was reduced to 28 ºC for 30 minutes.  The protein
expression was induced by addition of IPTG to a final concentration of 800
mM.  After induction, cells were incubated at 28 ºC for 3 hours, harvested by
centrifugation at 8,000 rpm at 4 ºC for 20 minutes, and stored frozen at - 80
ºC until ready for use.
Cells were thawed on ice, resuspended in 60 mM imidazole, 0.5 M
NaCl and 20 mM Tris, pH 7.9 containing protease inhibitors (1 mM PMSF, 1
mM leupeptin, 1 mM antipain, 1 mM pepstatin), lysozyme, and DNAse and
RNAse.  Cells were disrupted by ultrasonication and the lysate was
centrifuged at 20,000 rpm at 4 ºC for 1 hour.
Recombinant truncated PBCV-P4H was purified with HisTrap HP (GE
Biosciences) Ni+2 Sepharose column as described previously in Chapter 3.
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The fractions were analyzed with SDS-PAGE and those containing pure
protein were pooled, concentrated using a 10,000 MWCO membrane in an
Amicon stirred cell concentrator (Millipore) and desalted with a HiTrap
desalting column (GE Biosciences) to remove imidazole. These partially
purified fractions were purified on Superdex 16/60 Size Exclusion column
fitted to an FPLC (Akta).  Truncated PBCV-P4H was eluted with 50 mM KPi,
150 mM KCl, pH 7.0.  Fractions containing the truncated PBCV-P4H (> 99%
purity) by SDS-PAGE were combined, concentrated to ~ 40 mg/mL, made
20% v/v with glycerol and stored frozen at - 80˚C.  Protein concentration was
determined with Bradford Assay (Pierce) using BSA as the protein standard.
A yield of 3.5 mg of protein was isolated per liter of culture.
MT325-P4H expression plasmid was transformed into BL21(DE3) E.
coli cells for expression. Pilot expression of MT325-P4H was performed in
500 mL LB-amp media.  Cells were grown at 37 ºC until the OD600 reached
0.6, and the protein expression was induced by addition of IPTG to a final
concentration of 200 µM.  After induction, cells were maintained at 37 ºC for 3
hours and then treated with Bug Buster (Novagen) containing Benzoase
Nuclease for expression analysis.  Soluble and insoluble samples were
separated and subjected to SDS-PAGE analysis.
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5.2.4 Cloning of chimera-p4h Constructs
5.2.4.1 Chimera1: human-1-pbd with Truncated pbcv-p4h
The NcoI/NdeI digest of 321 bp PCR product-encoding human-1-PDB
was then ligated into the truncated pbcv/pET-15b plasmid between restriction
sites NcoI and NdeI. This construct has no linker nucleotides between the
human-1-pdb and pbcv-p4h gene (Figure 5.1 A).
5.2.4.2 Chimera 2: human-p4h-1 pbd with Full-Length pbcv-p4h
Initially, the 321 bp gene encoding the PBD (Gly154-Ser260 residues)
of human-P4H-1 was cloned from the vector containing the full-length #2!2
human-p4h-1 (prepared by Dr. Hirakawa in the Limburg Lab).  PCR primers
5'-CATGCCATGGGAGTGAAACACAAATC-3' and 5'-GGAATTCCATATGAG
ACTTATTGACATC-3' were used to clone out the human-1-pdb.  The PCR
product was digested with NcoI/NdeI and the purified insert was ligated into
the full-length pbcv-p4h/pET-15b clone between restriction sites NcoI and
NdeI.  This construct has a linker of 64 bp nucleotide derived from pbcv-p4h
between the human-1-pdb and pbcv-p4h gene (Figure 5.1 B).
5.2.4.3 Chimera 3: human-1-pbd with Human-Linker Sequence and
Truncated pbcv-p4h
Cloning of a 561 bp gene fragment encoding the PDB domain (Gly154-
His340) and extra nucleotide linker from the human-p4h-1 sequence was
performed using PCR primers 5'-CATGCCATGGGAGTGAAACACAAATC-3'
and 5'-GGAATTCCATATGATGGAAGCGAATAATA-3'.  The PCR product
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was digested with NcoI and NdeI, and the purified product was inserted into
the truncated pbcv/pET-15b clone between restriction sites NcoI and NdeI.
This construct contains a linker of 81 bp nucleotides derived from human-p4h-
1 gene between the human-1-pdb and pbcv-p4h gene (Figure 5.1 C).
5.2.4.4 Chimera 4: human-1-pdb with Human-Linker Sequence and Full-
Length pbcv-p4h
The 561 bp gene fragment containing human-1-pdb and human-linker
sequence described above was inserted at NcoI and NdeI into the full-length
pbcv/pET15b construct.  This chimera contains both the 81 bp linker
originated from human-p4h-1 and the 64 bp linker originated from pbcv-p4h to
anneal the human-pdb-1 and pbcv-p4h  genes to achieve maximum
separation between the domains (Figure 5.1 D).
5.2.5 Expression of Four Chimera-P4H Proteins
Plasmids for expression of chimeras 1 and 2 were transformed into
BL21(DE3) E. coli cells and initial pilot expressions were tested.  Single
colonies of each chimera were grown in LB-amp media to an OD600 of 0.6 at
which time the protein expression was induced by addition of IPTG to a final
concentration of 200 µM.  1 mL aliquot of cell culture was taken every hour
post induction, centrifuged, supernatant decanted, and cell pellets were
stored frozen at - 20 ºC.  Lysis of the cells was performed by standard Bug
Buster protocol with Benzonase Nuclease.  The soluble fraction was analyzed
by SDS-PAGE.
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No protein expression was seen with the BL21(DE3) E. coli cells
therefore all chimera constructs were transformed into E. coli cell lines
BL21(DE3)plyseS and BL21Origami(DE3) (Invitrogen). The BL21(DE3)plyseS
cells provide a tighter control of protein expression by expressing T7
lysozyme, which reduces the basal expression of the protein of interest.
BL21Origami(DE3) cells contain mutation in both the thioredoxin reductase
and glutathione reductase genes to enhance disulfide bond formation. Cells
were grown, the protein expression was induced by addition of IPTG and the
cell culture was collected every hour as described for the protein expression
using the BL21(DE3) cells.  Cells were lysed using BugBuster and the protein
expression was analyzed by SDS-PAGE.  Protein production was seen with
BL21plyseS cells, however only in the insoluble fraction.  Cell growth time
was extended from 3 hours to overnight and the growth temperature was
decreased from 37 ºC to 20 ºC in attempt to obtain soluble protein.
5.3 Results
5.3.1 Cloning and Expression of Truncated and Full-Length pbcv-p4h
We have cloned the 621 bp truncated form of pbcv-p4h coding for
Glu36–Lys242 without the N-terminal secretion signal peptide as reported by
Eriksson and coworkers73 (Figure 5.2 A). The recombinant protein was
purified using a Ni2+ sepharose affinity column followed by a Superdex sizing
column (Figure 5.2 B).
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Although PBCV-P4H was initially isolated as a soluble protein as
reported,73 the protein was found to be not stable and precipitation was
observed upon final concentration and under storage at 4 °C. The protein
yield was lower compared to that of anthrax-P4H, 6 mg/L vs. 10mg/L,
respectively.  No protein yield was reported for the PBCV-P4H. We had
previously seen precipitation of a recombinant anthrax-P4H when it was
expressed with the N-terminal His-tag.  Therefore, we have cloned the 684 bp
full-length pbcv-p4h in the absence of the His-tag coding sequence. We have















Figure 5.2 Cloning and expression/purification of truncated PBCV-P4H.  A)




5.3.2 Cloning and Expression of Viral mt325-p4h
A BLAST search identified a 672 bp ORF of a putative p4h gene in the
genome of virus MT325. We PCR-cloned the mt325-p4h gene, and the
recombinant protein was expressed in BL21(DE3)  E. coli and found to be
soluble (Figure 5.3).
5.3.3 Cloning of human-1-pbd and pbcv-p4h Chimera Constructs
The expression constructs for four chimeric P4Hs containing both the
human-pbd and gene fragment encoding the catalytic core of PBCV-P4H
were prepared. Chimera 1 construct is 924 bp and does not contain a linker
Figure 5.3. Pilot expression of recombinant MT325-P4H.  Lane 1) soluble
fraction of cell lysate from pre-induction, 2) soluble fraction of cell lysates
after 3 hour post-induction, 3) soluble fraction of cell lysate from uninduced
cells, 4) soluble fraction of cell lysate uninduced at 3 hour, 5) insoluble
fraction of cell lysate from pre-induction, 6) insoluble fraction of cell lysate
from 3 hour post-induction, 7) insoluble fraction of cell lysate from
uninduced cells, 8 insoluble fraction of cell lysate from uninduced cells at 3
hours uninduced.
172
between the pbd and pbcv-p4h genes (Figure 5.1 A).  We used the gene
fragment lacking the putative signal peptide coding sequence of pbcv-p4h in
this clone.  This corresponds to the gene fragment encoding the C-terminal
end of the # subunit and the P4H catalytic core of human-p4h.
We incorporated linker sequences on three of the chimera constructs
in attempt to help proper protein folding. Chimera 2 is a 1005 bp gene
containing the human-pbd and full-length pbcv-p4h (Figure 5.1 B). This
construct gives a 64 bp linker between the pbd and the corresponding gene
encoding the catalytic core of pbcv-p4h. Chimera 3 contains an 81 bp linker
from the human-p4h-1 downstream of the pbd to the pbcv-p4h, making up the
1185 bp gene (Figure 5.1 C).  The linker sequence was derived from the
sequence between the pbd and the gene encoding that catalytic core of the a-
subunit of human-p4h-1.  Chimera 4, a 1245 bp gene, is a blend of Chimera 1
and 3 incorporating both the viral and human linkers that form a 145 bp linker
(Figure 5.1 D).
5.3.4. Expression of Human-1-PDB and PBCV-P4H Chimeras
Pilot expression was tried on each of the chimera-p4h clones.
Screening of the host cells and cell growth and induction conditions were
performed.  The length for incubation time after induction was screened from
3 hours post induction to overnight, and growth temperatures were varied
from 37 ºC to 20 ºC.  None of the chimera-P4H proteins were found in the
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soluble protein after cell lysis (Figure 5.4 A).  Chimera 3 was expressed as an
inclusion body in BL21plyseS E. coli cells, overnight at 20 °C (Figure 5.4 B).
We have not screened the conditions to solubilize the inclusion body yet.
5.4 Discussion
5.4.1 PBCV- and MT325-P4H Model systems
In addition to anthrax-P4H, several other P4H systems have been
developed and studied in our laboratory. These include two different viral-
P4Hs and four chimera-P4Hs, containing both the human-1 PBD and catalytic
core of the monomeric PBCV-P4H.
Further insight into the mechanism of P4H catalysis and substrate
specificity can be gained through comparative study on the two viral forms.
Figure 5.4. Pilot expression of four Chimeric P4H proteins in BL21plyseS E.
coli cells.  A) Soluble fractions of cell lysate: uninduced and induced,
Chimera 1 (lanes 2 and 3), Chimera 2 (lanes 4 and 5), Chimera 3 (lanes 6
and 7), Chimera 4 (lanes 8 and 9). B) Insoluble fractions: uninduced and
induced, Chimera 1 (lanes 2 and 3), Chimera 2 (lanes 4 and 5), Chimera 3
(lanes 6 and 7) indicated by arrow, Chimera 4 (8,9).
A B
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The function of P4H in PBCV-1 is currently unknown.  Identifying the role of
PBCV-P4H may help explain the role P4Hs have structurally in vivo in lower
organisms and may correlate with its role in anthrax-P4H. Prior to the
characterization of PBCV-P4H, it was thought that viruses and bacteria did
not produce Hyp.  However, this not the case as Hyp has been detected in
viruses as well as B. anthracis (chapter 2), and collagen-like repeat
sequences have been identified in both viral and bacterial genomes. The
biological role of collagen-like peptides in chlorella viruses is not well
understood.  In B.anthracis, BclA is not responsible for the toxicity nor the
spore formation but it seems to contribute to the hydrophobicity of the surface
of the spore, potentially have roles in protecting spore from host cell
defense.98,186,187
5.4.2 The Role of PBD can be Determined with a Chimera-P4H
The PBD of human-P4H-1 is composed of  ~100 residues (Gly138 -
Ser244) and is present only in the type (I) human-P4H.14,127 This domain is
distinct structurally from previously identified proline-rich-peptide binding
proteins, which mainly consist of !-strands and forms a TRP protein domain
discussed in Chapter 4.188 Research in the Limburg lab has continued
searching for the best model system to understand the structure/function
relationship of human-P4H-1 in order to develop more selective inhibitors to
target fibrosis.
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A model system that incorporates the PBD functions of human-P4H to
the catalytic core of P4H is desirable as none of the available recombinant
forms of P4H contain this domain.  However, anthrax-P4H and At-P4H-1 bind
(GPP)10 with similar affinity as human-P4H-1 (18 µM), 9 µM, and 60 µM,
respectively.37,69 The structure of Cr-P4H-1 identified a shallow groove
proposed to be essential for peptide binding.  Point mutations identified
residues Arg93, Ser95, Glu127, Tyr140, Arg161, and His245 (Cr-P4H-1
numbering) as involved in substrate binding/recognition.90 These residues are
all conserved in human-P4H-1 and correspond to residues Arg362, Ser364,
Glu356, Tyr409, Arg432, and His501 (human-P4H-1 numbering).  His501 has
been shown to be essential in #KG binding in human-P4H-1 and therefore
most likely does not play a role in substrate recognition.40 Additional
mutations (Trp99, Gln130, and Trp243 Cr-P4H-1 numbering) in the groove
also showed an increase in the Km of poly(L-proline).90 These residues are all
also conserved in human-P4H-1 (Trp385, Gln406, and Trp499 human-P4H-1
numbering). This suggests that there may be alternative roles of the PBD that
have not yet been determined. A high yielding, soluble expression system for
human-P4H-1 in E. coli has successfully been developed in our laboratory as
previously discussed.  Comparative mechanistic studies on the recombinant
forms of human-P4H-1 and anthrax-P4H, in particular to define the substrate
recognition, should provide insights into the role of PDB domain.
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An alternative approach for defining the role of PDB is the
development of chimeric P4Hs.  The expression of four chimeric forms of the
PBD and PBCV-P4H have been examined (Figure 5.1).  Chimeras were
expected to be more soluble than the #2 domain of human-P4H-1. However,
we have not been able to obtain soluble protein yet. Chimera 3, which
contains a 27 amino acid residues linker, yielded inclusion bodies.  We have
not screened conditions to solubilize the inclusion body.
We have now characterized the biochemical and structural properties
of the recombinant anthrax-P4H (Chapter 2-4), where we have shown that the
anthrax-P4H is #2 dimer and exhibits the similar catalytic properties as
human-P4H-1. Anthrax-P4H may serve as a better catalytic component for
the chimera proteins than PBCV-P4H.  The crystal structure of anthrax-P4H is
also known and shows the N-terminus is accessible (Chapter 3) and in an
orientation where PBD can attach.
5.5 Conclusions
Attempts have been made to prepare alternate forms of P4Hs in order
to conduct comparative structure/function studies.  Two viral P4Hs, one from
PBCV-1 and the other from MT325, have been expressed.  Future goals of
these proteins include optimizing conditions to obtain soluble MT325-P4H.
Identification of the native substrates of both PBCV- and MT325-P4H is also
desired to help ascertain the role of P4H in these organisms in vivo. The
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constructs of four chimeric P4Hs expression system were made, however
none produced soluble proteins.  Chimeric proteins incorporating anthrax-
P4H as the catalytic subunit may be more fruitful as its it binds (GPP)10 with a
similar affinity as human-P4H-1.
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6.1 Final Conclusions
The current available system for a recombinant human-P4H expression
gives low yield and low purity enzyme, which is not sufficient for
spectroscopic studies or structure determination.  Both spectroscopic and
structural knowledge can aide in new strategies for the design of potential
therapeutic agents that target fibrosis.  We proposed to characterize collagen-
P4H from B. anthracis (anthrax-P4H) as a structural and spectroscopic model
for human-P4H. However, we initially had to determine if "Sterne B. anthracis
produced Hyp as it is common belief that prokaryotes do not stabilize their
collagens through Hyp.
B. anthracis contains BclA which forms a collagen-like triple helix structure
and contains (GPT)n repeats.  The Thr residues have been shown to be
glycosylated, but we believe Pro is undergoing hydroxylation at the Xaa
position as seen in P4Hs from lower organisms such as hydrothermal vent
worms and Cr-P4H-1.  Hydroxylation at the Xaa position has been shown to
further stabilize model peptides with glycosylation at the Yaa position.  We
were able to grow "Sterne B. anthracis cells and spores and isolate their
proteins by varying solubility.  Double derivatization and HPLC detected the
presence of Hyp in both B. anthracis cells and spores.  This is the first
evidence of Hyp in B. anthracis.  Our results show that there is a significant
amount of Hyp associated with sporulation in B. anthracis. This strongly
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suggests that a P4H-like protein that can catalyze the formation of Hyp exists
in B. anthracis.
BLAST search analysis identified a collagen-P4H protein in the B.
anthracis genome. We have cloned and expressed the first known bacterial
P4H as a recombinant protein in E. coli (anthrax-P4H).  Anthrax-P4H is
expressed in high yield, highly soluble, and is monodispersed. Through gel
filtration experiments, anthrax-P4H is predicted to be a homodimer, and site-
directed mutagenesis studies show that it is a non-covalent dimer. Dialysis
experiments and MALDI-TOF MS data support anthrax-P4H as a homodimer.
This is the first known P4H present as a homodimer.
Characterization studies showed enzyme activity dependence on Fe(II),
#KG, and O2, which fits its classification of an #KG/Fe(II)-oxygenase.
Anthrax-P4H binds (GPP)10 with the same affinity as human-P4H. Anthrax-
P4H is an improved model for human-P4H, and can aide in the development
of improved, selective inhibitor design.
We have crystallized, collected data, and solved the structure of the apo
form of anthrax-P4H to 1.4 Å.  This is the second structure of a Collagen-
P4H. The structure of anthrax-P4H has the DSBH or "jellyroll" core fold
characteristic of the #KG/Fe(II) oxygenases.  The active site also has the
characteristic H1-X-D/E-Xn-H2 facial triad motif. It has been shown that self-
hydroxylation of active site residues leads to inactivation of enzyme. The
180
inactivation is due to the self-hydroxylation of a Phe, Tyr or Trp residue in the
active site, where the blue chromophore is assigned as a charge transfer
complex of hydroxylated product to Fe(III). The self-hydroxylation occurs
concomitantly with decarboxylation of #KG and resulting enzyme is
inactivated. Structural overlays of anthrax-P4H with TauD and AlkB we
proposed that F178 in the active site is the most likely candidate that
undergoes self-hydroxylation.  Spectral shifts were seen with F178A and
F18Y mutations compared to WT, providing evidence that F178 is responsible
for the self-hydroxylation.
A putative peptide-binding groove has been identified in algal-P4H, and is
also conserved in anthax-P4H. Anthrax-P4H has been shown to catalyze
(Gly-Pro-Pro)10 with similar Km values as human C-P4H, and its homodimeric
property can provide insights into the # domain interactions of human C-P4H
and catalytic property. We aim to determine the difference in substrate
specificity between anthrax-P4H and algal-P4H, with their structures that are
so similar.
Alternate P4H systems have also been developed in the laboratory.
These include viral systems, PBCV- and MT325-P4H.  Little is known about
the function of these proteins in vivo or their native substrates.  Chimera P4H
proteins incorporating the PBD of human-P4H-1 and catalytic domain of
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PBCV-P4H were also developed.  The chimera P4Hs can be used to
establish the role of the PBD in human-P4H peptide recognition.
The biochemical characterization and structure determination of anthrax-
P4H has established new avenues for inhibitor development.  Current work in
the Limburg lab is focusing on the development of inhibitors targeting the
substrate specificity of the PBD and the Fe(II) binding site of the catalytic
core. Future work includes identifying the residues that play a key role in
catalysis and inactivation, most importantly the residues conserved between
anthrax-P4H and human-P4H-1. The identification of mechanistic
intermediates is also proposed to fully understand the P4H mechanism to aid
in the long-term goal of the development of selective fibrosis inhibitors.
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